Final Programme

Final Programme



Final Programme

16 th European Congress of Clinical

Microbiology and Infectious Diseases

Nice / France, Nice, April 1–4, 1 – 4, 2006

For the treatment of refractory invasive fungal infections

Copyright © 2006, SP Europe, Brussels, Belgium. All rights reserved. 03/06


40 mg/ml, oral suspension

NOXAFIL is indicated in adults with the following

diseases that are refractory* or intolerant to 1 :

• Invasive aspergillosis—amphotericin B (both conventional

and lipid formulations) or itraconazole

• Fusariosis—amphotericin B (both conventional and

lipid formulations)

• Chromoblastomycosis and mycetoma—itraconazole

• Coccidioidomycosis—amphotericin B (both conventional

and lipid formulations), itraconazole, or fluconazole

*Refractory defined as progression of infection or failure to improve after a minimum of 7 days

of prior therapeutic doses of antifungal therapy. 1

Please see Summary of Product Characteristics for full

prescribing information.

Reference: 1. NOXAFIL [summary of product characteristics]. SP Europe, Brussels, Belgium; 2005.

Visit the Schering-Plough booth

at ECCMID 2006 for more information


A20337 IR.02.2006/6.5

Table of Contents

Scientific Programme Overview _______________________________________________________ 2–5

Congress Venue Overview ____________________________________________ 7

Welcome Address ______________________________________________________________________________ 9

ESCMID – News from the President ____________________________________________________ 11

Important Addresses ________________________________________________________________________ 12

Acknowledgements __________________________________________________________________________ 13

Committees ________________________________________________________________________________ 14–17

ESCMID Awards 2006 ___________________________________________________________________ 18–23

Introduction to the Scientific Programme ____________________________________________ 24

Instructions for Authors ____________________________________________________________________ 25

ESCMID Study Group and other Business Meetings _____________________________ 26

Scientific Programme __________________________________________________________________ 27–67

Saturday, April 1, 2006_______________________________________ 27– 32

Sunday, April 2, 2006 ___________________________________________________________ 33–46

Monday, April 3, 2006 _______________________________________ 47–58

Tuesday, April 4, 2006 _______________________________________ 59–67

Poster Sessions _________________________________________________________________________ 68–148

Sunday, April 2, 2006 _______________________________________ 68–95

Monday, April 3, 2006 ______________________________________ 96–124

Tuesday, April 4, 2006 ________________________________________________________ 125–148

List of Chairpersons _________________________________________________________________________ 149

List of Authors _________________________________________________________________________ 150–171

General Information __________________________________________________________________ 172–174

Social Events __________________________________________________________________________________ 175

Tours ______________________________________________________________________________________ 176–178

Industrial Exhibition __________________________________________________________________ 179–203

Exhibition Overview __________________________________________________________________ 180/181

List of Exhibitors _____________________________________________________________________________ 182

Exhibitors’ Guide _______________________________________________ 183–203

Future ECCMIDs ______________________________________________________________________________ 206

City Map of Nice ______________________________________________________________________________ 207

Shuttle Bus Schedule _______________________________________________________________________ 208

page 1


April 1, 2006


April 2, 2006

Scientific Programme Overview























page 2 Final Programme

Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris

13.30 – 15.30

13.30 – 15.30

13.30 – 15.30

13.30 – 15.30

13.30 – 15.30

Practical and

theoretical aspects of


typing: the paradigms

of S. aureus

and S. pyogenes

ESGEM Work -

shop p.27

Quality control


standardisa tion

in molecular


ESGMD Work -

shop p.27

Management of Current control

nosocomial measures for

infections – Toxoplasma

learning from infection in preg-

clinical cases nant women and

new-born children

ESGNI Work - ESGT Work -

shop p.27 shop p.27



of microbial


ESGB Workshop


15.30 – 17.30

Evidence and ex- 15.45 – 16.45

15.45 – 16.45

perience: the role Dendograms in Antimicrobial resis -

microbial phylogene- tance in anaerobic

of echinocandins

tics and epidemio - bacteria. Experiences

in the manage- lo gical typing in Europe and USA



ment of invasive

16.45 – 17.45

16.45 – 17.45

fungal infections


MSD p.31 Meeting Meeting



15.45 – 17.15


and prevention

of nosocomial

infections –

new aspects


17.15 – 17.45

ESGNI Meeting

15.45 – 16.45

15.45 – 17.15

News in the How to prevent

field of toxo- microbial biofilm


formation on

16.45 – 17.45 medical devices




17.15 – 17.45

p.26 ESGB Meeting

18.00 – 21.00








Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris

07.15 – 08.15

07.15 – 08.15

07.15 – 08.15

Lab diagnosis of Current issues in What is the role

invasive fungal the treatment of of serology in

HBV-HIV co-infected




p.33 p.33 p.33

08.30 – 10.30

08.30 – 10.30

08.30 – 10.30

08.30 – 10.30

08.30 – 10.30

08.30 – 10.30

New diagnostic Tailoring initial The challenge for Neurological Quinolone Viruses and

techniques antifungal antibiotic therapy sequelae of resistance and viral

for the

therapy in treating bacterial and efflux diagnostics

microbiology according to complicated viral infections

laboratory and epidemiological infections: how


trends broad is enough?

practitioner Schering-Plough

p.34 p.37 MSD p.37 p.34 p.34 p.35

11.00 – 12.00



Award Lecture

11.00 – 12.00

Impact of microbial

genomics on

epidemiology and

control of ID

Poster Session I: 12.00–13.00

Poster Session II: 13.00–14.00

Poster Walks

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

The year in Is microbiological The hyper-virulent Dissemination

infectious work-up in community- strain of C. difficile: of molecular

diseases medicine acquired pneumonia sharing experiences in resistance traits

p.41 still useful? p.41 Europe and USAp.41


Diabetes and



Pump it out

and resist


15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

Current Readdressing the Addressing

aspects on importance of macrolide issues

MRSA Gram-negative re- in communitysistance:pathoacquired


gens, practice

patterns, and


p.43 Wyeth p.45 Pfizer p.46


of infectious


new science






clinical trials





17.45 – 18.45

Late breaker

Session on

Avian influenza


p.38 p.38


13.30 – 17.30

Pharmaco -



pharmaco -

dynamics of






Keynote, Award and Special Lectures

Oral Sessions

Satellite- & Integrated Symposia

Meet-the-Expert Sessions & Educational Workshops

Business Meetings

Poster Sessions

Clio Erato Calliope Registration


13.30 – 15.30

The management of

neutropenic patients

with fever undergoing

chemotherapy for the

treatment of haematological


13.30 – 14.30



14.30 – 15.30


13.30 – 15.30





Wyeth p.31 p.26 p.26

15.45 – 17.15


utilisation in

Europe: future


15.45 – 17.45




10.30 – 12.30



Committees and




15.45 – 17.15

Guidelines for

Helicobacter pylori

infections revisited.

The Maastricht-3 2005

consensus report





Meeting Room 3

13.30 – 17.30



of nosocomial




and use

in ICUs



Hermes Clio Erato Calliope Registration / Exhibition

07.15 – 08.15

07.15 – 08.15

07.15 – 08.15

Travel medicine and Surveillance of newly How to diagnose

evidence-based emerging pathogens and treat diabetic foot

recommendations and public health infections?

p.33 responses p.33 p.33

08.30 – 10.30

08.30 – 10.30

08.30 – 10.30

08.30 – 10.30

Evolution of In antimicrobial Clinical Addressing the

beta- therapy “use the epidemiology challenge of

lactamases best one first”: of nosocomial nosocomial

examining the


infections MRSA infections

Bayer HealthCare


p.34 p.37 p.35 p.38

11.00 – 12.00

11.00 – 12.00

Biofilms – Emerging viral

a highly organised infections



Poster Session I: 12.00–13.00

Poster Session II: 13.00–14.00

Poster Walks

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

Blood-borne viruses

in health care

facilities – the silent

enemy? p.41

Viral congenital


diseases p.41






15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

Foreign body Redesigning Rapid Advances in

infections ß-lactams to methods for antifungal

combat identification therapy

resistance of bacterial

clones and



Gilead Sciences

p.43 p.46 p.45 p.46


p.32 p.32


17.15 – 17.45

ESGAP Meeting


17.15 – 17.45

EHSG Meeting

p.26 p.26





























April 1, 2006


April 2, 2006

page 3

page 4


April 3, 2006


April 4, 2006

Scientific Programme Overview























Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris

08.30 – 10.30

The pros and

cons of




Final Programme

08.30 – 10.30


tract infections:

at risk patients,

who are they?

08.30 – 10.30

Extending the



07.15 – 08.15

07.15 – 08.15

07.15 – 08.15

Recent treatment

issues in tuberculosis

and nontuberculosis


Epidemiology and How to interpret

typing in outbreak laboratory test


p.47 results? p.47

08.30 – 10.30

Emerging viral


in Europe

08.30 – 10.30





08.30 – 10.30

Infections in

the immunocompromised


sanofi aventis Pfizer

p.48 p.51 p.51 p.48 p.48 p.48

11.00 – 12.00

11.00 – 12.00

Antimicrobial intelli - WHO patient

gence: how euka ryotes

combat the quorum safety challenge

sensing strat.

11.00 – 12.00

Human papilloma -

virus: impact of

11.00 – 12.00


Investigator Award


p.52 p.52

disease and vaccine


p.52 p.52

Poster Session III: 12.00–13.00

Poster Session IV: 13.00–14.00

Poster Walks

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00

Emergence of

transferable quinolone


The year in HIV



Infectivity and Infection in the

emergence of immunocompromised

resistance in animal host (except HIV)

models p.54 p.54

Hepatitis Multidrug-resistant

Gram-negative organisms

in the hospital

p.53 and community



15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

15.30 – 16.30

15.30 – 17.30

15.30 – 17.30

How to The heart Fungal infections: To treat or not Antibacterial Epidemiology

detect the next of the matter: host defences to treat susceptibility of MRSA





resistance in


sanofi aventis


and clinical





16.30 – 17.30

Problems in the

treatment of HIV





and drug



in Europe


Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris

08.30 – 10.30


and therapy

of sepsis

08.30 – 10.30


therapy for

Candida –

the case for


07.15 – 08.15

07.15 – 08.15

07.15 – 08.15

Empirical antibiotic How to defend your Antibiotic prophylaxis

therapy for ICU- clinical microbiology in immunocomproacquired



in times of budget mised hosts, including

restrictions? p.59 transplant patients


08.30 – 10.30


RTI's –

current state of

the art

08.30 – 10.30


pharmaco -

kinetics and

pharmaco -


08.30 – 10.30



a diversity of

mechanisms and

host responses


Neutec Pharma

p.62 p.60 p.60 p.61

11.00 – 12.00

11.00 – 12.00

11.00 – 12.00


determinants of

the genetic diversityof

viruses p.63

Toxins from


bacteria p.63

Sexually transmitted

diseases and urinary

tract infections


Poster Session V: 12.00–13.00

Poster Walks

13.00 – 15.00



diagnosis and




13.00 – 14.00

RTI in the




13.00 – 15.00



resistance and

epidemiology of

fungal infections


Hermes Clio Erato Calliope Registration / Exhibition

07.15 – 08.15

07.15 – 08.15

Minimal requirements Beta-lactamases:

for an effective

infection control from bench to

surveillance bedside

08.30 – 10.30




resistance and


14.00 – 15.00



08.30 – 10.30

Fighting the

threat of



07.15 – 08.15

Clinical trials

and clinical


08.30 – 10.30

Pneumonia and


08.30 – 10.30


the class of 2006



p.48 p.51 p.49 p.51

11.00 – 12.00

Human genetic

susceptibility to

infection p.52

15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

15.30 – 17.30

Paediatric viral Evidence-based Diagnosis of sep- Limiting

respiratory tract preventive and sis: the need for antibiotic

infections: control measures fast molecular usage in the

the major killers for selected microbiological community:

nosocomial methods benefits and






collateral effects


p.56 p.58

17.45 – 19.00




Poster Session III: 12.00–13.00

Poster Session IV: 13.00–14.00

Poster Walks





Hermes Clio Erato Calliope Registration / Exhibition

07.15 – 08.15

07.15 – 08.15

07.15 – 08.15

How to manage


infections? p.59

Routine suscepti- Emergence of risk

bility testing: which

factors and treatment

issues for Clostridium

antibiotic to choose difficile -associated

p.59 diarrhoea p.59

08.30 – 10.30

Risk assessment

in primary care:

clairvoyance or



13.00 – 15.00



of low-level



p.47 p.47 p.47

08.30 – 10.30

Compliance in


the last chance?

08.30 – 10.30

Antisepsis and

the prevention of

skin and soft

tissue infections

Pfizer Shuelke-Mayr

p.60 p.62 p.60 p.60

11.00 – 12.00

Issues in travel


13.00 – 15.00



a tool for public


11.00 – 12.00


Poster Session V: 12.00–13.00

Poster Walks


Keynote, Award and Special Lectures

Oral Sessions

Satellite- & Integrated Symposia

Meet-the-Expert Sessions & Educational Workshops

Business Meetings

Poster Sessions

14.00 – 15.00

14.00 – 15.00

14.00 – 15.00


Management of Galactomannan PK/PD for the clinician:

antigen detection in should we use

endocarditis invasive aspergillosis continuous infusion

(interactive) Bio-Rad p.55 techniques? p.54


13.00 – 15.00





08.30 – 10.30

Update on the


pandemic threat

11.00 – 12.00

Implications of



barrier injury

p.63 p.64 p.63

13.00 – 15.00



p.65 p.65 p.66 p.65




























April 3, 2006


April 4, 2006 page 5

You are invited to a Pfizer-sponsored integrated symposium

Addressing the Challenge of

Nosocomial MRSA Infections

Sunday, 2 April, 2006 08:30-10:30

Salon Calliope, Nice Acropolis Congress Centre

Scientific Agenda

Chairs: Gary French (UK), Kamal Itani (USA)

08:30 Introduction: Addressing the Challenge of Nosocomial MRSA


Gary French (UK)

08:40 MRSA Update: Present and Future Threats

Peter Wilson (UK)

09:00 Challenges of MRSA Nosocomial Surgical Site and Complicated

Skin and Soft-Tissue Infections

Kamal Itani (USA)

09:20 MRSA in the ICU: Catheter-Related Skin and Bloodstream Infections

Emilio Bouza (Spain)

09:40 Nosocomial Pneumonia: Early Diagnosis, Better Treatments

Jean-Yves Fagon (France)

10:00 Panel Discussion and Questions

Gary French (UK)

10:25 Summary and Conclusions

Kamal Itani (USA)

Supported by an educational grant from Pfizer Inc, a platinum medal sponsor

Level 3

Level 2



(main auditorium)

Level 1



Congress Venue Overview


Shuttle Buses






On-site Registration


Business Center




Méditerranée 2




Poster Desk





Press Centre


Lounge Speakers

Service Centre



Clio Erato Calliope

Meeting Rooms

Méditerranée 1

to Rooms Méditerranée


Méditerranée 3

to/from Exhibition


Lecture Halls

Poster Area


Registration, Secretariat and Smaller Rooms





page 7

Integrated symposium

In antimicrobial

therapy use the

best first: examining

the evidence

Sunday, April 2, 2006, 8:30 – 10:30 a.m.

Acropolis Congress Centre, Level 3, Room Clio

Integrated symposium arranged by

Chairmen: Patrick Francioli (Lausanne, CH)

Donald Low (Toronto, CA)

08:30 Introduction

Donald Low (Toronto, CA)

Patrick Francioli (Lausanne, CH)

08:40 Differentiating antibiotics on basis of

preclinical data – determining superior

antimicrobial activity

Francesco Blasi (Milan, IT)

09:10 Treatment of lower respiratory tract

infections – assessing clinical superiority

Robert Read (Sheffield, UK)

09:40 Treatment of surgical infections including

SSSIs – assessing clinical superiority

Johannes Bogner (Munich, DE)

10:10 Panel discussion

Donald Low (Toronto, CA)

10:20 Conclusions

Donald Low (Toronto, CA)

Patrick Francioli (Lausanne, CH)

Welcome Address

Dear Friends, Dear Colleagues,

Welcome to Nice and to the 16 th ECCMID, one of the major congresses in Clinical Microbiology and Infectious

Diseases in 2006! I hope you are comfortably settled and that you will also find some time to enjoy the city

and its surroundings, which offer a great variety of cultural and tourist attractions. Such surroundings could be

a concern for the President of a meeting as it is tough competition even for a premier scientific programme

covering a wide range of interesting topics in the infection fields.

Delegates will be pleased to find a top-notch programme organisationally as well as scientifically. Sessions

have been scheduled in such a way as to avoid simultaneous presentations on similar themes. Speakers in

symposia have been invited to present their data because they are considered the most knowledgeable

specialists on the selected subjects, speakers in oral sessions have been chosen among the authors of the best

abstracts, according to the rating by three reviewers. The selection of these free communications is very

wide-ranging, thanks to a large number of submissions received for presentation at 16 th ECCMID in Nice.

Major topics of current concern will be discussed. This includes a late-breaker symposium on Sunday evening,

April 2, on avian influenza addressing the Turkish experience and the global threat by this disease.

The ever-increasing number of attendees from year to year attests to the fact that a high degree of scientific

expertise is “behind” ECCMID, making it a major event in the fields of clinical microbiology and infectious

diseases. The Scientific and Organising Committees have worked diligently to make your visit to Nice highly

satisfactory for both scientific and personal reasons and wish you a successful meeting.

Prof. Pierre Dellamonica Prof. Andreas Voss

16 th ECCMID President ECCMID Programme Director

page 9

ESCMID – News from the President

Dear Colleagues and Members of European Society of Clinical Microbiology and Infectious Diseases

I would like to join Professor Pierre Dellamonica and Professor Andreas Voss in welcoming you to

this year’s ECCMID. Judging from the great number of abstracts received it is likely to become one

of the largest ECCMIDs ever.

Clearly ECCMID has now become the major European congress of clinical microbiology and infectious

diseases. We feel that the Programme Committee has managed to gradually improve the scientific

quality with a very broad range of keynote lectures, symposia and free communications. This could

not have been achieved without the large number of high quality abstracts submitted during these

last years.

ECCMID is the most important means for ESCMID to serve its members. However, the Society

also has many other activities which the members can benefit from. Each year we support young

members, especially from Eastern Europe, so that they can attend ECCMID and other activities.

We also support several postgraduate courses in various parts of Europe. Another important

part of our activities is to support and strengthen Clinical Microbiology and Infectious Diseases

as medical specialities in Europe.

Our involvement in infection-related science is mainly through the ESCMID study groups, which

cover a broad range of topics. They offer opportunities for European scientists to co-operate,

communicate and present new findings during ECCMIDs.

During the last years the co-operation between ESCMID and the European Union has increased.

ESCMID has received a grant from the EU, which partly funds EUCAST (European Committee on

Antimicrobial Susceptibility Testing). This has enabled an intensified activity within EUCAST and the

Committee has been able, in a record time, to achieve consensus on susceptibility break-points of

most antibiotics within Europe.

ESCMID has also, together with the European Respiratory Society (ERS), become a partner in GRACE,

a large EU-funded research project on community-acquired lower respiratory tract infections.

ESCMID and ERS will be responsible for the educational activities within GRACE.

Both EUCAST and GRACE are important milestones for ESCMID since they mean that ESCMID is

now recognised as a full partner in EU-sponsored projects. The Society has also been recognised by

the new European Centre for Disease Prevention and Control, ECDC where ESCMID holds a seat on

the Advisory Forum, the scientific council of the agency.

The strength of ESCMID depends on its membership. The more members we get, the stronger we

will become. I hope those of you who are not yet ESCMID members will consider the advantages

of joining us. Membership benefits include registration at a reduced price for all ESCMID events,

including ECCMID, eligibility for travel awards and access to our news service.

For more details on the advantages of being an ESCMID members come and visit us at the ESCMID

booth located on level 1 close to the main entrance.

I wish you the best of possible experiences in Nice during ECCMID.

Prof. S. Ragnar Norrby

ESCMID President

page 11

Important Addresses

Address during 16 th ECCMID 2006 Phone +33 4 93 92 81 07

the Congress Nice Acropolis Fax +33 4 93 92 81 08

1, esplanade Kennedy E-mail

06302 Nice Cedex 4


Congress President Prof. Pierre Dellamonica Phone +33 4 92 035515

CHUN – Hôpital de L’Archet Fax +33 4 93 965454

Maladies Infectieuses E-mail

et Tropicales

151, Route St. Antoine de Ginestière

BP 3079

F-06202 Nice Cedex 3


Scientific Secretariat 16 th ECCMID 2006 Phone +41 61 686 77 99

c/o ESCMID Executive Office Fax +41 61 686 77 98

P.O. Box E-mail

CH-4005 Basel


Administrative Secretariat 16 th ECCMID 2006 Phone +41 61 686 77 11

c/o AKM Congress Service Fax +41 61 686 77 88

P.O. Box E-mail

CH-4005 Basel


Accommodation AKM Travel AG Phone +41 61 690 94 11

Messeplatz 10 Fax +41 61 690 94 14

P.O. Box E-mail

CH-4016 Basel


Local Agency Mediaxa Phone +33 4 97 038597

27, rue Massena Fax +33 4 97 038598

F-06000 Nice E-mail


page 12 Final Programme

page 13


The Organising Committee expresses its thanks and appreciation to those who are

generously contributing to the success of the 16 th European Congress of Clinical

Microbiology and Infectious Diseases.

Platinum Medal Sponsors Pfizer


Gold Medal Sponsors Bayer HealthCare AG

Merck Sharp & Dohme


Wyeth Pharmaceuticals

Silver Medal Sponsors Astellas



Gilead Sciences


NeuTec Pharma

Sponsors BioMérieux

Bio-Rad Laboratories

Roche Diagnostics

Schülke & Mayr

ESCMID and the ECCMID Programme ISID International Society for Infectious Diseases

Committee are proud to acknowledge Emerging viral exotica in Europe (page 48)

the scientific input from the following

organisations in setting up joint symposia: ICHS International Immunocompromised Host Society

Infections in the immunocompromised host (page 48)

EUPHA European Public Health Association

Molecular epidemiology: a tool for public health

(page 65)

ISF International Sepsis Forum

Pathogenesis and therapy of sepsis (page 60)

ICAAC Programme Committee of the Interscience

Conference on Antimicrobial Agents and


Emergence of transferable quinolone resistance

(page 53)

ASM American Society for Microbiology

Origin, epidemiology, diagnosis and

management of CA-MRSA (page 65)

FEMS Federation of European Microbiological Societies

Mechanisms of infectious diseases:

new science and novel insights (page 43)

page 13


Organising Committee

Pierre Dellamonica

Nice, FR

Congress President

S. Ragnar Norrby

Stockholm, SE

ESCMID President

ESCMID Executive Committee

S.R. Norrby, Stockholm, SE


H. Aubry-Damon, Maisons Alfort, FR

Professional Affairs Officer – Clinical Microbiology

G. Cornaglia, Verona, IT


P. Francioli, Lausanne, CH

Secretary General

J. Garau, Barcelona, ES

Education Officer

Ex officio members

P. Dellamonica, Nice, FR

President 16 th ECCMID

C.E. Nord, Stockholm, SE

Editor CMI Supplements

B. Ruf, Leipzig, DE

President 17 th ECCMID & 25 th ICC

page 14 Final Programme

Peter Schoch

Basel, CH

ESCMID Managing Director

Andreas Voss

Nijmegen, NL

ECCMID Programme Director

E. Nagy, Szeged, HU


R. Read, Sheffield, UK

Professional Affairs Officer -– Infectious Diseases

M. Struelens, Brussels, BE

Past President

J. Vila, Barcelona, ES

Scientific Affairs Officer

A. Voss, Nijmegen, NL

ECCMID Programme Director

P. Schoch, Basel, CH

Managing Director

K. Towner, Nottingham, UK

CMI Editor-in-Chief

National Committee


C. Chidiac, Lyon

J. C. Desenclos, Saint Maurice

L. Gutmann, Paris

ECCMID Programme Committee

A. Voss, Nijmegen, NL

ECCMID Programme Director

G. Cornaglia, Verona, IT

P. Dellamonica, Nice, FR

B. de Pauw, Nijmegen, NL

J.C. Desenclos, Saint Maurice, FR

R. Fouchier, Rotterdam, NL

P. Francioli, Lausanne, CH

J. Garau, Barcelona, ES

ESCMID Education Committee

J. Garau, Barcelona, ES

ESCMID Education Officer

M. Falagas, Athens, GR

R. Filip, Suceava, RO

I.M. Hoepelman, Utrecht, NL

L.M.V. Peixe, Porto, PT

ESCMID Scientific Advisory Committee

J. Vila, Barcelona, ES

ESCMID Scientific Affairs Officer

T. Pal, Pecs, HU

G.-M. Rossolini, Sienna, IT

J. van Eldere, Leuven, BE

V. Jarlier, Paris

O. Lortholary, Paris

J. P. Stahl, Grenoble

C. Hatz, Basel, CH

M. Herrmann, Homburg, DE

V. Jarlier, Paris, FR

R. Leclerc, Caen, FR

S. R. Norrby, Stockholm, SE

R. Read, Sheffield, UK

B. Ruf, Leipzig, DE

M. Struelens, Brussels, BE

A. van Belkum, Leiden, NL

J. Vila, Barcelona, ES

L. Martinez-Martinez, Santander, ES

G. Schmid, Geneva, CH

A. Schwenk, London, UK

G.M. Scott, London, UK

D. Christman, Strasbourg, FR

M. Gniadkowski, Warsaw, PL

R. Canton, Madrid, ES

M. Bonten, Utrecht, NL

T. J. Evans, Glasgow, UK

C. Cordonnier, Paris, FR

A. Widmer, Basel, CH

I. Nilsson-Ehle, Lund, SE

page 15


ESCMID Study Groups Chairpersons

Antibiotic Policies I. C. Gyssens, Rotterdam, NL

Antimicrobial Resistance in Anaerobic Bacteria C.E. Nord, Stockholm, SE

Antimicrobial Resistance Surveillance F. Baquero, Madrid, ES

Clostridium difficile I. R. Poxton, Edinburgh, UK

Epidemiological Markers P. Tassios, Athens, GR

Primary Care Topics T. Verheij, Utrecht, NL

Helicobacter L. Percival Andersen, Copenhagen, DK

Molecular Diagnostics M. Ieven, Edegem, BE

Nosocomial Infections S. Ünal, Ankara, TR

Coxiella, Anaplasma, Rickettsia and Bartonella P. Brouqui, Marseille, FR

Fungal Infection D. Denning, Manchester, UK

Toxoplasmosis B. Evengård, Stockholm, SE

Biofilms N. Høiby, Copenhagen, DK

European Committee on G. Kahlmeter, Växjö, SE

Antimicrobial Susceptibility

Testing (EUCAST)

ESCMID European Council – Representatives of Affiliated Societies

Österreichische Gesellschaft für Infektionskrankheiten H. Pichler, Wien, AS

Belgian Society of Infectious Diseases and J. van Eldere, Leuven, BE

Clinical Microbiology

Croatian Society of Infectious Diseases T. Jeren, Zagreb, HR

Croatian Society for Medical Microbiology and J. Subic-Skrlin, Zagreb, HR

Parasitology-Croatian Medical Association

Czech Society for Epidemiology and Microbiology J. Jelinkova, Prague, CZ

Danish Society for Clinical Microbiology J. Moller, Aarhus, DK

Finnish Society for Infectious Disease Physicians J. Lumio, Tampere, FI

Finnish Society for the Study of Infectious Diseases T. Vuorinen, Turku, FI

Société de Pathologie Infectieuse de Langue Francaise J.-P. Stahl, Grenoble, FR

page 16 Final Programme


Society Française de Microbiologie H. Monteuil, Strasbourg, FR

Deutsche Gesellschaft für Hygiene u. Mikrobiologie M. Frosch, Würzburg, DE

Hungarian Society of Infectiologists L. Rokuskz, Budapest, HU

Irish Society of Clinical Microbiology M. Cormican, Galway, IE

Israeli Society for Infectious Diseases I. Shalit, Petach-Tikvah, IL

Associazione Microbiologi Clinici Italiani G. Fortina, Novara, IT

Italian Society of Virology G. Palù, Padova, IT

Lithuanian Society for Infectious Diseases A. Ambrozaitis, Vilnius, LV

Dutch Society for Medical Microbiology G. J. Ruijs, Zwolle, NL

Netherlands Society for Medical Mycology J. F. Meis, Nijmegen, NL

Norwegian Society of Medical Microbioloy F. Müller, Oslo, NO

Polish Society of Epidemiology and Infectious Diseases J. Cianciara, Warsaw, PO

Polish Society of Microbiology W. Hryniewics, Warsaw, PO

Interregional Association for Clinical Microbiology R. Kozlov, Smolensk, RU

and Antimicrobial Chemotherapy

Slovak Society for Clinical Microbiology D. Kotulova, Bratislava, SR

of the Slovak Medical Association

Slovenian Association of Clinical Microbiology I. Muzlovic, Ljubljana, SI

and Hospital Infections of the SMC

Swedish Society of Infectious Diseases A. Ortqvist, Stockholm, SE

Swedish Society of Medical Microbiology A. Schwan, Uppsala, SE

Swiss Society for Infectious Diseases D. Nadal, Zürich, CH

Infectious Diseases Society of Turkey M. Ceyhan, Ankara, TR

Turkish Society of Clinical Microbiology and H. Eraksoy, Istanbul, TR

Infectious Diseases

Turkish Society for Microbiology Ö. Ang, Istanbul, TR

Association of Medical Microbiologists A. Howard, Cardiff, UK

Scottish Microbiology Association F. MacKenzie, Aberdeen, UK

British Society for Antimicrobial Chemotherapy A. Macgowan, Birmingham, UK

Paul-Ehrlich-Gesellschaft für Chemotherapie P. Kern, Ulm, DE

Scandinavian Society of Antimicrobial Chemotherapy O. Öktedalen, Oslo, NO

page 17

ESCMID Awards 2006

Award for Excellence in Clinical Microbiology

and Infectious Diseases

Roland Leclercq

born 1949 in Paris, France;

MD, PhD, Professor of

Microbiology, Head of the

Department of Microbiology

and of a research group at

the University Hospital of

Caen, France, in recognition

of his outstanding contributions to our

understanding of antimicrobial resistance

mechanisms, especially in Gram-positive

organisms, their epidemiology and clinical

implications. He reported and elucidated

resistance mechanisms to lincosamides,

glycopeptides, aminoglycosides, macrolides

and streptogramins, and demonstrated that

multiresistance in Staphylococcus aureus

from cystic fibrosis patients was due to

hypermutable strains. In addition to being a

successful researcher Roland Leclercq is a

restless and dedicated teacher.

Roland Leclercq will be presented the Excellence

Award by Prof. Ragnar Norrby, ESCMID

President, on April 2, 2006, on which occasion

he will give his award lecture on Resistance to

antimicrobials: from emergence to clinical

relevance (pag 38).

Research Interests

Roland Leclercq’s research focus is on antimicrobial

resistance in Gram-positive organisms.

In particular, he reported the major types of

resistance to glycopeptides in enterococci and

a variety of new mechanisms of resistance to

macrolides and related antibiotics in streptococci

and staphylococci. More recently,

he studied the adaptation of Staphylococcus

aureus to its host via hypermutability and

its influence on antibiotic resistance.

He also participated in the development of

new antimicrobials and anticipated development

of resistance by describing mechanisms

of resistance to some of these drugs in

laboratory-generated mutants. Beyond the

basic aspects of mechanisms of resistance

to antimicrobials, his studies extend to

the clinical relevance of the findings and

epidemiological aspects.

page 18 Final Programme

Young Investigator Award for Research in

Clinical Microbiology and Infectious Diseases

Gilbert Daniel Greub

born 1967 in Neuchatel,

Switzerland; MD, PhD,

researcher at the Institute

of Microbiology, University

of Lausanne, Switzerland,

in recognition of his

outstanding research

accomplishments in the field of Chlamydia-like

organisms. He described for the first time

the developmental cycle of Parachlamydia,

studied the genetic, evolutionary history,

and interactions of this obligate intracellular

organism with amoebae and macrophages,

and demonstrated a role of Parachlamydia

in pneumonia.

Gilbert Greub will be presented his award du -

ring the ESCMID Excellence Award session on

April 2, 2006 (page 38); on April 3, he will give

a talk during the ESCMID Young Investigator

Award session on Biology and Pathogenicity

of Chlamydia-like Organisms (page 52).

Research Interests

Discovering new agents of pneumonia is the

main objective of Gilbert Greub’s research

group. To reach this goal, he uses amoebal

co-culture to selectively grow amoebaeresisting

bacteria, which allows investigation

of their pathogenicity. Gilbert Greub provided

serological and molecular evidence suggesting

a role of Parachlamydia in pneumonia.

He showed that this Chlamydia-like organism

resists to human macrophages. Furthermore,

he demonstrated that Parachlamydia remains

unrecognised by macrophages and is able to

modulate the biogenesis of phagosomes.

He also showed the existence of the crescent

body, an infectious developmental stage only

present in Parachlamydiaceae. Recently, he

discovered a F-like tra operon in a genomic

island on the chromosome of a Parachlamydiarelated

bacteria. This is the first evidence of a

putative conjugative DNA transfer among

obligate intracellular bacteria. Further ongoing

research is directed at elucidating the biology

and pathogenicity of other amoebae-resisting

chlamydiae such as Waddlia and Simkania.

ESCMID Awards 2006

Young Investigator Award for Research in

Clinical Microbiology and Infectious Diseases


Stephan Jürgen Harbarth

born 1967 in Immenstadt,

Germany; MD, MS, Senior

Research Associate,

hospital epidemiologist

and attending physician

at the University Hospital,

Geneva, Switzerland, in

recognition of his outstanding contributions

in the field of infectious disease epidemiology,

focusing on prevention and control of nosocomial

infections and antimicrobial resistance in

hospitals. In addition, he pioneered studies on

the cultural and regulatory factors that influence

antimicrobial use in different countries.

Stephan Harbarth will be presented his award

during the ESCMID Excellence Award session

on April 2, 2006 (page 38); on April 3, he will

give a talk during the ESCMID Young

Investigator Award session on MRSA – from

Innovative Control Strategies to New

Challenges (page 52).

Research Interests

Stephan Harbarth’s research interest is

focused on the epidemiology and prevention

of antibiotic-resistant, healthcare-associated

infections. In particular, his studies on the

impact and control of nosocomial MRSA

transmission have increased our understanding

of the epidemiology of MRSA and improved

our ability to combat this microorganism.

His other important contributions to the field

of antibiotic resistance, which had an impact

on policy making, are his research on the

adverse effects of prolonged antibiotic prophylaxis

after surgery and on the ecologic

bias associated with group-level data analyses

of antibiotic-use-versus-resistance relationships

as well as several well conducted intervention

studies. For instance, in a recently

published article, Stephan Harbarth investigated

the clinical usefulness of a rapid on-admission

screening test for MRSA. A substantial

decrease in MRSA infections was seen in a

medical ICU after increasing compliance with

on-admission screening and implementing

a strategy that linked the rapid test to

pre-emptive isolation of MRSA patients.

Complementary research interests include

the molecular epidemiology of emerging

pathogens such as community-acquired

MRSA, the pharmaco-epidemiology of

antibiotic use (including international analyses

of macro-level determinants of antibiotic

overuse), and improved and rapid diagnosis

of severe infections in critically ill patients.

The Young Investigator Awards are

sponsored by Pfizer

ESCMID and bioMérieux Award for Advances

in Clinical Microbiology

Maja Rupnik

born 1967 in Maribor,

Slovenia; Assistant

Professor at Medical Faculty,

University of Maribor and

at the Institute of Public

Health, Maribor, Slovenia,

in recognition of her

outstanding contributions to our understanding

of the pathogenicity, epidemiology and

genetics of Clostridium difficile.

The toxinotyping scheme, which she developed

for differentiating strains with variant toxin

genes, is used throughout the world.

Maja Rupnik will be presented her award by

Prof Ragnar Norrby, ESCMID President, and

Dr Jean-Pierre Marcel, Medical Director of

bioMérieux, on April 2, during the ESCMID

Excellence Award session (page 38).

Research Interests

The main research focus of the awardee are

two large toxins (toxin A, TcdA and toxin B,

TcdB), both considered as the major virulence

factors of Clostridium difficile. Early research

on variability of the toxin coding region

resulted in establishment of toxinotyping –

a PCR-based method for analysis of entire

PaLoc region. Later, her research focused on

epidemiology of variant C. difficile strains,

in particular on TcdA-negative, TcdB-positive

strains (A - B + strains), and on strains that

produce an additional toxin, binary toxin CDT.

Another aspect of her research interests is the

biology of C. difficile toxins. Here she studied

the proteolytic processing of TcdB and the

crystal structure of receptor-binding regions

of TcdA. She promoted the discussion on the

unification of the nomenclature of C. difficile

toxins. The revised nomenclature is now supported

by all major groups active in the field.

page 19

ESCMID Awards 2006

ESCMID Research Fellowships

The ESCMID Research Fellowships 2006

will be presented during the Assembly

of Members on April 3, at 17:45 in the

Acropolis Congress Centre in Nice,

Room Hermes

Sofia K. Kasiakou

born 1975 in Athens, Greece;

MD, Research Fellow at the

Alfa Institute of Biomedical

Sciences, Marousi, Greece

and Resident in Internal

Medicine at the Sotira

General Hospital, Athens,



A multicentre, randomised, double-blind,

controlled trial of the effectiveness and safety

of intravenous colistin with or without intravenous

meropenem in ICU patients for

infections other than pneumonia due to

colistin-only-sensitive bacteria

Research Interests

The focus of Sofia Kasiakou’s research is on

projects related to the effectiveness and safety

of intravenous and aerosolised polymyxins for

the treatment of patients with multidrugresistant

Gram-negative bacterial infections.

Polymyxin B and polymyxin E (colistin),

the two polymyxins used in clinical practice,

are old antibiotics that were removed from

clinical use for many decades because of

toxicity concerns. However, the emergence

of highly-resistant pathogens brought them

back. In addition, she is interested in the

investigation of alternative modes of intravenous

administration of antibiotics,

specifically the continuous intravenous

infusion of antibiotics with time-dependent

antibacterial activity, in order to optimise

their pharmacokinetic and pharmacodynamic

properties, and thus improve clinical


page 20 Final Programme

Rocus R. Klont

born 1970 in Oldenzaal,

The Netherlands; MD,

Department of Medical

Microbiology, Radboud

University Nijmegen

Medical Centre, Nijmegen,

The Netherlands


Development of a serological system for the

diagnosis of invasive zygomycoses

Research Interests

The main research interest of Rocus Klont

is the development of a non-invasive

diagnostic method for invasive zygomycoses.

The incidence of this disease is increasing.

These moulds cause devastating infections

in the immunocompromised host with high

mortality and morbidity. Aggressive surgery

and treatment with antifungal agents are

required to improve the patients’ outcome.

Conventional diagnostic methods such as

microscopy and culture are not sensitive

enough. Experienced technicians can

indicate if the morphology of mycelia found

in tissue specimens is consistent with

zygomycoses, but identification to genus or

species level cannot be achieved. Recovery

of zygomycetes from tissue by culture can

be very difficult even in those cases where

hyphae are visible under the microscope.

The development of a non-invasive

diagnostic technique such as the detection

of circulating zygomycete antigens may

result in earlier diagnosis of the disease

and improve clinical outcome.

ESCMID Awards 2006

ESCMID / FEMS Research Fellowship

ESCMID and FEMS offer each year two joint

fellowships to foster outstanding research in

microbiology by young Europeans. We are

delighted to announce that the 2006 ESCMID /

FEMS fellowship goes to Surbi Malhotra-

Kumar from Antwerp, The Netherlands.

Surbi Malhotra-Kumar

born 1972 in Sirsa, India; MD,

PhD, post-doctoral fellow,

Belgian Reference Centre

for Group A Streptococcus,

Department of Medical

Microbiology, University of

Antwerp, Belgium


Analysis of novel genetic elements and

resistance mechanisms, fitness costs and

compensatory adaptations in macrolide-,

ketolide-, and fluoroquinolone-resistant

Group A Streptococcus

Research Interests

The research of Surbhi Malhotra-Kumar is

focused on the molecular epidemiology and

genetics of resistance to the macrolide-,

ketolide-, and fluoroquinolone group of

antimicrobials in oral streptococci, primarily

Group A Streptococcus (GAS). Using the

oro-pharyngeal flora in healthy individuals

as a model, Surbhi Malhotra-Kumar has also

analysed differences in selection pressure of

various macrolides and the resulting impact

on resistance. Continuing as a post-doctoral

fellow in the laboratory of Herman Goossens,

her current work includes: further analysis

of novel and emerging genetic elements

harboring macrolide resistance gene mutants,

elucidating the basis of ketolide resistance

in GAS, and the fitness costs of antibiotic

resistance gene carriage.

ISF Sepsis Award

Evangelos J. Giamarellos-


born 1971 in Athens, Greece;

MD, Assistent Professor of

Medicine at the Department

of Internal Medicine, Attikon

University Hospital, Athens,

Greece, in recognition of his

excellent abstract submitted for presentation at

the 16 th ECCMID.

Evangelos Giamarellos-Bourboulis will give a

short oral presentation on Blood monocytes

as a site of production of sTREM-1 in sepsis

during the joint ESCMID/ISF symposium

on Pathogenesis and Therapy of Sepsis

(page 60).


The pathophysiological role of blood

monocytes for the release of soluble triggering

receptor expressed on myeloid cells – 1

(sTREM-1) in patients with sepsis

E.J. Giamarellos-Bourboulis, C. Routsi,

D. Plachouras, I. Andrianakis, M. Raftogiannis,

C. Roussos, H. Giamarellou (Athens, GR)

Objective: sTREM-1 is the soluble counterpart

of the surface receptor TREM-1 that is highly

expressed on neutrophils and mature monocytes

after bacterial and fungal triggering. The

exact site of production of sTREM-1 remains

unclear. The present study aimed at investigating

the role of monocytes in the release

of sTREM-1 in patients with sepsis and its

correlation with monocyte apoptosis.

Methods: Peripheral blood monocytes

were isolated from 90 patients with septic

syndrome due to ventilator-associated pneumonia

on seven consecutive days after

presentation of sepsis, by density gradient

centrifugation of whole blood, incubation

in RPMI and removal of non-adherent cells.

Apoptotic rate on the first day was measured

by flow cytometry after incubation with

FITC-conjugated monoclonal antibodies to

Annexin-V and Propidium Iodide. Monocytes

were cultured in the absence and presence

of LPS and concentrations of sTREM-1 in

supernatants were estimated by an enzyme


page 21

ESCMID Awards 2006

ISF Sepsis Award (continued)

Results: Concentrations of sTREM-1 in

supernatants of isolated monocytes were

higher on the first day compared to the next

six days (a: p

Free Registration

ESCMID Awards 2006

Acosta Herrera, Belsy (Havana, CU)

Alecu, Florian Silviu (Bucharest, RO)

Allen, Vanessa (Toronto, CA)

Ambrasiené, Daiva (Kaunas, LT)

Ansari, Nasim Akhtar (New Delhi, IN)

Artemenko, Anatoly (Odessa, UA)

Balabanova, Yanina (London, UK)

Banasova, Katarina (Bratislava, SK)

Bartels, Mette Damkjaer (Hvidovre, DK)

Bednarova, Jana (Brno, CZ)

Berglund, Carolina (Örebro, SE)

Bourgeois-Nicolaos, Nadège (Paris, FR)

Bühling, Anke (Magdeburg, DE)

Castanheira, Mariana (Sao Paulo, BR)

Chanana, Vishal (Chandigarh, IN)

Christova-Tzvetanova, Iva Stefanova (Sofia, BG)

Comina, Elodie (Villeurbanne, FR)

Corrente, Marialaura (Valenzano, IT)

Dumitru, Irina (Constanta, RO)

Eisner, Alexandra (Graz, AT)

Ensor, Vicki (Birmingham, UK)

Faria, Nuno Alexandre Gomes (Oeiras, PT)

Foster, Niki Francis (Nedlands, AU)

Giotis, Efstathios (Belfast, IE)

Golkocheva, Elica (Sofia, BG)

Gonzalez-Zorn, Bruno (Madrid, ES)

Gosiewski, Tomasz (Cracow, PL)

Groussaud, Pauline (New Haw, Addlestone, UK)

Gupta, Vineet (New Delhi, IN)

Habibi, Effat (Teheran, IR)

Ikonomidis, Alexandros (Volos, GR)

Ilhan-Sungur, Esra (Istanbul, TR)

Jafari, Fereshteh (Tehran, IR)

Jashiashvili, Nino (Tbilisi, GE)

Jenkins, Claire (London, UK)

Kachanka, Elena (Minsk, BY)

Kardos, Gabor (Debrecen, HU)

Kocak Tufan, Zelina (Ankara, TR)

Kratzer, Christina (Vienna, AT)

Lochmanova, Jana (Brno, CU)

Machado, Ines (Gaia, PT)

Mahmutovic, Sabina (Sarajevo, BA)

Manolescu, Loredana (Bucharest, RO)

Markovska, Rumyana (Sofia, BG)

Maszewska, Agnieszka (Lodz, PL)

Muratov, Eugene (Odessa, UA)

Novais de Oliveira e Silva, Carla Alexandra

(Sra. Da Hora, Matosinhos, PT)

Orsolya, Dobay (Budapest, HU)

Papadopo ulos, Chelsea (Balcatta, AU)

Pinidiyapathirage, Mohitha Janani (Colombo, LK)

Popa, Mihaela (Bucharest, RO)

Popov, Dmitry A. (Moscow, RU)

Pubaibool, Jakrapun (Bangkok, TH)

Pujate, Elina (Jurmala, LT)

Raka, Lul (Kacanik, CS)

Ramazanzadeh, Rashid (Teheran, IR)

Rocha, Joana (Porto, PT)

Ruiz Blazquez, Joaquim (Badia del Valles, ES)

Schaffer, Kirsten (Dublin, IE)

Shahid, Mohammad (Aligarh, IN)

Torzewska, Agnieszka (Lodz, PL)

Türetgen, Irfan (Istanbul, TR)

Türk, Silver (Tartu, EE)

Uckay, Ilker Hasan (Geneva, CH)

Weiner, Marcin (Pulawy, PL)

Zidovec Lepej, Snjezana (Zagreb, HR)

page 23

Introduction to the Scientific Programme

Educational Workshops

Once again at the beginning of ECCMID on

Saturday, April 1, 2006, 13.30–15.30/17.30,

several educational workshops have been

organised in cooperation with ESCMID Study

Groups. Please note that educational workshops

are subject to a separate registration

fee and that places are limited.

Meet-the-Expert Sessions

Sunday through to Tuesday the day will start

at 07.15 with 6 Meet-the-Expert Sessions

given by experts in their field. These sessions

permit the attendees to participate actively.

After a short presentation the expert will

open the session for discussion.

Coffee will be offered.

Keynote and ESCMID Award Lectures

At 11.00 each morning, lectures of 60 min will

be given by opinion leaders in their fields as

well as by the winners of the ESCMID Award

for Excellence 2006 and the two ESCMID

Young Investigator Awards.


From 08.30–10.30, from 14.00–15.00 and from

15.30–17.30 each day, parallel symposia will

convene renowned speakers from Europe and

other continents who will cover a wide range

of recent developments in their field.

A number of symposia have been organised

in co-operation with ESCMID study groups

and some are joint sessions with other

societies or organisations.

Symposia arranged by the industry have been

organised in close co-operation with the

ECCMID Programme Committee. They are

an integral part of the scientific programme

(Integrated Symposia) or presented as a

Satellite Symposium on Saturday afternoon.

Oral Sessions

During the same time slots as the above

mentioned symposia, you will also find

sessions composed of abstracts selected for

oral presentation, to be recognised by the prefix

«O» before the programme numbers.

Poster Sessions

Most of the accepted abstracts are scheduled

for poster presentation from Sunday to

Tuesday. The selection was based on a blind

review by at least 3 experts in each field.

The posters will be displayed on level 3.

page 24 Final Programme

The poster exhibition is open to all participants

from 08.00 to 18.00. Please note that

posters are replaced daily. Poster authors

must be present at their posters for

discussion between 12.00 and 13.00 or

13.00 and 14.00, depending on the schedule

of their session (see page 25 for details).

Guided Poster Walks

Once again at ECCMID, guided poster walks

on selected topics will take place over lunch

time. For further details please see pages 40,

52, 53 and 64.

Publication Only

Due to the overwhelming response to the

call for abstracts, ESCMID was unable to

accommodate all worthy abstracts for

presentation during the meeting. Abstracts

in this category are not included in the

Final Programme but will be published on

the CD-ROM and the congress website.


All accepted abstracts have been published as

an electronic supplement to Clinical Microbiology

and Infection (CMI), the official journal of

the European Society of Clinical Microbiology

and Infectious Diseases. For the first time in

2006, accepted abstracts are made available

to participants on CD-ROM only. No printed

abstract book will be distributed. In addition,

the CD will also include most of the full

posters (sponsored by Schering-Plough).

On-line Meeting Planner on the 16th ECCMID


The final scientific programme including all

accepted abstracts is available at the congress


Go to link «scientific programme» to compose

your personalised programme of lectures.

You can use the search facility to find

keywords, speakers and chairpersons.

The internet corner is located on level 2 in the

industrial exhibition.

For your clarification, the following prefixes have been

used throughout the programme:

E=Meet-the-Expert Session K=Keynote Lecture

S=Symposium O=Oral Session P=Poster Session

Instructions for Authors

Audiovisual Equipment /

Speakers Service Centre (SSC)

The Speakers Service Centre (SSC) is centrally

located on Level 2 of the Nice Acropolis Congress

Centre (please refer to the overview on page 7).

All lecture rooms will be equipped with a PC

and a data projector for PowerPoint presentations

only. Presentations must be handed in

via floppy disk, CD-ROM, zip drive, memory

stick or via your own laptop before your


It is essential for the smooth running of the

congress that all speakers hand in their Power

Point presen tations at least one hour before

the beginning of the session. Enough time

must be allowed to check the presentation

carefully and for the staff to enter the data into

the system. Speakers will have the opportunity

to check their presentations on PC’s available

in the SSC.

Poster Sessions


All accepted abstracts will be published as an

electronic supplement to Clinical Microbiology

and Infection (CMI), the official journal of

ESCMID. This year, accepted abstracts will be

made available to the participants for the first

time on CD-ROM only. No abstract book will

be distributed. In addition, the CD will also

include most of the full posters!

Please take advantage of the on-line meeting

planner facility available on the computers

in the @-corner (level 2).

Date of Poster Session Poster No Poster Poster Poster

Mounting Presentation Removal

Sunday, April 2, 2006 (I) P441–P678 08.00–09.00 12.00–13.00 17.00–18.00

Sunday, April 2, 2006 (II) P679–P940 08.00–09.00 13.00–14.00 17.00–18.00

Monday, April 3, 2006 (III) P941–P1197 08.00–09.00 12.00–13.00 17.00–18.00

Monday, April 3, 2006 (IV) P1198–P1459 08.00–09.00 13.00–14.00 17.00–18.00

Tuesday, April 4, 2006 (V) P1460–P1884 08.00–09.00 12.00–13.00 15.00–16.00

The poster measurement is: width: 147 cm; height: 97 cm. Posters will be displayed for one full day. Authors

are requested to be present at their poster during the whole time of the poster presentation and to mount and

remove their posters at the above-mentioned times.

Posters that have not been removed by the author at 18.00 are removed and disposed of by the congress staff.

Poster Walks

Once again at ECCMID, guided poster walks

on selected topics will take place over lunch

time. During each of the above poster sessions

certain abstracts will be presented in a

moderated poster walk. Chairpersons will

select quality posters on the day and discuss

these in more detail. For further details please

see pages 40, 52 and 64.

page 25

Saturday, April 1, 2006

Calliope EUCAST National Committees and

10:30–12:30 General Committee Meeting


Room 2


ESCMID Study Group and other Business Meetings

Publications Advisory Board

Press Centre Press Conference


Calliope EUCAST Business Meeting


Erato ESCMID Study Group on Coxiella, Anaplasma,

13:30–14:30 Rickettsia and Bartonella (ESCAR)

Erato ESCMID Fungal Infection Study Group (EFISG)


Hotel Sofitel ESCMID European Council



Room 1



Room 2


ESCMID Study Group on Primary Care Topics


ESCMID Study Group on Molecular

Diagnostics (ESGMD)

Athena ESCMID Study Group on Epidemiological

16.45–17.45 Markers (ESGEM)

Méditerranée 1 ESCMID Study Group on Antimicrobial

16:45–17:45 Resistance in Anaerobic Bacteria (ESGARAB)

Méditerranée 3 ESCMID Study Group on Toxoplasmosis

16:45–17:45 (ESGT)


Room 1



Room 2


ESCMID Study Group on Clostridium difficile


ESCMID Study Group for Antimicrobial

Resistance Surveillance (ESGARS)

Méditerranée 2 ESCMID Study Group on Nosocomial

17:15–17:45 Infections (ESGNI)

Iris ESCMID Study Group on Biofilms (ESGB)


page 26 Final Programme

Clio ESCMID Study Group on Antibiotic Policies

17:15–17:45 (ESGAP)

Calliope European Helicobacter Study Group (EHSG)



Room 3



Room 3



Room 1



Room 1

Sunday, April 2, 2006

CMI Editorial Meeting

ESCMID Education Committee

IFAR Business Meeting

Monday, April 3, 2006

ESCMID Scientific Affairs Meeting

11:00–14:00 Scientific Advisory Committee

12:00–14:00 Study Group Chairs

Erato ECCMID Sponsors Meeting


Hermes ESCMID Assembly of Members


Scientific Programme Saturday, April 1, 2006

Educational Workshops *

Méditerranée 3 Current control measures for Toxoplasma

W1 13:30– infection in pregnant women and newborn

15:30 children

Convenor: Eskild Petersen (Aarhus, DK)


Eskild Petersen (Aarhus, DK)

Rodolphe Thiébaut (Bordeaux, FR)

Ruth Gilbert (London, UK)


Efficacy of pre- and postnatal treatment

The SYROCOT study:

a meta-analysis of 2000 Toxoplasma infected

pregnant women and their children

The size of the problem in Europe and how do

we control Toxoplasma infections in the future?

Is there a role for Toxoplasma-free food?

ESCMID Study Group on Toxoplasmosis (ESGT)

Athena Practical and theoretical aspects of sequence-

W2 13:30– based typing: the paradigms of Staphylococcus

15:30 aureus and Streptococcus pyogenes

Convenor: Alexander Friedrich (Munster, DE)


Alexander Friedrich (Munster, DE)

Wofgang Witte (Wernigerode, DE)

Shona Neal (London, UK)

Alexander Mellmann (Munster, DE)


spa typing of S. aureus

stability of DNA repeats

nucleotide differences occurring within repeats –

and how these affect interpretation of types

SCCmec typing of MRSA

emm typing of S. pyogenes

DNA sequence chromatogram editing

nucleotide differences vs. amino-acid differences

definition of identical vs. non-identical isolates

ESCMID Study Group on Epidemiological

Markers (ESGEM)

* All Educational Workshops are subject to separate registration.

Méditerranée 2 Management of nosocomial infections –

W3 13:30– learning from clinical cases

15:30 Convenor: Christian Ruef (Zurich, CH)


Marc Bonten (Utrecht, NL)

Christian Ruef (Zurich, CH)

Andrej Trampuz (Basel, CH)


Infections associated with intravascular devices

Surgical site infections after implant surgery

Ventilator-associated pneumonia

ESCMID Study Group on Nosocomial

Infections (ESGNI)

Méditerranée 1 Quality control and standardisation in

W4 13:30– molecular diagnostics

15:30 Convenor: Margareta Ieven (Antwerp, BE)


Hubert G.M. Niesters (Rotterdam, NL)

Paul Wallace (Glasgow, UK)

Anton M. van Loon (Utrecht, NL)


International standards: the use and utility of


QC within the clinical molecular microbiology

laboratory: controls, compliance & traceability

Improving molecular diagnostics through

international EQAS: a review of progress

over the last decade

Alternative approaches to QC and improving

molecular diagnostics in the routine clinical

diagnostic laboratory

ESCMID Study Group on Molecular Diagnostics

(ESGMD) and QCMD page 27

Instant protection

against waterborne



Water Filters

● New 14 day protection

for shower and tap

● Safeguarding patients

in hospital and the home

● Cost effective solution




Quick connection • Quick protection

Filtration. Separation. Solution. SM

Walton Road

Portsmouth PO6 1TD


+44 (0)23 9230 3452 tel

+44 (0)23 9230 3324 fax e-mail

, Pall and Pall-Aquasafe are trade marks of Pall Corporation.

Scientific Programme Saturday, April 1, 2006

Iris Antibiotic resistance of microbial biofilms

W5 13:30–

15:30 Convenor: Niels Høiby (Copenhagen, DK)


Peter Gilbert (Manchester, UK)

Michael Givskov (Copenhagen, DK)

Christine Imbert (Poitiers, FR)


Molecular biological methods to study bacterial

biofilms in flow cells

Interaction of conventional and biofilm-related

resistance mechanisms in bacteria

Physiology aspects on resistance to antibiotics

of bacterial biofilms

Quorum sensing inhibitors and bacterial


Activity of new antimicrobials on fungal biofilms

ESCMID Study Group on Biofilms (ESGB)

Hermes Pharmacokinetics and pharmacodynamics of

W6 13:30– anti-infective agents

17:30 Convenor: Johan W. Mouton (Nijmegen, NL)


William A. Craig (Madison, US)

Hartmut Derendorf (Gainesville, US)

Ursula Theuretzbacher (Vienna, AT)

Otto Cars (Uppsala, SE)

Inga Odenholt (Malmö, SE)

Paul M. Tulkens (Brussels, BE)


Introduction to PK/PD

PK/PD indices

Protein binding/tissue distribution

In vitro models

Animal models

PK/PD and resistance

Clinical applications of PK/PD

Arranged by the International Society of

Anti-infective Pharmacology (ISAP) and ESCMID


Room 3

European surveillance of nosocomial

infections, antimicrobial resistance and use

W7 13:30– in Intensive Care Units

17:30 Convenor: Jean Carlet (Paris, FR)


Barry Cookson (London, UK)

Hakan Hanberger (Linköping, SE)

Patricia Muñoz (Madrid, ES)

Mercedes Palomar (Barcelona, ES)

Carl Suetens (Brussels, BE)

Peet Tull (Stockholm, SE)


Surveillance of ICU-acquired infections in

Europe: overview of methodology, tools and

results of the HELICS-ICU surveillance network

How and when to use typing to support

infection control practices in the ICU

Unit-based surveillance of AMR and antibiotic

use in the ICU

HELICS case definition of ICU-acquired

pneumonia I: diagnosis in the ICU (invasive

diagnostic procedures vs. ETA)

HELICS case definition of ICU-acquired

pneumonia II: microbiology (quantitative

culture of respiratory samples – invasive BAL,

PB and non-invasive ETA)

ECDC response to and action plan for the

Clostridium difficile ribotype 027 epidemic in


Arranged by IPSE (Improving Patient Safety in

Europe) WP4 (HELICS) and WP5 in collaboration

with ESGNI and ESGARS page 29

While attending the 16 th European Congress of Clinical Microbiology and Infectious

Diseases, you are cordially invited to attend a satellite symposium entitled:









13:30 – 15:30

To register for this particular symposium,

please visit us online at:


Dr. Axel Glasmacher

Asst. Professor of Medicine

University of Bonn

Bonn, Germany

Dr. Jean-Pierre Marie

Head, Department of Haematology-Medical Oncology

Hotel-Dieu Hospital


Cedex France


Prof. Robin Williamson

Dean, The Royal Society of Medicine

London, England

Dr. Murat Akova

Professor of Medicine

Hacettepe University School of Medicine

Ankara, Turkey

Dr. David Weber

Professor of Medicine -

Pediatrics and Epidemiology

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, USA



Prof. Robin Williamson (Royal Society of


Introductions & Program Overview

Dr. Jean-Pierre Marie (Co-Chair)

Review of Resistance Patterns Over Time

with an Emphasis on Problem Pathogens

Dr. Murat Akova

An Evidence Based Review of the Available

Antibiotic Treatment Options and a

Recommendation for Treatment Guidelines

Dr. Axel Glasmacher (Co-Chair)

Collateral Damage and What the Future

Might Hold—The Need to Balance Prudent

Antibiotic Utilization and Stewardship with

Effective Patient Management

Dr. David Weber


Dr. Jean-Pierre Marie (Co-Chair & Moderator)

Sponsored by The Royal Society of Medicine

by an unrestricted educational grant from Wyeth Pharmaceuticals.

Satellite Symposia

Scientific Programme Saturday, April 1, 2006

Clio The management of neutropenic patients

13:30– with fever undergoing chemotherapy for the

15:30 treatment of haematological malignancies –

yesterday, today and tomorrow

Chairpersons: Jean-Pierre Marie (Paris, FR)

Axel Glasmacher (Bonn, DE)

13:30 Greeting

Introductions and programme overview

Robin Williamson (London, UK)

S1 Review of resistance patterns over time

13:40 with an emphasis on problem pathogens

Murat Akova (Ankara, TR)

S2 An evidence-based review of the available

14:10 antibiotic treatment options and a

recommendation for the treatment guidelines

Axel Glasmacher (Bonn, DE)

S3 Collateral damage and what the future might

14:40 hold – the need to balance prudent antibiotic

utilisation and stewardship with effective

patient management

David Weber (Chapel Hill, US)

15:10 Q & A

Moderator: Jean-Pierre Marie (Paris, FR)

Wyeth Pharmaceuticals satellite symposium

Apollon Evidence and experience: the role of

15:30– echinocandins in the management of invasive

17:30 fungal infections

Chairperson: Bertrand Dupont (Paris, FR)

15:30 Welcome and opening remarks

Bertrand Dupont (Paris, FR)

S4 Susceptibility, spectrum and methodology for

15:35 antifungal agents

David Perlin (Newark, US)

S5 Echinocandins for documented fungal

16:00 infections

Claudio Viscoli (Genoa, IT)

S6 Echinocandins for suspected fungal infections

16:25 Thierry Calandra (Lausanne, CH)

S7 Beyond the horizon: caspofungin

16:50 clinical update

Carole Sable (Rahway, US)

17:15 Panel discussion

17:25 Closing remarks

Bertrand Dupont (Paris, FR)

Merck, Sharpe & Dohme satellite symposium


Athena Dendograms in microbial phylogenetics and

15:45– epidemiological typing

16:45 Chairpersons: Paul Vauterin (Rochester, US)

Panayotis Tassios (Athens, GR)

S8 Evolutionary trees in microbiology

15:45 Barry Hall (Bellingham, US)

S9 Representations of strain similarities in

16:15 molecular microbial typing

Paul Vauterin (Ghent, BE)

Symposium arranged with the ESCMID Study

Group on Epidemiological Markers (ESGEM)

Méditerranée 1 Antimicrobial resistance in anaerobic bacteria.

15:45– Experiences in Europe and North America


Chairpersons: Carl Erik Nord (Stockholm, SE)

Ellie J.C. Goldstein

(Santa Monica, US)

S10 Is antimicrobial resistance a clinical problem

15:45 in North America?

Ellie J.C. Goldstein (Santa Monica, US)

S11 Antimicrobial susceptibility patterns in

16:15 different European countries

Elisabeth Nagy (Szeged, HU)

Symposium arranged with the ESCMID Study

Group on Antimicrobial Resistance in Anaerobic

Bacteria (ESGARAB) and the Anaerobic Society

of the Americas

Méditerranée 2 Pathogenesis and prevention of nosocomial

15:45– infections – new aspects

17:15 Chairpersons: Serhat Ünal (Ankara, TR)

Marc Bonten (Utrecht, NL)

S12 Infections associated with intravascular

15:45 devices

Bart Rijnders (Rotterdam, NL)

S13 Surgical site infections after implant

16:15 surgery: a diagnostic and therapeutic


Andreas Widmer (Basel, CH)

S14 Ventilator-associated pneumonia

16:45 Wolfgang Krüger (Tubingen, DE)

Symposium arranged with the ESCMID Study

Group on Nosocomial Infections (ESGNI) page 31

Scientific Programme Saturday, April 1, 2006

Méditerranée 3 News in the field of toxoplasmosis


16:45 Chairpersons: Birgitta Evengård (Stockholm, SE)

Francis Derouin (Paris, FR)

S15 Past, present and future drug treatment

15:45 of Toxoplasma gondii

Francis Derouin (Paris, FR)

S16 Detection and genotyping of Toxoplasma

16:15 gondii by real-time PCR and pyrosequencing

Benjamin Edvinsson (Stockholm, SE)

Symposium arranged with the ESCMID Study

Group on Toxoplasmosis (ESGT)

Iris How to prevent microbial biofilm formation

15:45– on medical devices

17:15 Chairpersons: Niels Høiby (Copenhagen, DK)

Gianfranco Donelli (Rome, IT)

S17 Analogues of natural signal molecules as

15:45 promising antibiofilm drugs

Michael Givskov (Copenhagen, DK)

S18 Drug releasing polyurethanes able to inhibit

16:15 microbial biofilm growth on medical devices

Gianfranco Donelli (Rome, IT)

S19 Candida biofilm formation on implanted

16:45 medical devices

Christine Imbert (Poitiers, FR)

Symposium arranged with the ESCMID Study

Group on Biofilms (ESGB)

Clio Antimicrobial utilisation in Europe:

15:45– future directions

17:15 Chairpersons: Inge C. Gyssens (Rotterdam, NL)

Barry Cookson (London, UK)

S20 Mapping antibiotic consumption and

15:45 resistance in the community

Maggie Heginbothom (Cardiff, UK)

S21 Can we and how do we benchmark antibiotic

16:15 consumption in hospitals?

Dominique L. Monnet (Copenhagen, DK)

S22 Point-prevalence surveys of anti-infective use

16:45 Bryony Dean Franklin (London, UK)

Symposium arranged with the ESCMID Study

Group on Antibiotic Policies (ESGAP)

page 32 Final Programme

Erato Nosocomial mould infections


17:45 Chairpersons: David Denning (Manchester, UK)

Manuel Cuenca-Estrella (Madrid, ES)

S23 Current recommendations for the prevention

15:45 of nosocomial infection: are they applicable

to moulds?

Rosemary Barnes (Cardiff, UK)

S24 Source of moulds in the hospital setting

16:15 Jean-Pierre Gangneux (Rennes, FR)

S25 Post-operative aspergillosis

16:45 Alessandro Pasqualotto (Manchester, UK)

S26 Nosocomial infections due to emerging

17:15 moulds

Manuel Cuenca-Estrella (Madrid, ES)

Symposium arranged with the ESCMID Fungal

Infections Study Group (EFISG)

Calliope Guidelines for Helicobacter pylori

15:45– infections revisited. The Maastricht-3 2005

17:15 consensus report

Chairpersons: Klaus Mönke-Müller

(Magdeburg, DE)

Francis Mégraud (Bordeaux, FR)

S27 Indications for H. pylori eradication revisited

15:45 Ernest Kuipers (Rotterdam, NL)

S28 Diagnosis and treatment of resistant

16:15 H. pylori infection

Francis Mégraud (Bordeaux, FR)

S29 Prevention of gastric cancer by H. pylori

16:45 eradication

Klaus Mönke-Müller (Magdeburg, DE)

Symposium arranged with the European

Helicobacter Study Group (EHSG)

Scientific Programme Sunday, April 2, 2006

Meet-the-Expert Sessions

Méditerranée 2 Laboratory diagnosis of invasive

E30 fungal infections

07:15– Experts: Emmanuel Roilides (Thessaloniki, GR)

08:15– Olivier Lortholary (Paris, FR)


– to discuss different methods (microbiological,

serological, radiological, molecular and

histological) to diagnose invasive fungal


– to provide examples of difficult cases of

invasive fungal infections and emphasise

the roles of different methods of laboratory


– to discuss laboratory criteria for defining a

case as definite or probable

Méditerranée 3 Current issues in the treatment of HBV-HIV

E31 co-infected patients

07:15– Experts: Dominique Salmon-Ceron (Paris, FR)

08:15 Will Irving (Nottingham, UK)


– to present case histories on the current

therapeutic issues for patients who need

HBV treatment but who do not need HAART

– to discuss the virological follow-up of

patients treated for both HIV and HBV

Iris What is the role of serology in pregnancy?

E32 Experts: Birgitta Evengård (Stockholm, SE)

07:15– Babill Stray-Pedersen (Oslo, NO)



– to discuss the importance of infections

for maternal and child health in Europe

– to define indications for screening for

toxoplasmosis and other infections during


– to present handling schemes for prevention

of mother-to-child transmission

– to discuss identification of infected mother

and offspring

Hermes Travel medicine and evidence-based

E33 recommendations

07:15– Experts: Alfons van Gompel (Antwerp, BE)

08:15 Christoph Hatz (Basel, CH)


– to provide background information for

rational advice on malaria prevention

– to define indications for travel-related


– to arrive at standardised “informed


– to provide a web-based differential diagnosis

programme to assess fever after return from

tropical and subtropical countries

Clio Surveillance of newly emerging pathogens

E34 and public health responses

07:15– Experts: Maxwell Hardiman (Geneva, WHO)

08:15 Johan Giesecke (Stockholm, ECDC)


– to implement Annex 1 of the new International

Health Regulations –

what action is needed in Europe?

– to analyse alternative/novel surveillance


– to discuss what surveillance is needed in an

established flu pandemic – different tools

from those used for “normal” flu?

– to assess surveillance for newly emerging

resistant strains (e.g. C. difficile)

Erato How to diagnose and treat diabetic foot

E35 infections?

07:15– Experts: Anthony Berendt (Oxford, UK)

08:15 Eric Senneville (Tourcoing, FR)


– to describe optimal diagnostics approaches

– to discuss pathogens involved in diabetic

foot infection and their susceptibility to


– to provide the evidence for appropriate

(empirical) treatment page 33


Scientific Programme Sunday, April 2, 2006

Apollon New diagnostic techniques for the

08:30– microbiological laboratory and general

10:30 practitioner

Chairpersons: Marc Struelens (Brussels, BE)

Roland Leclercq (Caen, FR)

S36 Breakthroughs in bacterial detection,

08:30 identification and typing

Marc Struelens (Brussels, BE)

S37 Progress in detection of bacteria responsible

08:50 for infections in challenging clinical situations

and of antimicrobial resistance

Roland Leclercq (Caen, FR)

S38 Molecular diagnostics in virology, overcoming

09:10 the hurdles

Hubert G.M. Niesters (Rotterdam, NL)

S39 Parasitology

09:30 t.b.c.

S40 Mycology

09:50 Emmanuel Roilides (Athens, GR)

Méditerranée 2 Neurological sequelae of bacterial

08:15– and viral infections

10:30 Chairpersons: Christian Chidiac (Lyon, FR)

Diederik van de Beek

(Amsterdam, NL)

S41 Campylobacter-induced Guillain-Barré

08:30 syndrome

Hubert P. Endtz (Rotterdam, NL)

S42 The involvement of Chlamydia pneumoniae

09:00 in multiple sclerosis

Enrico Fainardi (Ferrara, IT)

S43 Neurological complications of reactivated

09:30 varicella-zoster virus infection

Tomas Bergström (Göteborg, SE)

S44 Possible viral aetiology of multiple sclerosis

10:00 Peter G.E. Kennedy (Glasgow, UK)

Hermes Evolution of beta-lactamases


10:30 Chairpersons: Giuseppe Cornaglia (Verona, IT)

Patrice Nordmann (Paris, FR)

S45 Environmental bacteria as a reservoir for

08:30 newer beta-lactamases

Patrice Nordmann (Paris, FR)

S46 CTX-M beta-lactamases: the molecular story

09:00 of a clinical success in community and hospital

Rafael Cantón (Madrid, ES)

page 34 Final Programme

S47 The role of integrons in the spread of

09:30 beta-lactamases

Gian Maria Rossolini (Siena, IT)

S48 Evolution in class A beta-lactamases: tuning

10:00 between substrate range and hydrolysis


Marek Gniadkowski (Warsaw, PL)

Oral Sessions

Méditerranée 3 Quinolone resistance and efflux


10:30 Chairpersons: Emmanuelle Cambau (Paris, FR)

Vincent Jarlier (Paris, FR)

O49 Mini state-of-the-art-lecture on quinolones

08:30 Emmanuelle Cambau (Paris, FR)

O50 Type II topoisomerase mutations in

08:54 Enterobacter cloacae clinical isolates

harbouring QNR and implication for

quinolone resistance

E. Cambau, C. Lascols, J. Robert, V. Cattoir,

V. Jarlier, C.J. Soussy (Creteil, Paris, FR)

O51 Emergence of plasmid-mediated quinolone

09:06 resistance QnrS determinant in

enterobacterial isolates in Europe

L. Poirel, C. Leviandier, P. Nordmann

(Le Kremlin Bicetre, FR)

O52 Detection of QnrS in clinical isolates of

09:18 Enterobacter cloacae in Spain

M.E. Cano, J.M. Rodríguez-Martínez, J. Agüero,

A. Pascual, J.M. García-Lobo, C. Velasco,

L. Martínez-Martínez (Santander, Seville, ES)

O53 Determination of the QNR – DNA gyrase

09:30 interaction site by a genetic approach

A. Cesaro, V. Cattoir, C. Lascols, C.J. Soussy,

E. Cambau (Creteil, FR)

O54 Putative implication of YceE (transporter

09:42 protein) and ompN (porin) in the resistance to

quinolones in Escherichia coli

A. Fabrega, J. Sanchez-Cespedes, M.M. Tavio,

M. Ruiz, J. Vila (Barcelona, Las Palmas, ES)

O55 Potential of fluoroquinolones to induce

09:54 the expression of the acrAB efflux pump

and the global regulator marA in

Salmonella hadar

S. Schmidt, P. Heisig (Hamburg, DE)

O56 Horizontal gene transfer contributes to

10:06 fluoroquinolone resistance in Streptococcus


C.B. Duesberg, S. Malhotra-Kumar, T. Welte,

H. Goossens, M.W.R. Pletz (Hannover, DE;

Antwerp, BE)

Scientific Programme Sunday, April 2, 2006

O57 New mutation at the position 81 in GyrA

10:18 in clinical strains of Mycobacterium

tuberculosis resistant to quinolone:

report of two clinical cases and functional

analysis of DNA gyrase mutant enzymes

S. Matrat, N. Veziris, V. Jarlier, E. Cambau,

C. Truffot-Pernot, J. Camuset, E. Bouvet,

A. Aubry (Paris, Créteil, Argenteuil, FR)

Iris Viruses and viral diagnostics


10:30 Chairpersons: Ron Fouchier (Rotterdam, NL)

Françoise Brun-Vézinet (Paris, FR)

O58 HCMV infects and replicates in the adrenal

08:30 gland

M. Trevisan, G. Masi, R. Cusinato, K. Fincati,

A. Loregian, G. Palù, L. Barzon (Padua, IT)

O59 Simultaneous detection of the human

08:42 cytomegalovirus DNA and RNA by

targeting the UL73/74 gene region using

multiplex real-time polymerase chain

reaction assays

Y.-J. Chan, J.-C. Lin, C.-H. Tsai, W.-S. Weng,

D.M-T. Ho (Taipei, TW)

O60 Prospective comparison of real-time

08:54 quantitative PCR on blood with rapid culture

of urine and throat samples for monitoring

cytomegalovirus infection in hematopoietic

stem cell transplant recipients

I. Thoelen, W. Laffut, K. Van Vaerenbergh,

M. Develter, K. Theunissen, J. Maertens,

J. Van Eldere (Leuven, BE)

O61 Diagnostic relevance of screening clinical

09:06 specimens from patients attending infectious

diseases and haematology units for HHV6

DNA: a two-year experience

G. Parruti, A. Manna, A. Di Girolamo, M. Ciotti,

D. Racciatti, G. D’Amico, C. Favalli, E. Pizzigallo,

D. D’Antonio (Pescara, Chieti, Rome, IT)

O62 Echovirus 9: a prominent enterovirus

09:18 causing CNS disease in Kuwait

A. Dalwai, S. Ahmad, A. Pacsa, W. Al-Nakib

(Kuwait, KW)

O63 Detection of respiratory pathogens

09:30 by real-time PCR in clinical practice

J.W.A. Rossen, E.G. Klein Breteler,

A.J. Weersink, R. Schuurman, A.M. van Loon

(Utrecht, NL)

O64 Nucleic acid sequence based amplification

09:42 and molecular beacon detection for the realtime

identification of human metapneumo -

virus in paediatric respiratory specimens

R. Manji, F. Zhang, C. Ginocchio

(Lake Success, US)

O65 Development of a real-time NASBA for

09:54 human metapneumovirus

E. Bufflier, H. Savelli, F. Jacobs, C. Moore,

P. Van de Wiel (Grenoble, FR; Boxtel, NL;

Cardiff, UK)

O66 Viral induced asthma exacerbations not

10:06 associated with delayed viral clearance

and increased viral load

A.P.E. Sachs, L.J.R. van Elden, A.M. van Loon,

G. Kimman, T.J.M. Verheij, M. Nijhuis

(Utrecht, Bilthoven, NL)

O67 Quantitative detection of herpes simplex

10:18 virus DNA in the lower respiratory tract

J. Gooskens, K. Templeton, E. Claas,

M. van Bussel, V. Smit, A. Kroes (Leiden, NL)

Erato Clinical epidemiology of nosocomial

08:30– infections

10:30 Chairpersons: Jacques Fabry (Lyon, FR)

Geoffrey Scott (London, UK)

O68 Surgical site infections in Europe:

08:30 results from HELICS surveillance 2004

C. De Laet, C. Suetens, J. Fabry

(Brussels, BE; Lyon, FR)

O69 Deep sternal wound infections following

08:42 coronary artery bypass graft surgery:

risk factors and implications

M. Paul, C. Madar, E. Raz, R. Holinger, A. Fraser,

L. Leibovici, B. Rubinovitch (Petah Tikva, IL)

O70 Diagnosis and microbiology of prosthetic

08:54 shoulder infection

K. Piper, P. Anguita Alonso, M. Jacobson,

A. Trampuz, R. Cofield, J. Sperling,

J. Sanchez Sotelo, D. Osmon, R. Patel

(Rochester, US)

O71 The association between ventilator

09:06 associated pneumonia and ICU mortality:

approximation of attributable mortality

M. Koeman, E. Hak, A. de Smet,

G. van der Heyden, M.J.M. Bonten (Utrecht, NL)

O72 Pattern and dynamics of airways colonisation

09:18 in mechanically ventilated patients

J-E. Berdal, J. Bjørnholdt, A. Blomfeldt,

G. Bukholm, N. Smith-Erichsen (Nordbyhagen, NO)

O73 Factors influenced treatment failure

09:30 in pneumococcal pneumonia with


V. Huang, I. Pencu, S. Oprea, M. Zervos

(Atlanta, Royal Oak, Detroit, US) page 35

Integrated symposium

In antimicrobial

therapy use the

best first: examining

the evidence

Sunday, April 2, 2006, 8:30 – 10:30 a.m.

Acropolis Congress Centre, Level 3, Room Clio

Integrated symposium arranged by

Chairmen: Patrick Francioli (Lausanne, CH)

Donald Low (Toronto, CA)

08:30 Introduction

Donald Low (Toronto, CA)

Patrick Francioli (Lausanne, CH)

08:40 Differentiating antibiotics on basis of

preclinical data – determining superior

antimicrobial activity

Francesco Blasi (Milan, IT)

09:10 Treatment of lower respiratory tract

infections – assessing clinical superiority

Robert Read (Sheffield, UK)

09:40 Treatment of surgical infections including

SSSIs – assessing clinical superiority

Johannes Bogner (Munich, DE)

10:10 Panel discussion

Donald Low (Toronto, CA)

10:20 Conclusions

Donald Low (Toronto, CA)

Patrick Francioli (Lausanne, CH)

Scientific Programme Sunday, April 2, 2006

O74 Efficacy of the use of through-catheter

09:42 leukocyte cytospin blood culture for

monitoring haemodialysis catheter

colonisation. A prospective study designed

to prevent bloodstream-related infections

J.L. del Pozo, A. Aguinaga, M. Alonso, A. Serrera,

S. Hernaez, M.J. Garrido, N. García-Fernández,

J. Leiva (Pamplona, ES)

O75 Risk factors and treatment outcome of

09:54 bloodstream infections caused by

Pseudomonas aeruginosa isolates producing

the PER-1 extended-spectrum beta-lactamase

A. Endimiani, B. Pini, F. Luzzaro, G. Amicosante,

G.M. Rossolini, A. Toniolo (Varese, L’Aquila,

Siena, IT)

O76 Is transmission of MRSA frequent between

10:06 patients sharing the same hospital room?

D.S. Blanc, C. Balmelli, C. Petignat, G. Zanetti,

P. Francioli (Lausanne, CH)

O77 Outbreak of Burkolderia cenocepacia

10:18 bacteraemia associated with disinfection

napkin contamination in haemodialysis

M. Solbiati, B. Allegranzi, G. Lo Cascio,

M.G. Bonora, C. Loschiavo, N. Tessitore,

R. Fontana, E. Concia (Verona, IT)

Integrated Symposia

Athena Tailoring initial antifungal therapy

08:30– according to epidemiological trends

10:30– Chairpersons: Oliver Cornely (Cologne, DE)

Pierre Dellamonica (Nice, FR)

08:30 Opening remarks

Pierre Dellamonica (Nice, FR)

S78 Redefining the impact of antifungal

08:40 prophylaxis in high-risk patients

Oliver Cornely (Cologne, DE)

S79 Strategies for antifungal therapy in high-risk

09:10 patients: can we change what we are doing?

Christopher Kibbler (London, UK)

S80 Improving treatment decisions for antifungal

09:40 therapy: what tools are available?

Dimitrios Kontoyiannis (Houston, US)

10:10 Panel discussion

10:25 Closing remarks

Oliver Cornely (Cologne, DE)

Integrated symposium arranged by


Méditerranée 1 The challenge for antibiotic therapy in

08:30– treating complicated infections:

10:30 how broad is enough?

Chairpersons: Anthony Berendt (Oxford, UK)

Yehuda Carmeli (Tel Aviv, IL)

08:30 Opening remarks

Anthony Berendt (Oxford, UK)

S81 The change of epidemiology of

08:40 Gram-negative infections

Peter Hawkey (Birmingham, UK)

S82 The role of carbapenems in managing

09:00 Gram-negative infections

Yehuda Carmeli (Tel Aviv, IL)

S83 The role of ertapenem in the management of

09:20 diabetic foot infections

Benjamin Lipsky (Seattle, US)

09:40 Panel discussion

10:20 Closing remarks

Anthony Berendt (Oxford, UK)

Yehuda Carmeli (Tel Aviv, IL)

Integrated symposium arranged by

Merck, Sharp & Dohme

Clio In antimicrobial therapy «use the best one

08:30– first»: examining the evidence

10:30 Chairpersons: Patrick Francioli (Lausanne, CH)

Donald Low (Toronto, CA)

08:30 Introduction

Donald Low (Toronto, CA)

Patrick Francioli (Lausanne, CH)

S84 Differentiating antibiotics on basis of

08:40 preclinical data – determining superior

antimicrobial activity

Francesco Blasi (Milan, IT)

S85 Treatment of lower respiratory tract

09:10 infections – assessing clinical superiority

Robert Read (Sheffield, UK)

S86 Treatment of surgical infections including

09:40 SSSIs – assessing clinical superiority

Johannes Bogner (Munich, DE)

10:10 Panel discussion

10:20 Conclusions

Donald Low (Toronto, CA)

Patrick Francioli (Lausanne, CH)

Integrated symposium arranged by

Bayer HealthCare AG page 37

Scientific Programme Sunday, April 2, 2006

Calliope Addressing the challenge of nosocomial

08:30– MRSA infections

10:30 Chairpersons: Gary French (London, UK)

Kamal Itani (Boston, US)

08:30 Introduction: addressing the challenge of

nosocomial MRSA infections

Gary French (London, UK)

S87 MRSA update: present and future threats

08:40 Peter Wilson (London, UK)

S88 Challenges of MRSA nosocomial surgical

09:00 site and complicated skin and soft-tissue


Kamal Itani (Boston, US)

S89 MRSA in the ICU: catheter related skin

09:20 and bloodstream infections

Emilio Bouza (Madrid, ES)

S90 Nosocomial pneumonia:

09:40 early diagnosis, better treatments

Jean-Yves Fagon (Paris, FR)

10:00 Panel discussion

10:25 Summary and conclusions

Kamal Irani (Bostin, US)

Integrated symposium arranged by Pfizer

Award Lecture

Apollon Presentation of ESCMID Awards –

11:00– ESCMID Excellence Award Lecture

12:00 Chairpersons: S. Ragnar Norrby (Stockholm, SE)

Marc Struelens (Brussels, BE)

11:00 Presentation of the ESCMID/bioMérieux

Award for Advances in Clinical Microbiology

11:05 Presentation of the ESCMID Young

Investigator Awards for Research in Clinical

Microbiology and Infectious Diseases

11:10 Presentation of the ESCMID Award for

Excellence in Clinical Microbiology and

Infectious Diseases

11:15 ESCMID Excellence Award Lecture:

S91 Resistance to antimicrobials:

from emergence to clinical relevance

Roland Leclercq (Caen, FR)

(see also page 18)

page 38 Final Programme

Keynote Lecture

Athena The impact of microbial genomics on

11:00– epidemiology and control of infectious

12:00 diseases

Chairperson: Jordi Vila (Barcelona, ES)

K92 James M. Musser (Houston, US)


Oral Sessions

Erato Biofilms – a highly organised community


12:00 Chairpersons: Niels Høiby (Copenhagen, DK)

Christine Imbert (Poitiers, FR)

O93 AGR-genotyping of biofilm producing

11:00 Staphylococcus aureus

V. Cafiso, T. Bertuccio, M. Santagati, V. Demelio,

D. Spina, S. Stefani (Catania, IT)

O94 Structural comparison of biofilms

11:12 formed by Staphylococcus aureus,

Staphylococcus epidermidis, and other

coagulase-negative staphylococci

M.A. Horstkotte, S. Stepanovic, M. Lang,

D. Mack, J.K. Knobloch (Hamburg, DE;

Belgrade, CS; Swansea, UK)

O95 Differential importance of protein and

11:24 polysaccharide intercellular adhesin

mediated biofilm formation in

Staphylococcus aureus and Staphylococcus

epidermidis from prosthetic joint infections

H. Rohde, E. Burandt, L. Frommelt, N. Siemssen,

C. Burdelski, C.-J. Wang, S. Scherpe,

J.K.-M. Knobloch, J. Kaplan, D. Mack

(Hamburg, DE; Newark, US; Swansea, UK)

O96 The role of the quorum-sensing

11:36 “target of RNAIII activating protein” and

“RNAIII-inhibiting peptide” in staphylococcal

biofilm formation and control in vitro

C.A. Fux, D. Nguyen, S. Wilson, N. Balaban,

P. Stoodley (Berne, CH; Pittsburgh, Bozeman,

North Grafton, US)

O97 Using an efficient anti-biofilm procedure

11:48 to improve the safety of pacifiers

E. Comina, K. Marion, F. Renaud, E. Bergeron,

J. Freney (Lyon, FR)

Scientific Programme Sunday, April 2, 2006

Calliope Emerging viral infections


12:00 Chairpersons: Sabine Santibanez (Berlin, DE)

Christian Drosten (Hamburg, DE)

O98 Clinical features and molecular epidemiology

11:00 of coronavirus HKU1 associated communityacquired


P.C.Y. Woo, S.K.P. Lau, H.W. Tsoi, Y. Huang,

R.W.S. Poon, C-M. Chu, R.A. Lee, W-K. Luk,

G.K.M. Wong, B.H.L. Wong, V.C.C. Cheng,

B.S.F. Tang, A.K.L. Wu, R.W.H. Yung, H. Chen,

Y. Guan, K-H. Chan, K-Y. Yuen (Hong Kong, HK)

O99 Stability of SARS coronavirus to high

11:12 temperature and high relative humidity

W.H. Seto, K.H. Chan, S.Y. Lam, M. Peiris

(Hong Kong, HK)

O100 First identification of Toscana

11:24 virus and other phleboviruses in sandflies

from southern France

R.N. Charrel, A. Izri, S. Temmam, P. Delaunay,

I. Toga, P. Marty, H. Dumon, X. de Lamballerie,

P. Parola (Marseille, Paris, Nice, FR)

O101 Imported cases of chikungunya virus infection

11:36 from eastern Africa

R.N. Charrel, P. Brouqui, H. Tissot Dupont,

X. de Lamballerie (Marseille, FR)

O102 Crimean-Congo haemorrhagic fever in

11:48 the East Black Sea region of Turkey:

a report of 78 cases

N. Sucu, K. Aydin, I. Köksal, R. Caylan,

G. Yilmaz (Trabzon, TR) page 39

Poster Session I

Topics Session I

Presence of authors: 12:00–13:00

Scientific Programme Sunday, April 2, 2006

– Automated methods for antibiotic

susceptibility testing

● P441–P456

– Epidemiology of MRSA P457–P478

– Sepsis P479–P485

– Tigecycline in vitro studies – I P486–P501

– ESBL and cephalosporins P502–P516

– Molecular typing P517–P539

– Bacterial pathogenesis - I P540–P554

– Emerging microbial infections P555–P569

– Vaccines and immunotherapy P570–P595

– AIDS and HIV P596–P625

– Detection of viruses P626–P656

– Nosocomial infections

★ P657–P678


Guided Poster Walks Session I

Theme: Automated methods for antibiotic

susceptibility testing

Chairperson: Derek Brown (Cambridge, UK)

Meeting point: Poster P441 at 12:15

Posters selected from within the topic marked ●

Theme: Nosocomial infections

Chairpersons: Geoffrey Scott (London, UK)

Jean Carlet (Paris, FR)

Meeting point: Poster P657 at 12:15

Posters selected from within the topic marked ★

page 40 Final Programme


Poster Session II

Topics Session II

– Infection in the immunocompromised

host (except HIV)

● P679–P702

– Antibacterial susceptibility studies - I P703–P727

– Identification and antifungal susceptibility

testing for yeasts and moulds


– Virology – I P750–P766

– Hepatitis P767–P790

– Paediatric infections P791–P818

– Microbial biofilms P819–P845

– Brucella and Lyme borreliosis P846–P855

– Diagnositic and laboratory methods

in parasites and fungi


– Toxoplasmosis P871–P882

– Staphylococci and surgical infections P883–P895

– Streptococci – skin and soft tissue infections P896–P907

– ESBL and carbapemenase producing

Gram-negative organisms

★ P908–P924

– Metallo beta-lactamases and integrons ★ P925–P940


Guided Poster Walks Session II

Theme: Infection in the immunocompromised host

(except HIV)

Chairpersons: Murat Akova (Ankara, TR)

Mathew Falagas (Athens, GR)

Meeting point: Poster P679 at 13:00

Posters selected from within the topic marked ●

Theme: ESBL and metallo-beta-lactamases

Chairperson: David Livermore (London, UK)

Meeting point: Poster P908 at 13:00

Posters selected from within the topics marked ★


Scientific Programme Sunday, April 2, 2006

Apollon The year in infectious diseases medicine


15:00 Chairperson: Roger Finch (Nottingham, UK)

S103 The year in infectious diseases medicine (1)

14:00 Susanna Esposito (Milan, IT)

S104 The year in infectious diseases medicine (2)

14:30 Patrick Francioli (Lausanne, CH)

Athena Is microbiological work-up in community-

14:00– acquired pneumonia still useful?

15:00 Chairpersons: Tobias Welte (Hannover, DE)

Mark Woodhead (Manchester, UK)

S105 Pro

14:00 Margareta Ieven (Antwerp, BE)

S106 Contra

14:30 Johan Van Eldere (Leuven, BE)

Méditerranée 1 The hyper-virulent strain of Clostridium

14:00– difficile: sharing experiences in Europe and

15:00 North America

Chairpersons: Ian R. Poxton (Edinburgh, UK)

Clifford McDonald (Atlanta, US)

S107 Spread of the new variant 027 of Clostridium

14:00 difficile in the Netherlands and Europe

Ed J. Kuijper (Leiden, NL)

S108 Clostridium difficile-associated disease:

14:30 a growing threat to U.S. public health

Clifford McDonald (Atlanta, US)

Symposium arranged with the ESCMID

Study Group on Clostridium difficile (ESGCD)

Hermes Blood-borne viruses in health care facilities –

14:00– the silent enemy?

15:00 Chairpersons: Catherine Cordonnier (Paris, FR)

Winfried Kern (Freiburg, DE)

S109 An overview of transmission of BBV in

14:00 healthcare facilities

Shaheen Mehtar (Cape Town, ZA)

S110 Transmissions of hepatitis B, C and HIV

14:30 associated with healthcare in Europe

Jean-Claude Desenclos (Saint-Maurice, FR)

Clio Viral congenital paediatric diseases


15:00 Chairpersons: Babill Stray-Pedersen (Oslo, NO)

Vas Novelli (London, UK)

S111 Congenital CMV infection:

14:00 current controversies

Sergio Stagno (Birmingham, US)

S112 Congenital varicella syndrome and perinatal

14:30 varicella: epidemiology and management

Vas Novelli (London, UK)

Erato Brucellosis


15:00 Chairpersons: Emilio Bouza (Madrid, ES)

Georgios Pappas (Ioannina, GR)

S113 Molecular methods in the diagnosis of human

14:00 brucellosis

Javier Solera (Albacete, ES)

S114 What’s new in the treatment of human

14:30 brucellosis

Georgios Pappas (Ioannina, GR)

Oral Sessions

Méditerranée 2 Dissemination of molecular resistance traits


15:00 Chairpersons: Roxana Filip (Suceava, RO)

Kevin Towner (Nottingham, UK)

O115 Comparative genomic analysis of community-

14:00 acquired ST80-SCCmec IV Staphylococcus

aureus isolates by high-density microarray

R.V. Goering, A.R. Larsen, R. Skov, F.C. Tenover,

K. Anderson, P.M. Dunman

(Omaha, US; Copenhagen, DK; Atlanta, US)

O116 Presence of PVL among erythromycin-

14:12 and methicillin-resistant community-acquired

Staphylococcus aureus isolated from children

in Texas from 1999 to 2002

N. Aydin, T. Bogdanovich, S. Chavez-Bueno,

G. McCracken, B. Bozdogan, P.C. Appelbaum

(Aydin, TR; Hershey, Dallas, US)

O117 Identity of macrolide-resistant clones

14:24 of Streptococcus pyogenes in Portugal

supports Europe-wide dissemination of a

few lineages

C. Silva-Costa, M. Ramirez, J. Melo-Cristino

(Lisbon, PT) page 41

Scientific Programme Sunday, April 2, 2006

O118 Rapid dissemination of MDR CTX-M-15-

14:36 producing K. pneumoniae epidemic clone in


I. Damjanova, Á. Tóth, Z. Ozsvár, E. Bauer, J. Pászti,

M. Füzi (Budapest, Székesfehérvár, HU)

O119 Evidence for low rates of ciprofloxacin

14:48 and rifampicin resistance in persistent

Helicobacter pylori infection

S.A. Chisholm, R.J. Owen (London, UK)

Méditerranée 3 Diabetes and infection


15:00 Chairpersons: Anthony Berendt (Oxford, UK)

Eric Senneville (Tourcoing, FR)

O120 Stress hyperglycaemia as a prognostic

14:00 factor in patients with severe sepsis

L. Leonidou, M. Michalaki, A. Leonardou,

E. Polyzogopoulou, K. Fouka, M. Gerolimos,

P. Leonardos, E. Giannoulaki, V. Kyriazopoulou,

C.A. Gogos (Patras, GR)

O121 Diabetes mellitus and 30-day and 90-day

14:12 mortality after hospitalisation with

pneumonia: a population-based follow-up

study of 41,793 adult patients

R.W. Thomsen, J. Brommann, A. Riis,

H.-H. Lervang, H.C. Schønheyder, H.T. Sørensen

(Aalborg, Aarhus, DK)

O122 A clinical prediction rule for a complicated

14:24 course of urinary tract infections in patients

with type 2 diabetes in primary care

L.M.A.J. Muller, K.J. Gorter, G.E.H.M. Rutten,

A.I.M. Hoepelman, E. Hak (Utrecht, NL)

O123 Applicability of a clinical prediction rule for

14:36 lower respiratory tract infections

in elderly patients with diabetes mellitus:

a subgroup analysis

L.M.A.J. Muller, J. Bont, K.J. Gorter,

G.E.H.M. Rutten, T.J.M. Verheij, E. Hak

(Utrecht, NL)

O124 Diabetic foot infections: the evolving

14:48 characteristics, microbiology and

determinants of mortality

S. Gündes, Z. Yulugkural, M. Biyikli,

B. Buyukarslan (Kocaeli, TR)

page 42 Final Programme

Iris Pump it out and resist


15:00 Chairpersons: Patrick Plésiat (Besançon, FR)

David Livermore (London, UK)

O125 Which Mex efflux pumps are overexpressed

14:00 in multidrug-resistant Pseudomonas


D. Hocquet, R. Fabre, M. Roussel-Delvallez,

J.D. Cavallo, B. Dehecq, P. Plésiat

(Besancon, Bégin Saint-Mandé, Lille, FR)

O126 Expression of mexY and gene PA5471

14:12 in drug-induced amikacin resistant small

colony variants of P. aeruginosa

S. Islam, A. Vang, B. Wretlind (Stockholm, SE)

O127 Contribution of efflux pumps overexpression

14:24 to carbapenem heteroresistance in

Pseudomonas aeruginosa

A. Ikonomidis, S. Pournaras, N. Spanakis,

A. Tsakris, N.J. Legakis, A.N. Maniatis

(Larissa, Athens, GR)

O128 Identification of novel mutations

14:36 in MTR locus of clinical isolates of Neisseria


M. Ali, V. Kumar, P. Sachdeva, U. Chaudhry,

D. Saluja (Delhi, IN)

O129 Acquired beta-lactam resistance in three

14:48 Escherichia coli strains due to overexpression

of AcrAB, TolC and PBP3

M.M. Tavío, V. Aquili, N.T. Antunes,

J. Sánchez-Cespedes, Z. González-Lama, J. Vila

(Las Palmas de Gran Canaria, Barcelona, ES)

Calliope Mycobacterial infections


15:00 Chairpersons: Enzio Tortoli (Florence, IT)

Françoise Portaels (Antwerp, BE)

O130 Epidemiology and trend of leprosy

14:00 disease in the Iranian Qazvin province during

45 years (1958–2003)

R. Qassemi Barqi (Qazvin, IR)

O131 Mycobacterium kansasii: results of a 10-year

14:12 study in Zaragoza, Spain

S. Terraza, J.A. Amiguet, P. Arazo, C. Ramos,

A. Vitoria, M.A. Lezcano, J. Cuesta (Zaragoza, ES)

O132 Comparison of conventional antimicrobial

14:24 susceptibility and oligonucleotide chip

system for detection of drug resistance in

Mycobacterium tuberculosis isolates

H. Park, E.J. Song, E.S. Song, E.Y. Lee, C.M. Kim,

S.H. Jeong, J.H. Shin, J. Jeong, S. Kim, Y.K. Park,

G.-H. Bai C.L. Chang (Busan, Ulsan, Jinju, Seoul, KR)

Scientific Programme Sunday, April 2, 2006

O133 Clinical and microbiological data of

14:36 patients infected with multidrug-resistant

Mycobacterium tuberculosis strains

carrying gyrase mutations

N. Veziris, J. Robert, C. Truffot-Pernot, V. Jarlier,

E. Cambau, A. Aubry (Paris, Créteil, FR)

O134 Implementation of automated mycobacterial

14:48 interspersed repetitive unit – variable number

of tandem repeat (MIRU-VNTR) typing in a

routine laboratory setting

C. Allix, P. Supply, M. Fauville-Dufaux

(Brussels, BE; Lille, FR)


Apollon Current aspects on MRSA


17:30 Chairpersons: Jerôme Etienne (Lyon, FR)

Gary L. French (London, UK)

S135 Current status of rapid detection

15:30 Jacques Schrenzel (Geneva, CH)

S136 The current situation of community-acquired

16:00 MRSA in Europe

Jerôme Etienne (Lyon, FR)

S137 MRSA transmission dynamics in hospitals:

16:30 will control policies finally succeed?

Ben Cooper (London, UK)

S138 Role of new therapeutics

17:00 Harald Labischinski (Wurzburg, DE)

Méditerranée 2 Mechanisms of infectious diseases:

15:30– new science and novel insights

17:30 Chairpersons: Philippe Sansonetti (Paris, FR)

Christoph M. Tang (London, UK)

S139 Neisseria meningitidis: new genes that

15:30 effect invasion

Christoph M. Tang (London, UK)

S140 Cell biology and shigellosis

16:00 Philippe Sansonetti (Paris, FR)

S141 Innate immunity and Streptococcus

16:30 pneumoniae

Robert Read (Sheffield, UK)

S142 Brucellosis: novel virulence determinants

17:00 and cellular organelles

Jean-Pierre Gorvel (Marseille, FR)

Joint symposium arranged with the Federation of

European Microbiolobical Societies (FEMS)

Hermes Foreign body infections


17:30 Chairpersons: Mathias Herrmann (Homburg, DE)

Jean-Paul Stahl (Grenoble, FR)

S143 Staphylococci – versatile microorganisms

15:30 adapted to the foreign surface

Mathias Herrmann (Homburg, DE)

S144 Breast implant infection in aesthetic

16:00 and reconstructive surgery

Brigitte Pittet (Geneva, CH)

S145 Orthopaedic infections: tricky to diagnose,

16:30 hard to treat

Andrej Trampuz (Basel, CH)

S146 Piercing, tattooing and other body

17:00 modifications

Jean-Baptiste Guiard-Schmid (Paris, FR)

Oral Sessions

Méditerranée 3 Antimicrobial clinical trials


17:30 Chairpersons: Roman Kozlov (Smolensk, RU)

David Denning (Manchester, UK)

O147 Skin disinfection with octenidine dihydro-

15:30 chloride for central venous catheter placement

and care – a randomised controlled trial

M. Dettenkofer, C. Wilson, A. Gratwohl,

D. Bolliger, C. Schmoor, D. Heim, H. Bertz,

D. Luft, S. Schulz, F.D. Daschner,

A.F. Widmer (Freiburg, DE; Basel, CH)

O148 Pooled analysis of the mortality and cardiac

15:42 safety of moxifloxacin

S. Choudhri, F. Krüsmann, C. Reiter

(West Haven, US; Wuppertal, DE)

O149 Short-course fluoroquinolones vs. single dose

15:54 fosfomycin for acute uncomplicated cystitis:

systematic review and meta-analysis

V. Rafalskiy, T. Perepanova, V. Bistryukov

(Smolensk, Moscow, RU)

O150 A clinical and laboratory evaluation of

16:06 PAR-101 in patients with Clostridium

difficile-associated diarrhoea

T.J. Louie, M. Miller, C. Donskey, K. Mullane,

E.J.C. Goldstein, D.M. Citron, M. Corrado,

S.L. Gorbach, P. Sears, S. Shangle, B. Walsh,

Y.-K. Shue (Calgary, Montreal, CA; Cleveland,

Chicago, Santa Monica, New Hope, San Diego, US) page 43

Scientific Programme Sunday, April 2, 2006

O151 Therapeutic drug monitoring in adult patients

16:18 receiving imipenem or cefepime therapy:

one-year single-centre experience

S. Vora, A A. Pascual, S. Bolay, P. Francioli,

T. Calandra, O. Marchetti (Lausanne, CH)

O152 Integrated analysis of efficacy of

16:30 faropenem medoxomil in the treatment

of uncomplicated skin and skin structure


E.E.L. Wang, R. Echols, R. Tosiello (Louisville, US)

O153 One-week once-daily triple therapy with

16:42 esomeprazole, moxifloxacin and rifabutin is

effective in the treatment of Helicobacter

pylori resistant to both metronidazole and


S. Miehlke, W. Schneider-Brachert, A. Morgner,

A. Madisch, C. Kirsch, E. Bästlein, C. Haferland,

C. Jebens, H. Knoth, M. Stolte, N. Lehn

(Dresden, Regensburg, Cologne, Görlitz, Jülich,

Bayreuth, DE)

O154 Prospective randomised trial comparing

16:54 rifabutin-based triple therapy and high-dose

dual therapy for eradication of Helicobacter

pylori resistant to both metronidazole and


S. Miehlke, K. Hansky, W. Schneider-Brachert,

A. Madisch, A. Morgner, C. Kirsch, C. Haferland,

E. Bästlein, M. Buchner, E. Jacobs, M. Stolte,

N. Lehn (Dresden, Regensburg, Gorlitz, Cologne,

Ribnitz-Damgarten, Bayreuth, DE)

O155 A randomised study of cefuroxime vs.

17:06 ampicillin-sulbactam prophylaxis for

obstetrical and gynaecological operations:

an effect on Gram-negative anaerobic

bacteria associated postoperative surgical

site infections

E. Ziogos, K. Kanellakopoulou, A. Dervisoglou,

N. Galanakis, A. Papadimitriou, H. Giamarellou

(Nikaia, Haidari, GR)

O156 The efficacy and safety of cefepime:

17:18 systematic review and meta-analysis

M. Paul, D. Yahav, A. Fraser, N. Sarid,

L. Leibovici (Petah Tikva, IL)

page 44 Final Programme

Iris Epidemic influenza


17:30 Chairpersons: Albert Osterhaus (Rotterdam, NL)

Derek Smith (Cambridge, UK)

O157 Mini state-of-the-art lecture:

15:30 Global monitoring of epidemic influenza

Derek Smith (Cambridge, UK)

O158 Fatal cases of influenza-associated

15:54 encephalopathy in the Netherlands

J. Gooskens, T. Kuiken, E. Claas, H. Harinck,

H. Baelde, W. Spaan, A. Kroes

(Leiden, Rotterdam, NL)

O159 Lack of discriminating signs in clinical

16:06 diagnosis of influenza

M. van der Hoeven, M. Scholing, P. Wever,

M. Hermans, R. Fijnheer, P. Schneeberger

(‘s-Hertogenbosch, NL)

O160 Unusual summer influenza outbreak in

16:18 a nursing home. Diagnosis and prophylactic


J. Gaillat, G. Dennetiere, M. Valette,

E. Raffin-Bru (Annecy, Lyon, FR)

O161 Effects of statin therapy on the risk

16:30 of serious outcomes during influenza


E. Hak, T. Verheij, G. van Essen, M.J.M. Bonten,

A. Hoes on behalf of ESPRIT

O162 Influenza vaccination in health workers

16:42 included in high-risk group population

A. Piñón, S. Oropeza, B. Acosta, C. Aragones,

B. Galindo (Havana, CU)

O163 Efficacy of influenza vaccination in patients

16:54 with liver cirrhosis

H.J. Cheong, C.W. Park, S.Y. Ki, Y.M. Cho, J.Y. Song,

J.E. Yeon, K.S. Byun, W.J. Kim (Seoul, KR)

O164 Clinical effectiveness of influenza vaccination

17:06 in adults with diabetes mellitus

I. Looijmans-van den akker, T. Verheij, E. Buskens,

G. Rutten, E. Hak (Utrecht, NL)

O165 Immunogenicity of baculovirus-expressed

17:18 trivalent influenza HA vaccine: randomised,

double-blind, dose-escalation single

institution study in adult patients with B-cell


A. Safdar, A. Rodriguez, F. Luis, J. Romaguera,

F. Hagemeister, P. McLaughlin, L. Kwak, R.B. Couch

(Houston, US)

Scientific Programme Sunday, April 2, 2006

Erato Rapid methods for the identification of

15:30– bacterial clones and pathogens


Chairpersons: Paula Kriz (Prague, CZ)

Fred C. Tenover (Atlanta, US)

O166 Mixed whole genome microarray technology

15:30 discerns a hospital-adapted subtype of Enterococcus

faecium, comparable to multilocus

sequence typing clonal complex (CC) 17

H.L. Leavis, W.J.B. van Wamel, R.J.L. Willems,

F.H. Schuren, A.C. Fluit, M.J.M. Bonten

(Utrecht, Zeist, NL)

O167 Genetic relationship between Streptococcus

15:42 pneumoniae isolates responsible for a case of

meningitis and for asymptomatic carriage in

children attending a day-care centre in Lisbon

T. Figueiredo, M. Ramirez, I. Santos-Sanches,

S. Nunes, A. Brito-Avô, R.M. Barros, I. Peres,

H. de Lencastre (Lisbon, Oeiras, PT; New York, US)

O168 Changes in the distribution of hypervirulent

15:54 complexes of Neisseria meningitidis in the

Czech Republic

P. Kriz, J. Kalmusova, M. Musilek, J. Felsberg,

R. Haugvicova, D. Caugant, K. Jolley, M. Maiden

(Prague, CZ; Oslo, NO; Oxford, UK)

O169 Rapid diagnosis of bacterial vaginosis by

16:06 terminal restriction fragment length

polymorphism profiling

F. Thies, W. König, B. König (Magdeburg, DE)

O170 Development and validation of real-time

16:18 PCR assays for a multi-centre study to

assess the prevalence and epidemiology of

shiga-toxin producing Escherichia coli in the


T. Schuurman, A. Roovers, W.K. van der Zwaluw,

A.A. van Zwet, L.J.M. Sabbe, A.M.D. Kooistra-Smid,

Y.T.H.P. van Duynhoven (Groningen, Goes,

Bilthoven, Arnhem, NL)

O171 Based upon repeat patterns: variable

16:30 number of tandem repeat pattern analysis

to infer clonal groupings of Staphylococcus

aureus strains from spa typing data

T. Weniger, C. Berssenbruegge, A. Mellmann,

J. Rothgänger, M. Sammeth, J. Stoye,

D. Harmsen (Munster, Wurzburg, Bielefeld, DE)

O172 Multiple locus variable number tandem

16:42 repeat assays do not differentiate between

community-associated and healthcareassociated

lineages of methicillin-resistant

Staphylococcus aureus

F. Tenover, R. Vaughn, L. McDougal, G. Fosheim,

J. McGowan Jr. (Atlanta, US)

O173 Molecular typing of Mycobacterium

16:54 tuberculosis by mycobacterial interspersed

repetitive unit – variable-number tandem

repeat analysis in Lisbon in 2003

E. Fernandes, R. Macedo, C. Furtado, L. Brum,

I. Portugal (Lisbon, PT)

O174 Clinical impact of a rapid PCR-based

17:06 identification of staphylococci directly from

positive blood cultures

P. Agmon, I. Oren, R. Finkelstein, H. Sprecher

(Haifa, IL)

O175 Clinical evaluation of a molecular-based

17:18 assay for the detection of methicillin-resistant

Staphylococcus aureus and Staphylococcus

aureus in positive blood cultures

D. Fuller, T. Davis, M. Parker, R. Buckner, J. Talbott

(Indianapolis, US)

Integrated Symposia

Athena Readdressing the importance of

15:30– Gram-negative resistance: pathogens,

17:30 practice patterns, and pharmacotherapy

Chairpersons: Jacques F. Acar (Paris, FR)

Mark H. Wilcox (Leeds, UK)

15:30 Welcome and introduction

Jacques F. Acar (Paris, FR)

S176 Pathogens: a review of Gram-negative

15:40 resistance epidemiological data

Timothy R. Walsh (Bristol, UK)

S177 Practice patterns: current Gram-negative

16:10 treatment strategies

Mark H. Wilcox (Leeds, UK)

S178 Pharmacotherapy: new help in the fight

16:40 against Gram-negative resistance

Jean M. Carlet (Paris, FR)

17:10 Panel discussion – Questions and answers

Moderator: Jacques F. Acar (Paris, FR)

17:25 Concluding remarks

Jacques F. Acar (Paris, FR)

Integrated symposium arranged by

Wyeth Pharmaceuticals page 45

Scientific Programme Sunday, April 2, 2006

Méditerranée 1 Addressing macrolide issues in community-

15:30– acquired respiratory tract infections

17:30 Chairpersons: Hartmut Lode (Berlin, DE)

Jeff Blumer (Cleveland, US)

15:30 Introduction

Hartmut Lode (Berlin, DE)

S179 Do macrolides have a role in the era of

15:35 resistance?

Thomas File (Ohio, US)

S180 Serum versus tissue concentrations for

16:00 macrolides: both sides of the story

Jeff Blumer (Cleveland, US)

S181 Northern versus Southern Europe debate:

16:25 the value of macrolides in the management

of RTIs

Mark Woodhead (Manchester, UK);

Francesco Blasi (Milan, IT)

17:00 Panel discussion:

Importance of macrolides in RTIs

Co-chairs and faculty

17:25 Closing remarks

Jeff Blumer (Cleveland, US)

Integrated symposium arranged by Pfizer

Clio Redesigning beta-lactams to combat

15:30– resistance

17:30 Chairpersons: Gian Maria Rossolini (Siena, IT)

Fred Goldstein (Paris, FR)

15:30 Welcome and introduction:

combating resistance in a challenging,

changing environment

Fred W. Goldstein (Paris, FR)

S182 Local surveillance: location, location, location!

15:40 David M. Livermore (London, UK)

S183 Bridge to new treatment options: antibiotic

16:05 resistance in community-acquired MRSA

Patrice Courvalin (Paris, FR)

S184 In vitro profile of a new ß-lactam with activity

16:30 against MRSA

Mark Jones (Hilversum, NL)

S185 Clinical profile of ceftobiprole, a novel

16:55 ß-lactam antibiotic

Gary J. Noel (New Jersey, US)

17:20 Questions and answers

Gian Maria Rossolini (Siena, IT)

Integrated symposium arranged by Janssen-Cilag

page 46 Final Programme

Calliope Advances in antifungal therapy


17:30 Chairpersons: t.b.c.

S186 A revival of epidemiological data and impact

15:30 on pre-emptive strategy


S187 Treatment of aspergillosis, update on

16:10 available options

Oliver Cornely (Cologne, DE)

S188 Management of high risk patients

16:50 Ben de Pauw (Nijmegen, NL)

Integrated symposium arranged by

Gilead Sciences

Late Breaker Session

Apollon Avian influenza


18:45 Chairpersons: Andreas Voss (Nijmegen, NL)

Pierre Dellamonica (Nice, FR)

S2273 Avian flu – the Turkish experience

17:45 Serhat Ünal (Ankara, TR)

S2274 Avian flu – a threat to mankind?

18:15 Klaus Stöhr (Geneva, WHO)

Scientific Programme Monday, April 3, 2006

Meet-the-Expert Sessions

Méditerranée 2 Recent treatment issues in tuberculosis

E189 and non-tuberculosis mycobacteria

07:15– Experts: Richard Wallace (Tyler, US)

08:15– Bertrand Dautzenberg (Paris, FR)


– to be familiar with recently revised American

Thoracic Society recommendation for

treatment of M. avium complex (MAC) lung

disease, including a three-times-weekly


– to appreciate the limitations of susceptibility

testing for non-tuberculosis mycobacteria,

especially for MAC

– to be knowledgeable of current accepted

treatment regimens for PPD positive individuals

(converters or high risk individuals),

including those who are HIV positive

Méditerranée 3 The role of epidemiology and typing

E190 in outbreak investigation

07:15– Experts: Panayotis T. Tassios (Athens, GR)

08:15– Jean-Claude Desenclos (Saint-Maurice, FR)


– to describe the distinct but complementary

contributions of epidemiology and typing

– to assess different examples of outbreak

investigations, e.g.: common source vs.

person-to-person, community- vs. hospitalacquired

– to demonstrate the need for continuous

feedback between epidemiology and typing

at different stages of an investigation

Iris How to interpret laboratory test results?

E191 Experts: George Schmid (Geneva, WHO)

07:15– Achim Schwenk (London, UK)



– to interpret sensitivity, specificity, and

predictive values of laboratory tests in

clinical practice

– to understand how knowing the process of

determining cut-off values for separating

positive from negative tests results can

influence clinical practice

– to understand the concepts of pre-test and

post-test probability

– to understand the concept of numbersneeded-to-test

Hermes Minimal requirements for an effective

E192 infection control surveillance

07:15– Experts: Andreas Widmer (Basel, CH)

08:15– Marc Bonten (Utrecht, NL)


– to provide an overview of different

surveillance systems

– to establish sensitivity and specificity of

systems in comparison to workload

– to show principles and examples of computer

support for surveillance

– to examine practical issues:

incidence vs. prevalence, pitfalls

Clio Beta-lactamases: from bench to bedside

E193 Experts: Patrice Nordmann (Paris, FR)

07:15– Yehuda Carmeli (Tel Aviv, IL)



– to identify the main broad-spectrum betalactamase-mediated

resistance phenotypes

in Gram-negative rods

– to know the spread and distribution of the

expanded-spectrum beta-lactamases in

Gram-negative rods worldwide

– to discuss the therapeutic alternatives for

treating infected patients

Erato Clinical trials and clinical practice

E194 Experts: Ben de Pauw (Nijmegen, NL)

07:15– David Denning (Manchester, UK)



– to identify pitfalls in clinical trial on antifungal

agents, such as inclusion and exclusion

criteria, endpoints and others

– to translate trial data for use in treatment of

invasive fungal infections

– to discuss the relevance of meta-analysis

statistics page 47


Scientific Programme Monday, April 3, 2006

Apollon The pros and cons of combination

08:30– antimicrobial treatment

10:30 Chairpersons: Murat Akova (Ankara, TR)

Bernhard Ruf (Leipzig, DE)

S195 Single-drug therapy for community-acquired

08:30 pneumonia

Tobias Welte (Hannover, DE)

S196 Combination therapy for community-acquired

09:00 pneumonia

Antoni Torres (Barcelona, ES)

S197 Combination antifungals: in dubio agite

09:30 Murat Akova (Ankara, TR)

S198 Combination antifungals: in dubio abstine

10:00 Claudio Viscoli (Verona, IT)

Méditerranée 2 Emerging viral exotica in Europe


10:30 Chairpersons: Jean-Claude Desenclos

(Saint-Maurice, FR)

Carl Erik Nord (Stockholm, SE)

S199 West Nile fever in Europe – is there an issue?

08:30 Jean-Claude Desenclos (Saint-Maurice, FR)

S200 Rabies and other lyssaviruses in Europe 2006

09:00 Mary J. Warrell (Oxford, UK)

S201 Toscana virus: emergence in southern Europe

09:30 Remi N. Charrel (Marseille, FR)

S202 Viral haemorrhagic fever: diagnosis and

10:00 management of highly contagious diseases

Christoph Hatz (Basel, CH)

Joint symposium arranged with the International

Society for Infectious Diseases (ISID)

Iris Infections in the immunocompromised host


10:30 Chairpersons: Per Ljungman (Stockholm, SE)

Catherine Cordonnier (Paris, FR)

S203 Post-transplantation lymphoproliferative

08:30 disease – more surprises from EBV

David Nadal (Zurich, CH)

S204 Infections complications associated

09:00 with novel immunosuppressive therapies

Georg Maschmeyer (Potsdam, DE)

S205 Infections in non-myeloablative

09:30 stem-cell recipients

Catherine Cordonnier (Paris, FR)

page 48 Final Programme

S206 Vaccination strategies in transplant recipients

10:00 Per Ljungman (Stockholm, SE)

Joint symposium arranged with the International

Immunocompromised Host Society (ICHS)

Hermes Relationship between antimicrobial

08:30– resistance and virulence

10:30 Chairpersons: Tibor Pal (Pecs, HR)

Robert Moellering (Boston, US)

S207 Drug resistance and fitness in Mycobacterium

08:30 tuberculosis

Stewart Cole (Paris, FR)

S208 Connexion between efflux pump expression

09:00 and virulence in Pseudomonas aeruginosa

José Luis Martinez (Madrid, ES)

S209 Quinolone resistance and virulence

09:30 in uropathogenic Escherichia coli

Jordi Vila (Barcelona, ES)

S210 Efflux pump expression and bacterial

10:00 survival in Neisseria gonorrhoeae

William M. Shafer (Atlanta, US)

Oral Sessions

Méditerranée 3 Diagnostic and laboratory methods


10:30 Chairpersons: Johan van Eldere (Leuven, BE)

Luis Martinez-Martinez

(Santander, ES)

O211 Impact on mortality and cost- effectiveness

08:30 of rapid bacterial identification and antimicrobial

susceptibility testing in comparison with

standard methods

J.J. Kerremans, P. Verboom, W.H.F. Goessens,

L. Hakkaart-van Roijen, T. Stijnen, H.A. Verbrugh,

M.A. Vos (Rotterdam, NL)

O212 Comparison of NucliSens easyMAG,

08:42 NucliSens miniMAG and Qiagen nucleic acid

extraction systems using throat swabs for

the detection of M. pneumoniae and

C. pneumoniae

K. Loens, K. Bergs, D. Ursi, H. Goossens,

M. Ieven (Edegem, BE)

Scientific Programme Monday, April 3, 2006

O213 Intelligent sample preparation to improve

08:54 nucleic acid-based pathogen detection

S. Sachse, K.H. Schmidt, M. Lehmann,

S. Russwurm, E. Straube (Jena, DE)

O214 Point-of-care detection of group B streptococci

09:06 in labouring women: a new approach to

preventing early onset neonatal GBS disease

E.H. Smith, P. Milner, J. Gray, L. Spicer

(Birmingham, UK)

O215 Sepsis diagnosis by real-time PCR

09:18 (SeptiFast Kit, Roche Diagnostics):

preliminary results and possible application

A. Raglio, M. Rizzi, M. Amer, M. Mangia,

M.G. Lucà, A. Goglio (Bergamo, IT)

O216 Evaluation of four selective media

09:30 for the detection of methicillin-resistant

Staphylococcus aureus from surveillance


B.M. Willey, N. Kreiswirth, P. Akhavan, A. Tyler,

S. Malek, V. Pong-Porter, G. Small, N. Nelson,

A. McGeer, S.M. Poutanen, T. Mazzulli, D.E. Low,

M. Skulnick (Toronto, CA)

O217 Diagnostic value of procalcitonin to

09:42 distinguish monomicrobial blood stream

infection with coagulase-negative staphylococci

from contamination: a pilot study

P. Schuetz, B. Mueller, A. Trampuz (Basel, CH)

O218 Borrelia burgdorferi serodiagnosis: evaluation

09:54 of a novel Luminex bead-based recombinantantigen


D. Burki, S. Reymann, M. Toelge, J. Schipper,

L. Matter (Basel, CH; Neuried, DE)

O219 Development of a panfungal real-time PCR

10:06 H.P. Hinrikson, K. Jaton, D. Ciardo, M. Altwegg,

J. Bille, P.M. Hauser (Lausanne, Zurich, Lucerne, CH)

Erato Pneumonia and pneumococci


10:30 Chairpersons: Javier Garau (Barcelona, ES)

Waleria Hryniewicz (Warsaw, PL)

O220 The International Circumpolar Surveillance

08:30 System for population-based surveillance

of invasive pneumococcal disease, 1999–2004

M. Bruce, T. Cottle, S. Deeks, M. Lovgren,

L. Jette, T. Hennessy, D. Parks, K. Kristinsson,

K. Brinklov Jensen, O. Lovoll, P. Nuorti,

A. Nystedt, E. Herva, A. Koch, A. Parkinson

(Anchorage, US; Ottawa, Edmonton, Montreal,

CA; Reykjavik, IS; Nuuk, GL; Oslo, NO; Helsinki, FI;

Lulea, SE; Oulu, FI; Copenhagen, DK)

O221 Invasive pneumococcal disease in the era of

08:42 human immunodeficiency virus infection

O. Perovic, A. von Gottberg, C. Feldman,

O. Perovic (Johannesburg, ZA)

O222 Are Pneumonia Severity Index and CURB-65

08:54 useful for prediction of 30-day mortality in

community-acquired pneumonia?

K. Strålin, H. Holmberg (Örebro, SE)

O223 Tigecycline is as safe and effective as

09:06 levofloxacin in treating patients with

community-acquired pneumonia

N. Dartois, H. Gandjini, E.J. Ellis-Grosse

on behalf of the Tigecycline 313 Study Group

O224 Risk factors for Pseudomonas aeruginosa

09:18 isolation in sputum at hospital admission

in patients hospitalised for acute COPD


C. Garcia Vidal, P. Almagro, V. Romaní, H. Monzón,

L. Cuadra, M. Rodriguez, E. Cuchí, L. Canales,

J.L. Heredia, J. Garau (Terrassa, ES)

O225 Does low antibiotic consumption influence

09:30 microbiological findings in patients with

COPD exacerbations?

Z.B. Harboe, J.H. Wandall, J.D. Knudsen

(Frederiksberg, Hvidovre, DK)

O226 Management of severe community-

09:42 acquired pneumonia

C. Brun-Buisson, A.T. Kouatchet

for the French Severe Pneumonia Study Group

O227 Treatment and mortality from bacteraemic

09:54 pneumococccal disease in Toronto, Canada

K. Green, A. Shigayeva for the Toronto Invasive

Bacterial Diseases Network (TIBDN)

O228 Antimicrobial susceptibility of pneumococcal

10:06 isolates causing bacteraemic communityacquired

pneumonia in the public and private

sectors in Gauteng, South Africa

C. Feldman, A. Brink, A. von Gottberg,

L. de Gouviea, O. Perovic, K. Klugman

(Johannesburg, ZA)

O229 Outcome of adults with penicillin high-resistant

10:18 and susceptible invasive Streptococcus

pneumoniae community-acquired pneumonia

M. Mufson, G. Chan, R. Stanek (Huntington, US) page 49


PRESCRIBING INFORMATION. CUBICIN, 350 mg powder for concentrate

for solution for infusion. (Refer to Summary of Product Characteristics (SmPC)

before prescribing.) PRESENTATION: Powder for concentrate for solution for infusion. A pale

yellow to light brown lyophilised powder. Each vial contains 350 mg daptomycin. USES: For the

treatment of complicated skin and soft-tissue infections in adults caused by susceptible Gram positive

pathogens. DOSAGE AND ADMINISTRATION: 4 mg/kg administered by iv infusion and

administered over 30 minutes every 24 hours for 7-14 days or until the infection is resolved. CUBICIN

is not recommended for use in children and adolescents (< 18 years of age). In patients

with severe renal insufficiency the dose should be adjusted. See SmPC for full details.

CONTRAINDICATIONS: Hypersensitivity to the active substance or excipient. PRECAUTIONS:

CUBICIN is not recommended for use in patients with a concurrent bacteraemia, as data are limited.

CUBICIN is not effective in pneumonia. Creatine phosphokinase and myopathy: CPK levels

should be measured at baseline and at least once weekly. Patients with CPK > 5 times upper limit

normal at baseline and other patients at higher risk of developing myopathy should be monitored

more frequently. CUBICIN should only be administered to those patients taking other medication

associated with myopathy if it is considered that the benefit to the patient outweighs the risk. Patients

should be reviewed regularly for signs or symptoms of myopathy. Patients developing unexplained

muscle pain, tenderness, weakness or cramps should have CPK levels monitored every 2 days.

CUBICIN should be discontinued in the presence of unexplained muscle symptoms if CPK levels reach

> 5 times upper limit normal. Peripheral neuropathy: Patients developing signs or symptoms

should be investigated and consideration given to discontinuing treatment. Renal insufficiency:

Severe renal insufficiency may increase the risk of myopathy (see above). Dose adjustment is needed

in patients with creatinine clearance (CL/cr) < 30 ml/min (4 mg/kg q 48 hours). Caution is advised

before commencing and during therapy in patients with some degree of renal insufficiency (CL/cr

< 80 ml/min). Regular monitoring of renal function is advised during concomitant administration

of potentially nephrotoxic agents. Caution is recommended in very obese patients. Appropriate

measures should be taken if super infection occurs or if antibiotic-associated or pseudo membranous

colitis are suspected. Pregnancy and lactation: CUBICIN should not be administered in pregnancy

unless the potential benefit outweighs the risk. Breastfeeding should be discontinued during treatment

with CUBICIN. Interactions: No CYP 450 interactions are expected. It is recommended that

other medications associated with myopathy should, if possible, be temporarily discontinued during

treatment with CUBICIN unless the benefit of concomitant administration outweighs the risk. Caution

is advised when daptomycin is co-administered with any other medicinal product known to reduce

renal filtration. If unexplained abnormalities or PT/INR are observed in patients taking daptomycin,

consideration should be given to a possible in vitro interaction with the laboratory test. ADVERSE

REACTIONS: For subjects in clinical trials who received CUBICIN, the most frequently reported

adverse reactions were headache, nausea, vomiting, diarrhoea, muscle pain, fungal infections, rash,

infusion site reaction, increased Creatine phosphokinase (CPK) and abnormal liver enzymes; Alanine

aminotransferase (ALT), Aspartate aminotransferase (AST) and Alkaline phosphatase. Consult SmPC

for detailed listing. PACKAGE QUANTITIES AND BASIC NHS PRICE: £62 per single vial.

MARKETING AUTHORISATION NUMBER: EU/1/05/328/001 held by Chiron Corporation

Ltd, Symphony House, 7 Cowley Business Park, High Street, Cowley, Uxbridge UB8 2AD. LEGAL

CATEGORY: POM. Date of preparation: January 2006.CUBICIN ® is a registered trademark.

Information about adverse event reporting can be found at and adverse events should be reported

to the MAA holder: Chiron Corporation Ltd, Symphony House,

7 Cowley Business Park, High Street, Cowley, Uxbridge UB8 2AD.


Integrated Symposia

Scientific Programme Monday, April 3, 2006

Athena Respiratory tract infections: at-risk patients,

08:30– who are they?

10:30 Chairpersons: Alasdair Geddes (Birmingham, UK)

Jean-Pierre Sollet (Argenteuil, FR)

08:30 Introduction: at-risk patient definition

Alasdair Geddes (Birmingham, UK)

S230 At-risk pathogens: what are they?

08:35 Rafael Cantón (Madrid, ES)

S231 Clinical and therapeutic significance of

09:00 risk factors in RTI patients

Hartmut Lode (Berlin, DE)

S232 Guide to selection of appropriate treatment

09:30 in pneumonia

Wolfgang Graninger (Vienna, AT)

S232A Pharmacoeconomic consideration for the

10:00 use of fluoroquinolones in the treatment of

at-risk patients

Gary Milkovich (Woodbridge, US)

10:25 Conclusion

Jean-Pierre Sollet (Argenteuil, FR)

Integrated symposium arranged by


Méditerranée 1 Extending the antifungal armamentarium


10:30 Chairpersons: Thomas Patterson (San Antonio, US)

Patricia Ribaud (Paris, FR)

08:30 Welcome and opening remarks

Patricia Ribaud (Paris, FR)

S233 Recent developments in the mycology

08:35 laboratory

Mahmoud Ghannoum (Cleveland, US)

S234 Impact of early therapy on invasive

09:00 fungal infections

Thomas Patterson (San Antonio, US)

S235 New treatment options for candidemia –

09:25 azoles versus candins

Bart-Jan Kullberg (Nijmegen, NL)

Markus Ruhnke (Berlin, DE)

10:15 Panel discussion

10:25 Concluding remarks

Thomas Patterson (San Antonio, US)

Integrated symposium arranged by Pfizer

Clio Fighting the threat of resistance:

08:30– an interactive symposium

10:30 Chairpersons: Robert Masterton (Kilmarnock, UK)

Philippe Montravers (Paris, FR)

08:30 Welcome and introduction

Philippe Montravers (Paris, FR)

S236 Porins, pumps, enzymes and other

resistance threats

David Livermore (London, UK)

S237 Novel dosage regimens to fight resistance

George Drusano (Albany, US)

Panel discussion

S238 Interactive case history: a patient with

a severe abdominal gunshot wound

Robert Masterton (Kilmarnock, UK)

Philippe Montravers (Paris, FR)


Philippe Montravers (Paris, FR)

Integrated symposium arranged by AstraZeneca

Calliope Lipopeptide: the class of 2006


10:30 Chairpersons: Roger Finch (Nottingham, UK)

Adolf Karchmer (Boston, US)

S239 Gram-positive infections:

08:30 lessons learnt and novel solutions

Roger Finch (Nottingham, UK)

08:50 Questions and answers

S240 Test results

09:00 Bernd Wiedemann (Bonn, DE)

09:20 Questions and answers

S241 From theory to practice

09:30 Adolf Karchmer (Boston, US)

09:50 Questions and answers

S242 Daptomycin: graduation day

10:00 Marc Bonten (Utrecht, NL)

10:20 Questions and answers

Integrated symposium arranged by Chiron page 51

Keynote Lectures

Scientific Programme Monday, April 3, 2006

Apollon Antimicrobial intelligence: how eukaryotes

11:00– combat the quorum sensing strategy

12:00 Chairperson: Robert Read (Sheffield, UK)

K243 Andrea Sbarbati (Verona, IT)


Athena Clean care is safer care: a WHO initiative

11:00– to improve patient safety worldwide

12:00 Chairperson: Andreas Voss (Nijmegen, NL)

K244 Didier Pittet (Geneva, CH)


Méditerranée 1 Human papillomavirus: impact of disease

11:00– and vaccine intervention

12:00 Chairperson: S. Ragnar Norrby (Stockholm, SE)

K245 Mario Poljak (Ljubljana, SI)


Calliope Human genetic susceptibility to infection:

11:00– from basic research to society issues

12:00 Chairperson: Pierre Dellamonica (Nice, FR)

K246 Amalio Telenti (Lausanne, CH)


Award Lectures

Méditerranée 2 ESCMID Young Investigator Award Lectures


12:00 Chairperson: Marc Struelens (Brussels, BE)

S2271 Biology and pathogenecity of Chlamydia-like

11:00 organisms

Gilbert Greub (Lausanne, CH)

S2272 MRSA – from innovative control strategies to

11:30 new challenges

Stephan Harbarth (Geneva, CH)

The ESCMID Young Investigator Awards are

sponsored by Pfizer (see also page 18/19)

page 52 Final Programme

Poster Session III

Topics Session III

Presence of authors: 12:00–13:00

– Molecular detection of microbes

● P941–P963

– Molecular detection of respiratory microbes ● P964–P975

– Diagnostic and laboratory methods

for bacteria – I


– Bloodstream infections P999–P1013

– ICU infections P1014–P1028

– Gastro-intestinal and hepatic infections P1029–P1038

– Respiratory tract infections P1039–P1062

– Sexually transmitted diseases P1063–P1068

– Travel medicine, tropical and

parasitic diseases


– Seroepidemiology P1093–P1101

– Mycobacterial infections P1102–P1142

– Experimental infections: treatment

and pathogenesis


– Bacterial pathogenesis – II

★ P1159–P1197


Guided Poster Walks Session III

Theme: Molecular detection

Chairperson: Margareta Ievens (Edegem, BE)

Meeting point: Poster P941 at 12:15

Posters selected from within the topics marked ●

Theme: Bacterial pathogenesis

Chairpersons: Christoph Tang (London, UK)

William Shafer (Atlanta, US)

Meeting point: Poster P1159 at 12:15

Posters selected from within the topic marked ★

Poster Session IV

Topics Session IV

Presence of authors: 13:00–14:00

Scientific Programme Monday, April 3, 2006

– Mechanism of antifungal action and ● P1198–P1232

resistance to antifungals in fungal disease

– Antimicrobial resistance, P1233–P1257

permeability and fitness

– Antimicrobial susceptibility testing P1258–P1286

– Antibacterial susceptibility studies – II P1287–P1310

– Tigecycline in vitro studies – II P1311–P1329

– Nosocomial infection control: P1330–P1340


– Regional spread and outbreaks caused P1341–P1354

by nosocomial pathogens

– Multidrug-resistant Gram-negative P1355–P1372

organisms: survey and risk factors

– Epidemiology of resistance to antibiotics – I P1373–P1402

– Beta-lactamases P1403–P1420

– Non-molecular diagnostics of MRSA ★ P1421–P1431

– Antibiotic susceptibility testing:

★ P1432–P1459

management, specific organisms and

resistant traits


Guided Poster Walks Session IV

Theme: Mechanisms of antifungal action

Chairpersons: Jacques Bille (Lausanne, CH)

David Denning (Manchester, UK)

Meeting point: Poster P1198 at 13:00

Posters selected from within the topic marked ●

Theme: MRSA diagnostics and susceptibility testing

Chairpersons: Wolfgang Witte (Wernigerode, DE)

Jerome Etienne (Lyon, FR)

Meeting point: Poster P1421 at 13:00

Posters selected from within the topics marked ★


Apollon Emergence of transferable quinolone

14:00– resistance

15:00 Chairpersons: David Hooper (Boston, US)

Laurent Gutmann (Paris, FR)

S247 World emergence of qnr, a novel family

14:00 of quinolone resistance genes

David Hooper (Boston, US)

S248 The toxin-antitoxin systems: function

14:30 and distribution in the bacterial world

Laurence Van Melderen (Gosselies, BE)

Joint symposium arranged with the

ICAAC Program Committee

Athena The year in HIV medicine


15:00 Chairperson: Giovanni Di Perri (Turin, IT)

S249 The year in HIV medicine (1)

14:00 Françoise Brun-Vezinet (Paris, FR)

S250 The year in HIV medicine (2)

14:30 Frank-Detlef Goebel (Munich, DE)

Méditerranée 3 Hepatitis


15:00 Chairpersons: Andy Hoepelman (Utrecht, NL)

Will Irving (Nottingham, UK)

S251 Co-infection with HIV, HBV and HCV

14:00 Dominique Salmon-Ceron (Paris, FR)

S252 Hepatitis C is still a nosocomial infection

14:30 Will Irving (Nottingham, UK)

Clio Management of endocarditis


15:00 Chairpersons: Patrick Francioli (Lausanne, CH)

José Miró (Barcelona, ES)

S253 Antibiotic treatment of infective endocarditis

14:00 due to antibiotic resistant bacteria

José Miró (Barcelona, ES)

S254 Management of complicated endocarditis

14:30 Bruno Hoen (Besançon, FR) page 53

Scientific Programme Monday, April 3, 2006

Calliope PK/PD for the clinician: should we use

14:00– continuous infusion techniques?

15:00 Chairpersons: William Craig (Madison, US)

George Drusano (Albany, US)

S255 Beta-lactams

14:00 Johan Mouton (Nijmegen, NL)

S256 Glycopeptides

14:30 Niels Frimodt-Moller (Copenhagen, DK)

Oral Sessions

Méditerranée 1 Infectivity and emergence of resistance

14:00– in animal models

15:00 Chairpersons: Gian Maria Rossolini (Siena, IT)

Philippe Moreillon (Lausanne, CH)

O257 Infectivity of probiotic Lactobacillus

14:00 rhamnosus and Lactobacillus paracasei in a

rat model of experimental endocarditis

V. Vankerckhoven, S. Piu, P. Moreillon,

M. Vancanneyt, H. Goossens, J.M. Entenza

(Wilrijk, BE; Lausanne, CH; Ghent, BE)

O258 Dissemination of Borrelia burgdorferi

14:12 sensu lato in mice: influence of the species

and of the primary human isolation site

S.J. De Martino, C. Sordet, Y. Piemont,

C. Barthel, E. Collin, J. Sibilia, B. Jaulhac

(Strasbourg, FR)

O259 Subinhibitory concentrations of phenyl lactic

14:24 acid produced by Lactobacillus probiotic

strains attenuate the virulence of

Peudomonas aeruginosa and Staphylococcus

aureus in mouse infection model

M.C. Balotescu, V. Lazar, A. Israil, L. Ditu,

C. Larion, I. Alexandru, C. Bleotu, R. Cernat

(Bucharest, RO)

O260 Rifampin induction of resistance in

14:36 Acinetobacter baumannii, in vitro and in

an experimental pneumonia murine model

M.E. Pachón-Ibáñez, F. Fernández-Cuenca,

F. Docobo-Pérez, J. Pachón, A. Pascual

(Seville, ES)

O261 Experimental dose regimen modelling

14:48 of intestinal emergence of Enterococcus

faecalis resistant to linezolid in gnotobiotic


N. Bourgeois-Nicolaos, B. Couson, L. Massias,

A. Andremont, F. Doucet-Populaire

(Paris, Le Chesnay, FR)

page 54 Final Programme

Méditerranée 2 Infection in the immunocompromised

14:00– host (except HIV)

15:00 Chairpersons: Nicole Blijlevens (Nijmegen, NL)

Leonard Leibovici (Petah-Tiqva, IL)

O262 Epidemiology of fungal infections in

14:00 haematological stem cells transplanted

patients: SEIFEM 2004 study

L Pagano, M. Caira, M.T. Van Lint, G. Irrera,

A Bonini, A. Candoni, C. Caramatti, M. Picardi,

R. Invernizzi, D. Mattei, L. Fianchi, P. Falcucci,

G. Reddiconto, C.G. Valentini, L. Melillo,

M.R. Fadda, A. Nosari, C. Girmenia, F. Aversa

on behalf of SEIFEM (Sorveglianza Epidemiologica

Infezioni Fungine Nelle Emopatie Maligne)

O263 Clustering of Pneumocystis jiroveci

14:12 pneumonia cases in renal transplant

recipients: coincidence or a clue for patientto-patient


M.G.J. de Boer, L.E.S. Bruijnesteijn van

Coppenraet, A. Gaasbeek, S.P. Berger,

L.B.S. Gelinck, E.J. Kuijper, F.P. Kroon,

J.P. Vandenbroucke (Leiden, NL)

O264 Nosocomial legionellosis outbreak occurring

14:24 in immunosuppressed patients in a cancer


C. Gudiol, J. Carratala, M.A. Dominguez,

R. Verdaguer, A. Fernandez-Sevilla, F. Gudiol

(Barcelona, ES)

O265 Implications of the evidence for antibiotic

14:00 prophylaxis for cancer patients with

neutropenia: updated meta-analysis

L. Leibovici, A. Gafter-Gvili, M. Paul, A. Fraser,

M. Cullen (Petah Tikva, IL; Birmingham, UK)

O266 Bacteraemia in Danish patients with

14:36 haematological malignancies: coverage and

impact of inappropriate empirical antibiotic

treatment on 7-day and 30-day mortality

M. Nørgaard, H. Larsson, G. Pedersen,

H.C. Schønheyder, H.T. Sørensen

(Aalborg, Aarhus, DK)

Iris Multidrug-resistant Gram-negative

14:00– organisms in the hospital and community

15:00 Chairpersons: Rafael Cantón (Madrid, ES)

Marek Gniadkowski (Warsaw, PL)

O267 Risk factors for faecal carriage of extended

14:00 spectrum beta-lactamase producing

Escherichia coli and Klebsiella spp. in the


Ö.K. Azap, H. Arslan, S.Ö. Karaman,

T. Togan (Ankara, TR)

Scientific Programme Monday, April 3, 2006

O268 Differences in the epidemiology of

14:12 extended-spectrum beta-lactamase producing

Escherichia coli according to the types of


J. Rodríguez-Bano, M.D. Navarro, L. Romero,

M.A. Muniain, J.R. Hernández-Bello, A. Pascual

(Seville, ES)

O269 Frequency and predictors of colonisation

14:24 of the respiratory tract by Gram-negative

bacteria with the blaVIM gene in patients of a

newly established intensive care unit

M. Horianopoulou, N. Legakis, M. Kanellopoulou,

S. Lambropoulos, A. Tsakris, M. Falagas (Athens, GR)

O270 Epidemiological investigation of quinolone

14:36 resistance in infections due to extendedspectrum


Enterobacteriaceae in a tertiary hospital

A. Katsandri, A. Vasilakopoulou, V. Mela,

G.L. Petrikkos, C. Kosmidis, J. Papaparaskevas,

A. Avlamis (Athens, GR)

O271 The changing epidemiology of sequential

14:48 outbreaks of multiresistant Acinetobacter

baumannii bacteraemia: a ten-year study in

an intensive care unit

J.J. Camarena, R. Gonzalez, R. Zaragoza,

J.C. Navarro, S. Sancho, A. Artero, J.M. Nogueira

(Valencia, ES)

Hermes Infection control


15:00 Chairpersons: Benedetta Allegranzi (Vicenza, IT)

Serhat Ünal (Ankara, TR)

O272 New World Health Organization alcohol-

14:00 based formulations to implement handrubbing

as the gold standard for hand hygiene worldwide

B. Allegranzi, A. Voss, M. Rotter, S. Sattar,

W. Griffiths, S. Dharan, L. Donaldson, D. Pittet

(Verona, IT; Nijmegen, NL; Vienna, AT; Ottawa CA;

Geneva, CH)

O273 Decrease of external ventricular- or lumbar

14:12 drain-related infections by a multidisciplinary


M.A. Leverstein-van Hall, T.E.M. Hopmans,

H.E.M. Blok, J.W. Berkelbach van der Sprenkel,

M.J.M. Bonten on behalf of the UMCU Working

Party Neurosurgical Drain infections

O274 Evidence for the effectiveness of ‘Search

14:24 and destroy’ of methicillin-resistant

Staphylococcus aureus in the Netherlands

M.J.C.A. van Trijp, D.C. Melles, A. Ott,

W.D.H. Hendriks (Rotterdam, NL)

O275 Reducing the impact of methicillin-

14:36 resistant Staphylococcus aureus infection in

an intensive care unit: a nine-year analysis

A. Pan, E. Raineri, P. Mondello, L. Ferrari,

G. Carnevale, A. Acquarolo, S. Lorenzotti, S. Magri,

L. Soavi, L. Crema (Brescia, Cremona, IT)

O276 Comparison of the bacterial efficacy

14:48 and acceptability of an alcohol-based hand

rinse with two alcohol-based hand gels

during routine patient care

F. Barbut, E. Maury, L. Goldwirt, D. Neyme,

R. Aman, B. Rossi, P. Boelle, G. Offenstadt

(Paris, FR)

Integrated Symposium

Erato Galactomannan antigen detection in

14:00– invasive aspergillosis: test optimisation and

15:00 impact on patient management

Chairpersons: Jacques Bille (Lausanne, CH)

Paul E. Verweij (Nijmegen, NL)

S277 Optimisation of the cut-off value of the

14:00 Platelia Aspergillus ELISA

Paul E. Verweij (Nijmegen, NL)

S278 Galactomannan and computed tomography-

14:30 based preemptive antifungal therapy in

neutropenic patients at high risk for invasive

fungal infections

Johan Maertens (Leuven, BE)

Integrated symposium arranged by

Bio-Rad Laboratories


Apollon How to detect the next emerging pathogen


17:30 Chairpersons: Xavier De Lamballerie (Marseille, FR)

Marion Zambon (London, UK)

S279 From clinicians and microbiologists to

15:30 the WHO: expectations from the new

international health regulations

Maxwell Hardiman (Geneva, WHO)

S280 What is the role of the European CDC for

16:00 the detection of emerging pathogens?

Johan Giesecke (Stockholm, ECDC)

S281 Lessons learnt from SARS, H7N7 and

16:30 H5N1 avian flu

Christian Drosten (Hamburg, DE)

S282 How to detect new viral agents and

17:00 what Europe should do

Xavier de Lamballerie (Marseille, FR) page 55

Scientific Programme Monday, April 3, 2006

Méditerranée 2 To treat or not to treat


16:30 Chairpersons: Frank Detlef Goebel (Munich, DE)

Wolfgang Graninger (Vienna, AT)

S283 Positive blood culture with Staphyloccus

15:30 epidermidis

Winfried V. Kern (Freiburg, DE)

S284 Candida infections

16:00 Wolfgang Graninger (Vienna, AT)

16:30– Problems in the treatment of HIV


Chairpersons: Frank Detlef Goebel (Munich, DE)

Wolfgang Graninger (Vienna, AT)

S285 HIV-treatment: when, how and against what –

16:30 recent surprises

Jens Lundgren (Copenhagen, DK)

S286 The management of therapeutic failure

17:00 Giovanni Di Perri (Turin, IT)

Hermes Paediatric respiratory tract infections:

15:30– the major killers

17:30 Chairpersons: S. Ragnar Norrby (Stockholm, SE)

Annika Linde (Solna, SE)

S287 The link between asthma and viral respiratory

15:30 infections

Nikos Papadopoulos (Athens, GR)

S288 Paediatric influenza: severity and need

16:00 for protection

Annika Linde (Solna, SE)

S289 Human metapneumovirus infections

16:30 in children: approaches for prevention

Bernadette van den Hoogen (Rotterdam, NL)

S290 Paediatric tuberculosis: not to be forgotten

17:00 Sam Walters (London, UK)

Clio Evidence-based preventive and control

15:30– measures for selected nosocomial pathogens:

17:30 a critical appraisal

Chairpersons: Christian Ruef (Zurich, CH)

Andreas Voss (Nijmegen, NL)


15:30 Marc Bonten (Utrecht, NL)

S292 Multi-drug resistant Gram-negative bacteria

16:00 Yehuda Carmeli (Tel Aviv, IL)

S293 Norovirus

16:30 Andreas Widmer (Basel, CH)

page 56 Final Programme

S294 Risk factors for the acquisition of

17:00 vancomycin-resistant enterococci (VRE) and

clinical practice

Evelina Tacconelli (Rome, IT)

Calliope Limiting antibiotic usage in the community:

15:30– benefits and collateral effects


Chairpersons: Dominique L. Monnet

(Copenhagen, DK)

Hermann Goossens (Edegem, BE)

S295 What impact does the European ban of

15:30 antibiotics in animal feed have on antibiotic

resistance of animal bacteria?

Frank M. Aarestrup (Copenhagen, DK)

S296 What is the impact of reductions in antibiotic

16:00 use on antibiotic resistance in the community?

Pentti Huovinen (Turku, FI)

S297 Have reductions in antibiotic use in

16:30 general practice led to re-emergence of


Richard Wise (Birmingham, UK)

S298 Clinical and public health impact of

17:00 antibiotic resistance

Brigitte Dunais (Nice, FR)

Oral Sessions

Méditerranée 3 Antibacterial susceptibility studies:

15:30– activities, mechanisms and drug interactions

17:30 Chairpersons: Timothy Walsh (Bristol, UK)

Gunnar Kahlmeter (Växjö, SE)

O299 Evaluation of drug interactions and CYP450

15:30 inhibition with faropenem medoxomil

A. Beaudry, F. Dean, S.C. Gill, C. Black, K. Khan

(Louisville, Austin, US)

O300 Bactericidal activities of daptomycin

15:42 and vancomycin in vancomycin-susceptible

Staphylococcus aureus and heterogeneously

vancomycin intermediate S. aureus strains

M. Wootton, T.R. Walsh, A.P. MacGowan

(Bristol, UK)

O301 The high activity of meropenem against

15:54 Gram-negative bacteria from a paediatric

intensive care unit in Poland (1997–2005)

J.A. Patzer, D. Dzierzanowska, A. Pawinska,

P.J. Turner (Warsaw, PL; Macclesfield, UK)

O302 Morphological and bactericidal effects

16:06 of amoxicillin and clarithromycin on

Helicobacter pylori

F. Can, M. Demirbilek, G. Karabay, H. Arslan

(Ankara, TR)

Scientific Programme Monday, April 3, 2006

O303 A comparison of susceptibility to antibiotics

16:18 in nosocomial and non-nosocomial infections

in a hospital in Israel

A. Zalounina, S. Andreassen, M. Paul, L. Leibovici

(Aalborg, DK; Tel-Aviv, IL)

O304 Comparative minimum inhibitory and mutant

16:30 prevention concentrations of contemporary

(2004–2005) urinary tract pathogens tested

against ciprofloxacin and levofloxacin

J. Blondeau, S. Borsos, C. Hesje (Saskatoon, CA)

O305 Activity of moxifloxacin against community-

16:42 acquired MRSA and other quinolone-susceptible

MRSA isolates

J. von Freyberg, S. Scherpe, M.A. Horstkotte,

J.K. Knobloch (Hamburg, DE)

O306 Antimicrobial susceptibility patterns

16:54 correlate with staphylococcal cassette

chromosome mec types for hospital- and

community-acquired methicillin-resistant

Staphylococcus aureus

A. Kilic, H.J. Li, S.E. Sefers, C.W. Stratton,

Y.W. Tang (Nashville, US)

O307 Comparative MIC and MPC results for

17:06 5 quinolone compounds repeatedly tested

against American type culture collection

control strains: suggested MPC quality

control value ranges

J. Blondeau, C. Hesje, S. Borsos, L. Blondeau,

B. Blondeau (Saskatoon, CA)

O308 Investigation of tolerance to triclosan of

17:18 five international MRSA clones

Z. Al-Doori, D. Morrison, G.F.S. Edwards,

C.G. Gemmell (Glasgow, UK)

Iris Epidemiology of MRSA in Europe


17:30 Chairpersons: Hajo Grundmann (Bilthoven, NL)

Didier Pittet (Geneva, CH)

O309 MRSA incidences and proportions: how well

15:30 do these correlate on a European level?

M.E.A. de Kraker, N. van de Sande, J. Monen,

M.A. Borg, G. Kahlmeter, J. Kolman,

H. Grundmann and EARSS participants

O310 Statistical analysis of trends in mandatory

15:42 MRSA bacteraemia in NHS acute hospital


A. Pearson, A. Charlett (London, UK)

O311 Massive spread of the New York/Japan

15:54 MRSA clone (ST5-SCCmec II) in a European


T. Conceição, M. Aires de Sousa, M. Füzi, Á. Tóth,

J. Pászti, E. Ungvári, W. van Leeuwen,

A. van Belkum, H. Grundmann, H. de Lencastre

(Oeiras, PT; Budapest, HU; Rotterdam, Bilthoven NL;

New York, US)

O312 Molecular characterisation of MRSA in

16:06 the south-eastern part of Norway from 1991

to 2005

A.E. Fossum, K. Alm-Kristiansen, G. Bukholm

(Lørenskog, NO)

O313 National Danish case-control study of

16:18 community onset infections caused by

methicillin-resistant Staphylococcus aureus

S. Böcher, A. Gervelmeyer, D.L. Monnet,

K. Mølbak, R. Skov (Copenhagen, DK)

O314 EUREGIO MRSA-net Twente/Münsterland:

16:30 A Dutch-German cross-border network for

surveillance and control of methicillinresistant

S. aureus

A.W. Friedrich, F. Verhoeven, A. Mellmann,

A.K. Sonntag, L.J.E.W.C. Gemert-Pijnen,

I. Daniels-Haardt, M.G.R. Hendrix

(Munster, DE; Enschede, NL)

O315 Prospective surveillance and decolonisation

16:42 of Panton-Valentine leucocidin-positive MRSA

among residents and staff of three German

nursing homes

F.M.E. Wagenlehner, H.J. Linde, E. Bambl,

U. Raab, D. Kahlau, C. Höller, N. Lehn,

W. Witte, K.G. Naber (Straubing, Regensburg,

Oberschleissheim, Wernigerode, DE)

O316 The first national methicillin-resistant

16:54 Staphylococcus aureus prevalence study in

Belgian nursing homes indicates high carriage

rates among residents

B. Jans, C. Suetens, O. Denis, M. Struelens

(Brussels, BE)

O317 The EPISA study: characterisation of fusidic

17:06 acid and methicillin-resistant Staphylococcus

aureus causing skin and soft tissue infections

in outpatients in France

A.R. Larsen, A. Santerre Henriksen, V. Jarlier,

P. Menday, R.L. Skov (Copenhagen, Ballerup, DK;

Paris, FR)

O318 Methicillin-resistant Staphylococcus

17:18 aureus in children with allergy

I. Kuznecovs (Riga, LV) page 57

Integrated Symposia

Scientific Programme Monday, April 3, 2006

Athena The heart of the matter:

15:30– managing resistance in RTIs

17:30 Chairpersons: Robert C. Moellering Jr (Boston, US)

David Farrell (London, UK)

15:30 Introduction

Robert C. Moellering Jr (Boston, US)

S319 What are the antibiotic attributes involved in

15:40 resistance developmentt

Steve Jenkins (New York, US)

S320 Recent key findings from multinational

16:00 resistance surveys

David Farrell (London, UK)

S321 The impact of antimicrobial resistance on

16:20 therapeutic outcome in RTIs

Robert C. Moellering Jr (Boston, US)

S322 Redefining sinusitis management:

16:40 the French experience

Christian Dubreuil (Lyon, FR)

17:00 Question and answers

17:20 Concluding remarks

David Farrell (London, UK)

Integrated symposium arranged by sanofi-aventis

Méditerranée 1 Fungal infections: host defences and

15:30– clinical interventions

17:30 Chairpersons: Olivier Lortholary (Paris, FR)

William Steinbach (Durham, US)

15:30 Welcome and introduction

Olivier Lortholary (Paris, FR)

S323 Host defence to invasive fungal infections

15:35 and opportunities for immunotherapy

Bart Jan Kullberg (Nijmegen, NL)

S324 Current and future treatment options

16:00 in yeast infections

Helen Sambatakou (Athens, GR)

S325 Micafungin in the treatment of invasive

16:20 candidiasis: results of a randomised

phase III study

Olivier Lortholary (Paris, FR)

S326 New insights on antifungal use in children

16:50 and neonates

William Steinbach (Durham, US)

17:15 Panel discussion and concluding remarks

Integrated symposium arranged by

Astellas Pharma

page 58 Final Programme

Erato Diagnosis of sepsis: the need for fast

15:30– molecular microbiological methods

17:30 Chairpersons: Georg Peters (Munster, DE)

Marc Struelens (Brussels, BE)

15:30 Introduction

Georg Peters (Munster, DE)

S327 Inadequate treatment in bloodstream

15:40 infections

Emilio Bouza (Madrid, ES)

S328 Evaluation of a new PCR-based assay for

16:05 rapid pathogen detection in patients with

clinical sepsis

Klaus-Peter Hunfeld (Frankfurt, DE)

S329 A clinician’s perspective: potential value

16:30 of nucleic acid based diagnosis

Lutz Lehmann (Bonn, DE)

16:55 Panel discussion – Question and answers

17:20 Closing remarks

Marc Struelens (Brussels, BE)

Integrated symposium arranged by

Roche Diagnostics

Scientific Programme Tuesday, April 4, 2006

Meet-the-Expert Sessions

Méditerranée 2 Empirical antibiotic therapy for ICU-acquired

E330 infections

07:15– Experts: John Marshall (Toronto, CA)

08:15– Jean Carlet (Paris, FR)


– to provide attendees with microbiological

results, such as susceptibility data, needed

to guide empirical therapy

– to outline the PK/PD issues

– to evaluate the impact of appropriate empirical

therapy on outcome, in particular in the light

of recent international guidelines

– to explain the ecological impact of broad

antibiotic therapies

– to describe the concept of de-escalation

Méditerranée 3 How to defend your clinical microbiology in

E331 times of budget restrictions?

07:15– Experts: Vincent Jarlier (Paris, FR)

08:15– Matthias Herrmann (Homburg, DE)


– to develop select aspects on pre-analytical,

analytical and post-analytical measures for

enhancing the impact and cost effectiveness

of clinical microbiological diagnostics

– to formulate outlines for convincing budget

directors of the cost effectiveness of

decentralised diagnostic microbiology and

of the assurance of prompt microbiological


– to define the risks of inappropriate management

as a result of insufficient diagnostics

Iris Antibiotic prophylaxis in immunocompromised

E332 hosts, including transplant patients:

07:15– when and how?

08:15– Experts: Georg Maschmeyer (Potsdam, DE)

Thierry Calandra (Lausanne, CH)


– to identify the subgroups of patients expected

to benefit from antimicrobial prophylaxis

– to define the goals of prophylaxis for these


– to give an overview on strategies for infection


– to discuss results of clinical studies on anti -

biotic prophylaxis in immunocompromised


– to assess potential benefits, risks and costs

of antibiotic prophylaxis

Hermes How to manage catheter-related infections?

E333 Experts: Emilio Bouza (Madrid, ES)

07:15– Niels Høiby (Copenhagen, DK)



– to review the epidemiology of catheterrelated

bloodstream (CR-BSI) infections

– to review the diagnostic methods of CR-BSI

including methods with or without catheter


– to review the indications to withdraw or

maintain the infected catheter

– to review drugs, duration and procedures of

administration of antimicrobial agents to

control CR-BSI

– to review information regarding prevention

of CR-BSI with evidence-based criteria

Clio Routine susceptibility testing:

E334 which antibiotic to choose?

07:15– Experts: Laurent Gutmann (Paris, FR)

08:15– Philippe Moreillon (Lausanne, CH)


– to better define which antibiotic should be


– to better define why this antibiotic should be


– to better define which interpretations can be

deduced from the expected phenotypes

Erato Emergence of risk factors and treatment

E335 issues for Clostridium difficile-associated

07:15– diarrhoea (CDAD)

08:15– Experts: Ed Kuijper (Leiden, NL)

Clifford McDonald (Atlanta, US)


– to understand the changing epidemiology of

CDAD and possible reasons for this change

– to identify important infection control issues

and controversies that are unique to the

control of CDAD

– to define the optimal diagnostic approach

for CDAD

– to analyse therapeutic implications of CDAD

due to toxinotype III, ribotype 027

– to show examples of CDAD as an emerging

community-acquired disease page 59


Scientific Programme Tuesday, April 4, 2006

Athena Pathogenesis and therapy of sepsis


10:30 Chairpersons: John Marshall (Toronto, CA)

Thierry Calandra (Lausanne, CH)

08:30 Presentation of the International

Sepsis Forum Award 2006

(see also page 21)

S336 Blood monocytes as a site of

08:35 production of sTREM-1 in sepsis

E.J. Giamarellos-Bourboulis (Athens, GR)

S337 TLRs and NLRs in the pathogenesis of sepsis

08:50 Thierry Calandra (Lausanne, CH)

S338 Host defense in pneumococcal pneumonia

09:15 Tom van der Poll (Amsterdam, NL)

S339 Sepsis markers in 2006

09:40 John Marshall (Toronto, CA)

S340 Methicillin and vancomycin resistance in

10:05 severe staphylococcal infections

Philippe Moreillon (Lausanne, CH)

Joint symposium arranged with the

International Sepsis Forum (ISF)

Méditerranée 2 Non-pneumococcal community-

08:30– acquired respiratory tract infections

10:30 – current state of the art

Chairpersons: Nicole Guiso (Paris, FR)

Peter Appelbaum (Hershey, US)

S341 The role of H. influenzae and B. pertussis

08:30 in community-acquired respiratory

tract infection

Javier Garau (Barcelona, ES)

S342 Changing drug susceptibility in

09:00 H. influenzae with special reference to

macrolides, azalides, ketolides and


Peter C. Appelbaum (Hershey, US)

S343 Legionnaires disease 2006: update

09:30 on diagnosis and clinical management

Jordi Carratala (Barcelona, ES)

S344 Pertussis vaccine in perspective

10:00 Nicole Guiso (Paris, FR)

page 60 Final Programme

Hermes Risk assessment in primary care:

08:30– clairvoyance or evidence-based medicine?

10:30 Chairpersons: Theo Verheij (Utrecht, NL)

Thierry Christiaens (Ghent, BE)

S345 Lower respiratory tract infections:

08:30 quantitative and qualitative perspectives

Chris Butler (Cardiff, UK)

S346 Cystitis, mostly simple but not always

09:00 Thierry Christiaens (Ghent, BE)

S347 Prognosis of otitis media

09:30 Paul Little (Southampton, UK)

S348 Bacterial meningitis in adults

10:00 Diederik van de Beek (Amsterdam, NL)

Symposium arranged with the ESCMID Study

Group on Primary Care Topics (ESPRIT)

Calliope Update on the influenza pandemic threat


10:30 Chairpersons: Ron Fouchier (Rotterdam, NL)

Christian Drosten (Hamburg, DE)

S349 H5N1 and other pandemic threats

08:30 Ron Fouchier (Rotterdam, NL)

S350 Vaccine development

09:00 Sylvie van der Werff (Paris, FR)

S351 Diagnosis and treatment

09:30 Maria Zambon (London, UK)

S352 Pandemic preparedness

10:00 Johan Giesecke (Stockholm, ECDC)

Oral Sessions

Méditerranée 3 Antimicrobial PK/PD


10:30 Chairpersons: Niels Frimodt-Møller

(Copenhagen, DK)

Ursula Theuretzbacher (Vienna, AT)

O353 Impact of sample size on the performance

08:30 of multiple model pharmacokinetic


V.H. Tam, S. Kabbara, R.F. Yeh, R.H. Leary

(Houston, Los Angeles, US)

O354 Continuous versus intermittent intravenous

08:42 administration of antibiotics with timedependent

antibacterial action: a systematic

review of pharmacokinetic and pharmaco -

dynamic parameters

S. Kasiakou, K. Lawrence, N. Choulis, M. Falagas

(Athens, GR)

Scientific Programme Tuesday, April 4, 2006

O355 Testing the mutant selection window

08:54 hypothesis with in vitro dynamic models:

pros and cons

A. Firsov, I. Lubenko, S. Zinner

(Moscow, RU; Cambridge, US)

O356 Pharmacodynamic evaluation of the

09:06 bactericidal activity of telavancin against extracellular

and intracellular MSSA and MRSA

M. Barcia-Macay, M. Mingeot-Leclercq,

P.M. Tulkens, F. Van Bambeke (Brussels, BE)

O357 Comparative pharmacodynamics (PD)

09:18 of moxifloxacin and levofloxacin against

S. pneumoniae following exposure to

bioequivalent PD-surrogate parameters

A. Dalhoff, S. Schubert, H. Stass

(Kiel, Wuppertal, DE)

O358 Pharmacokinetics of moxifloxacin in tissues

09:30 of the female urogenital tract

H. Stass, H. Delesen, D. Kubitza, A. Halabi,

C.H. Gleiter (Wuppertal, Kiel, Tubingen, DE)

O359 Pharmacokinetics of moxifloxacin in

09:42 tissues of the GI-tract

H. Stass, A.D. Rink, H. Delesen, D. Kubitza,

M.W. Buechler, C.M. Seiler, K.-H. Vestweber

(Wuppertal, Heidelberg, Leverkusen, DE)

O360 Evaluation of tigecycline penetration

09:54 into colon wall tissue and epithelial lining

fluid using a population pharmacokinetic

model and Monte Carlo simulation

C.M. Rubino, L. Ma, S.M. Bhavnani,

J. Korth-Bradley, J. Speth, E.J. Ellis-Grosse,

P.G. Ambrose, G.L. Drusano

(Albany, Philadelphia, US)

O361 Pharmacokinetic-pharmacodynamic analyses

10:06 of efficacy using estimates of serum and

effect site tigecycline exposures in patients

with complicated intra-abdominal infections

S.M. Bhavnani, C.M. Rubino, P.G. Ambrose,

J. Korth-Bradley, J. Speth, E.J. Ellis-Grosse,

G.L. Drusano (Albany, Philadelphia, US)

O362 Ceftazidime dose and dosing interval deter-

10:18 mine the selection of resistant Enterobacter

cloacae isolates in the intestinal flora of rats

treated for a Klebsiella pneumoniae pulmonary


W.H.F. Goessens, J.W. Mouton, M. ten Kate,

A. Ott, I.A.J.M. Bakker-Woudenberg

(Rotterdam, Nijmegen, NL)

Iris Microbial pathogenesis: a diversity of

08:30– mechanisms and host responses

10:30 Chairpersons: Jean-Pierre Gorvel (Marseille, FR)

Alex van Belkum (Leiden, NL)

O363 The role of triggering receptor expressed

08:30 on myeloid cells-1 (trem-1) and of its soluble

form for the evolution of septic syndrome

M. Raftogiannis, V. Markaki, D. Plachouras,

I. Validakis, M. Kontogiorgi, E.J. Giamarellos-

Bourboulis, C. Roussos, H. Giamarellou

(Athens, GR)

O364 Caenorhabditis elegans killing model:

08:42 a new tool to study uropathogenic

Escherichia coli virulence

J.P. Lavigne, A.B. Blanc-Potard, G. Blossier,

D. O’Callaghan, A. Sotto (Nîmes, FR)

O365 Clumping factor B is essential for human

08:54 Staphylococcus aureus nasal colonisation

H. Wertheim, H.A.M. Boelens, D.C. Melles,

H. Verbrugh, T. Foster, A. van Belkum

(Rotterdam, NL; Dublin, IE)

O366 Alanine esters of enterococcal lipoteichoic

09:06 acid have a role in biofilm formation and

resistance to antimicrobial peptides

F. Fabretti, C. Theilacker, A. Kropec, S. Koch,

J. Huebner (Freiburg, DE; Boston, US)

O367 Quinolones induce the partial and total loss of

09:18 uropathogenic Escherichia coli pathogenicity

islands by two different pathways

S. Soto, M.T. Jimenez de Anta, J. Vila

(Barcelona, ES)

O368 Recombinant expression and characterisation

09:30 of putative streptococcal pyrogenic exotoxins

SPEGdys, SPELdys, and SPEMdys from Strepto -

coccus dysgalactiae, subsp. equisimilis

K.H. Schmidt, S. Sachse, S. Rödiger, D. Gerlach,

E. Straube, J. Rödel (Jena, DE)

O369 Release of activin A by microglial cells upon

09:42 stimulation with bacterial TLR-agonists

S. Ebert, R. Nau, U. Michel (Gottingen, DE)

O370 Regulation of putative extra cellular virulence

09:54 factors in Staphylococcus epidermidis by the

alternative sigma factor sigmaB

J.C. Kneschke, S. Jaeger, D. Mack, J.K. Knobloch

(Hamburg, DE; Swansea, UK)

O371 Oral lactobacilli and periodontitis

10:06 A.K. Szkaradkiewicz, B. Tukiendorf,

J. Stopa (Poznan, PL) page 61

Integrated Symposia

Scientific Programme Tuesday, April 4, 2006

Méditerranée 1 Combination therapy for candida –

08:30– the case for biologicals

10:30 Chairpersons: Bertrand Dupont (Paris, FR)

Markus Ruhnke (Berlin, DE)

S372 21st century yeasts

08:30 Rosemary Barnes (Cardiff, UK)

S373 HSP90 the eukaryotic problem

09:00 James Burnie (Manchester, UK)

S374 Immunomodulatory therapy in yeast

09:30 infections

Jorge Garbino (Geneva, CH)

S375 A rational approach to combination therapies

10:00 Tomas Walsh (Bethesda, US)

Integrated symposium arranged by

Neutec Pharma

Clio Compliance in antibiotics: the last chance?


10:30 Chairpersons: Giuseppe Cornaglia (Verona, IT)

Jean-Claude Pechère (Geneva, CH)

08:30 Introduction

S376 Reassessing antibiotic resistance:

08:40 the compliance conundrum

Giuseppe Cornaglia (Verona, IT)

S377 Surveys of patient compliance

09:00 Jean-Claude Pechère (Geneva, CH)

S378 Health and economic outcomes:

09:20 why compliance matters

Dyfrig Hughes (Bangor, UK)

S379 Taking action: transforming results

09:40 into practice

Thomas File (Ohio, US)

10:00 Panel discussion and closing remarks

Integrated symposium arranged by Pfizer

page 62 Final Programme

Erato Antisepsis and the prevention of skin and

08:30– soft tissue infections

10:30 Chairpersons: Curtis G. Gemmell (Glasgow, UK)

Christian Ruef (Zurich, CH)

S380 Overview of old and new antiseptic agents

08:30 Curtis G. Gemmell (Glasgow, UK)

S381 Susceptibility of multi-resistant Gram-

08:55 positive cocci to various antiseptic agent

Donald Morrison (Glasgow, UK)

S382 The use of local antisepsis to prevent catheter

09:20 infections

Marcus Dettenkofer (Freiburg, DE)

S383 Catheter care in the immunocompromised

09:45 host

Andreas Tietz (Basel, CH)

S384 Mode of action of antiseptic agents

10:10 Peter Geroncy-Bermes, (Nordenstedt, DE)

Integrated symposium arranged by

Schülke & Mayr

Keynote Lectures

Scientific Programme Tuesday, April 4, 2006

Athena Epidemiological determinants of the

11:00– genetic diversity of viruses

12:00 Chairperson: Alex van Belkum (Leiden, NL)

K385 Neil Ferguson (London, UK)


Méditerranée 1 Mitochondria: a newly discovered target for

11:00– Gram-positive and -negative bacterial toxins

12:00 Chairperson: Elisabeth Nagy (Szeged, HU)

K386 Patrice Boquet (Nice, FR)


Calliope Implications of chemotherapy-related

11:00– mucosal barrier injury

12:00 Chairperson: Claudio Viscoli (Genoa, IT)

K387 Nicole Blijlevens (Nijmegen, NL)



Clio Issues in travel medicine


12:00 Chairpersons: Christoph Hatz (Basel, CH)

David Hill (London, UK)

S388 Immunisation for travel – new developments

11:00 David Hill (London, UK)

S389 Treatment of imported malaria

11:30 Tomas Jelinek (Berlin, DE)

Oral Sessions

Méditerranée 3 Sexually transmitted diseases and urinary

11:00– tract infections


Chairpersons: Susanne Esposito (Milan, IT)

Kurt Naber (Straubing, DE)

O390 Rectal lymphogranuloma venereum in

11:00 San Francisco in the 1980s

J. Schachter, J. Moncada, J. Spaargaren

(San Francisco, US; Amsterdam, NL)

O391 The role of Chlamydia trachomatis in chronic

11:12 prostatitis/chronic pelvic pain syndrome

M. Sukhorukova, R. Kozlov, I. Malev, O. Shipulina,

L. Stratchounski (Smolensk, Moscow, RU)

O392 Acceptability of self-taken vaginal swabs and

11:24 first-catch urine samples for the diagnosis

of urogenital Chlamydia trachomatis and

Neisseria gonorrhoeae with an amplified DNA

assay in young women attending a public

health STD clinic

C.J.P.A. Hoebe, C.W. Rademaker, E.E.H.G. Brouwers,

H.L.G. Ter Waarbeek (Heerlen, NL)

O393 Asymptomatic bacteriuria, a lasting

11:36 or fluctuating condition among elderly living

in the community?

N. Rodhe, M. André, L. Englund, S. Mölstad

(Falun, Jönköping, SE)

O394 Recurrent urinary tract infections caused

11:48 by Escherichia coli

S. Gualandris, A. Endimiani, G. Brigante,

F. Luzzaro, A. Toniolo (Varese, IT) page 63

Scientific Programme Tuesday, April 4, 2006

Erato AIDS and HIV


12:00 Chairpersons: Pierre Marie Roger (Nice, FR)

Giovanni Di Perri (Turin, IT)

O395 AIDS indicative diseases across Europe

11:00 G. Likatavicius, I. Devaux, J. Alix, A. Nardone

on behalf of EuroHIV

O396 Polymorphisms in toll-like receptors

11:12 influence susceptibility to HIV infection

and its clinical course

P.-Y. Bochud, M. Hersberger, P. Taffé, M. Bochud,

C. Stein, T. Calandra, P. Francioli, A. Telenti,

R.F. Speck, A. Aderem & The Swiss HIV

Cohort Study

O397 Chronic immune activation as a major

11:24 determinant of AIDS pathogenesis:

role of the type I interferon response

S. Staprans, S. Klucking, A. Barry, R. Chavan,

K. Dalbey, G. Silvestri, M. Feinberg (Atlanta, US)

O398 Elevated circulating HLA-G levels in

11:36 HIV-infected patients with and without

visceral leishmaniasis

L. Donaghy, F. Gros, L. Amiot, C. Mary,

A. Maillard, C. Guiguen, J-P. Gangneux

(Rennes, Marseille, FR)

O399 Study on the genotypic resistance of

11:48 archived and circulating viral strains in blood

of treated HIV-infected individuals

O. Turriziani, C. Scagnolari, C. Stano, G. Forte,

M. Bucci, F. Bellomi, C. Fimiani, I. Mezzaroma,

G. D’Ettorre, C. D’Agostino, E. Riva, S. Vita,

C. Ajassa, G Antonelli (Rome, IT)

page 64 Final Programme

Poster Session V

Topics Session V

Presence of authors: 12:00–13:00

– Antibiotic prescribing - quality indicators ● P1460–P1487

– Professional and public health issues ● P1488–P1492

– Pharmacoeconomics and electronic



– Antimicrobial PK / PD P1512–P1556

– New and not so new antimicrobials P1557–P1585

– Resistance, linezolid, glycopeptides

and inhibitors of protein synthesis


– Epidemiology of resistance to

antibiotics – II


– Clostridium difficile revisited P1635–P1649

– Virology - II P1650–P1675

– Bacterial pathogenesis – III P1676–P1701

– Antimicrobial clinical trials P1702–P1718

– Diagnostic and laboratory

methods for bacteria – II


– Molecular detection of microbial

ribosomal genes


– Antibacterial susceptibility studies – III P1765–P1778

– Tigecycline in vivo studies P1779–P1787

– Nosocomial infection: control

of environment, viral infections


– Regional spread of antibiotic resistance P1802–P1823

– Interesting case reports P1824–P1829

– Meningitis and endocarditis

★ P1830–P1841

– Epidemiology and outbreaks

★ P1842–P1851

– Urinary tract infection P1852–P1861

– FUO, soft tissue and miscellaneous


★ P1862–P1874

– Paediatric viral infections

★ P1875–P1884


Guided Poster Walks Session V

Theme: Antibiotic prescribing – quality indicators

Chairpersons: Herman Goossens (Edegem, BE)

Dominique Monnet (Copenhagen, DK)

Meeting point: Poster P1460 at 12:15

Posters selected from within the topics marked ●

Theme: A closer look at outbreaks & infections

Chairpersons: Wolfgang Graninger (Vienna, AT)

Ethan Rubinstein (Winnipeg, CA)

Meeting point: Poster P1830 at 12:15

Posters selected from within the topics marked ★


Scientific Programme Tuesday, April 4, 2006

Méditerranée 2 Origin, epidemiology, diagnosis, and

13:00– management of community-acquired

15:00 MRSA

Chairpersons: Robert Skov (Copenhagen, DK)

Stephen Lerner (Detroit, US)

S400 Origin

13:00 Mark C. Enright (London, UK)

S401 Epidemiology

13:30 Fred Tenover (Atlanta, US)

S402 Diagnosis

14:00 Robert Skov (Copenhagen, DK)

S403 Management

14:30 Henry F. Chambers (San Francisco, US)

Joint symposium arranged with the American

Society for Microbiology (ASM)

Hermes Clinical implications of low-level

13:00– antimicrobial resistance

15:00 Chairpersons: Gunnar Kahlmeter (Vaxjö, SE)

Johan Mouton (Nijmegen, NL)

S404 Staphylococcus aureus

13:00 Fred Goldstein (Paris, FR)

S405 Streptococcus pneumoniae

13:30 Javier Garau (Barcelona, ES)

S406 Escherichia coli

14:00 Niels Frimodt-Møller (Copenhagen, DK)

S407 Pseudomonas aeruginosa

14:30 Alasdair MacGowan (Bristol, UK)

Symposium arranged with the European

Committee on Antimicrobial Susceptibility

Testing (EUCAST)

Clio Molecular epidemiology:

13:00– a tool for public health

15:00 Chairpersons: Alexander Krämer (Bielefeld, DE)

Sara Haeggman (Solna, SE)

S408 Reconstructing HCV transmission history

13:00 using phylogenetic and population genetic


Oliver G. Pybus (Oxford, UK)

S409 Molecular typing for surveillance of MRSA at

13:30 national level

Sara Haeggman (Solna, SE)

S410 Genotyping of measles viruses to monitor

14:00 the elimination process of the disease

Sabine Santibanez (Berlin, DE)

S411 Using RFLP fingerprinting for outbreak

management in tuberculosis control

Gerard de Vries (Rotterdam, NL)

Joint symposium arranged with the

European Public Health Association (EUPHA)

Calliope Mycobacterial infections


15:00 Chairpersons: Richard Wallace (Tyler, US)

Stewart Cole (Paris, FR)

S412 Molecular biology for diagnosis

13:00 and identification of mycobacteria

Enrico Tortoli (Florence, IT)

S413 Infections due to mycobacteria other

13:30 than M. tuberculosis (MOTT) in non-HIV


Richard Wallace (Tyler, US)

S414 Buruli ulcer (M. ulcerans)

14:00 Françoise Portaels (Antwerp, BE)

S415 New anti-mycobacterial agents

14:30 Vincent Jarlier (Paris, FR) page 65

Oral Sessions

Scientific Programme Tuesday, April 4, 2006

Méditerranée 3 Respiratory tract infection in the community

13:00– revisited


Chairpersons: Daniel Christmann (Strasbourg, FR)

Thomas File (Akron, US)

O416 The management of sore throat by

13:00 Finnish general practitioners

P.O. Honkanen, U.-M. Rautakorpi, S. Huikko,

T. Klaukka, P. Huovinen, E. Palva, R. Roine,

H. Sarkkinen, H. Varonen, M. Mäkelä

for MIKSTRA collaborative study group

O417 Prevalence of Streptococcus viridans isolates

13:12 in nasopharyngeal samples from children

attending day-care centres in the Alpes

Maritimes, France

H. Carsenti-Dellamonica, G. Melica, C. Pradier,

B. Dunais, G. Mancini, M. Sabah, P. Bruno,

P. Toubol, P. Dellamonica for the GEPIE Group

O418 Erythromycin-resistance in commensal

13:24 throat streptococci in asylum seekers

C.J.P.A. Hoebe, E.J.W.N. Niekamp, P.J.P. Tolsema,

E. Stobberingh (Heerlen, Maastricht, NL)

O419 The role of antibiotics in acute uncomplicated

13:36 maxillary sinusitis in ambulatory care:

a randomised controlled trial

L. Prezas, A. Antoniadou, P. Panagopoulos,

T. Tsaganos, A. Agathagelides, G. Danielides,

T. Stathas, M. Rigatou, N. Karvelis, E. Moshavakis,

T. Papaeliadis, E. Ferekidis, S. Symeonidis,

H. Giamarellou (Athens, Salonica, Patra, GR)

O420 Prevalence of respiratory diseases in

13:48 sheltered homeless in Marseille, France

S. Badiaga, H. Richet, P. Azass, F. Rey, H. Tissot

Dupont, C. Foucault, C. Rovery, M. Drancourt,

D. Raoult, P. Brouqui (Marseille, FR)

page 66 Final Programme

Iris Treatment, antifungal resistance

13:00– and epidemiology of fungal infections


Chairpersons: Manuel Cuenca-Estrella (Madrid, ES)

Emmanuel Roilides

(Thessaloniki, GR)

O421 Posaconazole as prophylaxis for invasive

13:00 fungal infections in high-risk patients: efficacy

and safety results from two clinical trials

J. Maertens, A.J. Ullmann, S. Durrant,

J. Holowiecki, J.H. Lipton, D. Stockelberg,

D.J. Winston, J. Perfect, N. Boparai, C. Hardalo,

D. Angulo-Gonzalez, O.A. Cornely

(Leuven, BE; Mainz, DE; Brisbane, AU;

Katowice, PL; Toronto, CA; Gothenburg, SE;

Los Angeles, Durham, Kenilworth, US; Cologne, DE)

O422 Mortality in patients at high risk for invasive

13:12 fungal infection: effect of posaconazole


O.A. Cornely, J. Maertens, S. Durrant,

J. Holowiecki, J.H. Lipton, D. Stockelberg,

D.J. Winston, J. Perfect, R. Suresh, L. Pedicone,

H. Patino, A.J. Ullmann (Cologne, DE; Leuven, BE;

Brisbane, AU; Katowice, PL; Toronto, CA;

Gothenburg, SE; Los Angeles, Durham,

Kenilworth, US; Mainz, DE)

O423 Epidemiology of fungal infections in

13:24 haematological malignancies in Italy:

SEIFEM-2004 study (Sorveglianza Epidemiologica

Infezioni Fungine nelle Emopatie


L. Pagano, M. Caira, A. Candoni, L. Corvatta,

M. Offidani, B. Martino, D. Pastore, M. Picardi,

A. Bonini, A. Chierichini, R. Fanci, C. Caramatti,

C. Benatti, A. Gallamini, M.R. Fadda, L. Melillo,

B. Allione, L Fianchi, P. Falcucci, C.G. Valentini,

M.T. Van Lint, A. Nosari, C. Girmenia

on behalf of SEIFEM (Studio Epidemiologico

Infezioni Fungine nelle Emopatie Maligne)

O424 Micafungin versus liposomal amphotericin B

13:36 in the treatment of invasive candidiasis in

neutropenic and non-neutropenic patients

O. Lortholary, E. Kuse, P. Chetchotisakd,

C. Arns da Cunha, M. Ruhnke, C. Barrios,

D. Raghunadharao, J.S. Sekhon, S. Koblinger

(Paris, FR; Hannover, DE; Khon Kaen, TH;

Curitiba, BR; Berlin, DE; Porto Alegre, BR;

Hyderabad, Ludhiana, IN; Munich, DE)

O425 Clinical effects of micafungin, an

13:48 echinocandin antifungal agent, on systemic

fungal infection in the areas of surgery,

emergency, and intensive care medicine

N. Aikawa, S. Kusachi, S. Oda, Y. Takesue,

H. Tanaka (Tokyo, Chiba, Hiroshima, JP)

Scientific Programme Tuesday, April 4, 2006

O426 Universal role of glucan synthase subunit

14:00 Fks1p in echinocandin resistance

D. Perlin, S. Park (Newark, US)

O427 Human serum alters antifungal efficacy

14:12 of echinocandin drugs

D. Perlin, S. Park (Newark, US)

O428 In vitro resistance to amphotericin B and

14:24 caspofungin in clinical isolates of C. glabrata

were confirmed in a mouse model

M. Krogh-Madsen, M.C. Arendrup, L. Heslet,

J.D. Knudsen (Hvidovre, Copenhagen, DK)

O429 Effects of amphotericin B formulations

14:36 on antifungal activity of human monocytes

and neutrophils against medically important

filamentous fungi

J. Dotis, M. Simitsopoulou, M. Dalakiouridou,

T. Konstantinou, T. Walsh, E. Roilides

(Thessaloniki, GR; Bethesda, US)

O430 Determination of the effect of aminocandin

14:48 on Aspergillus fumigatus and Candida

albicans morphology and ultrastructure

using confocal scanning laser microscopy

and scanning electron microscopy

M.A. Ghannoum, S. Dutta, J. Chandra

(Cleveland, US)

Erato Antibiotic prescribing quality indicators


15:00 Chairpersons: Ethan Rubinstein (Winnipeg, CA)

Inge Gyssens (Rotterdam, NL)

O431 Developing valid antibiotic prescribing

13:00 quality indicators for ambulatory care based

on European Surveillance of Antimicrobial

Consumption (ESAC)

S. Coenen, M. Ferech, H. Goossens

and the ESAC Project Group

O432 Surveillance of antimicrobial use and

13:12 antimicrobial resistance in German intensive

care units (SARI) – data summary from 2001

to 2004

E. Meyer, F. Schwab, P. Gastmeier, H. Ruden,

K. de With, F. Daschner, D. Jonas

(Freiburg, Berlin, Hannover, DE)

O433 Marked change in the distribution

13:24 of antibiotics used in Danish hospitals:

is Denmark becoming less conservative?

A. Muller, C.T. Brandt, L. Bagger-Skjøt,

N. Frimodt-Møller, D.L. Monnet

(Copenhagen, DK)

O434 Dose regimen as an explanatory factor

13:36 for the variation of outpatient antibiotic

use between European countries

M. Ferech, S. Coenen, P. Stephens,

H. Goossens and the ESAC Project Group

O435 Antimicrobial prescribing practices by

13:48 physician specialty in the United States

K.J. Suda, K.W. Garey, C.T. Bertram,

L.H. Danziger (Memphis, Houston,

Deerfield, Chicago, US)

O436 Impact of a French local community-

14:00 oriented antibiotic-reducing programme

on the incidence of invasive diseases

A. Malicki, V. Blanc, P. Bruno, P. Touboul,

F. Berthier, P. Hofliger, T. Fosse, B. Dunais,

P. Dellamonica, C. Pradier on behalf of GEPIE

O437 Evolution of antibiotic consumption in a

14:12 geriatric ward of a university hospital:

results of a five-year policy involving

a multidisciplinary collaboration team

B. Delaere, D. Schoevaerdts, C. Swine,

Y. Glupczynski (Yvoir, BE)

O438 Determinants of antibiotic overprescribing

14:24 in lower respiratory tract infections in primary


M. Kuyvenhoven, A. Akkerman, J. van der Wouden,

T. Verheij (Utrecht, Rotterdam, NL)

O439 Antibiotic use in two cohorts of German

14:36 intensive care units, 2001–2002

K. de With, E. Meyer, M. Steib-Bauert,

F. Schwab, F.D. Daschner, W.V. Kern

(Freiburg, Berlin, DE)

O440 Benefit of appropriate empirical antibiotic

14:48 treatment: 30-day mortality and duration of

hospital stay

A. Fraser, M. Paul, N. Almanasreh, E. Tacconelli,

U. Frank, R. Cauda, S. Borok, S. Andreassen,

A.D. Nielsen, L. Leibovici

on behalf of the TREAT Study Group page 67

Poster Sessions Sunday, April 2, 2006


Automated methods for antibiotic susceptibility


P441 Vancomycin reformulation in a MicroScan

Dried Overnight Panel: a multicentre

evaluation with Gram-positive cocci

including VRSA

B. Zimmer, S. Mirrett, L.B. Reller, M. Weinstein,

J. Hindler, R. Carey, S. McAllister, D. Bruckner,

J. Johnston, K. Sei (West Sacramento, Durham,

New Brunswick, Los Angeles, Atlanta, US)

P442 Direct identification and susceptibility testing

of Gram-positive cocci from positive Bactec

blood cultures with BD Phoenix Automated

Microbiology System

T.-D. Huang, C. Laurent, J. Gigi, A. Simon

(Brussels, BE)

P443 Evaluation of MicroScan WalkAway 96 for

susceptibility testing of Gram-negative bacilli

to quinolones

M. Armengol, J. Calvo, L. Martinez-Martinez

(Santander, ES)

P444 False resistance to amikacin in Pseudomonas

aeruginosa with the MicroScan WalkAway

96 system

F. Unda, J. Calvo, M. Armengol, L. Martínez-

Martínez (Santander, ES)

P445 Evaluation of identification and antimicrobial

susceptibility testing of bacterial pathogens

by VITEK 2 Compact System

E. Stefaniuk, A. Mrowka, W. Hryniewicz

(Warsaw, PL)

P446 Evaluation of the Vitek-2 system using AST-

N020 y AST-N041 cards for susceptibility

testing of beta-lactam-resistant Escherichia

coli and Klebsiella pneumoniae strains of

clinical origin

J. Calvo, C. Salas, J.R. Hernández, B. Ruiz,

M.C. Conejo, M. Armengol, A. Pascual,

L. Martinez-martinez (Santander, Seville, ES)

P447 Susceptibility testing of unusual species of

Enterobacteriaceae: comparison of disk

diffusion, Vitek 2, and broth microdilution

N. Stone, C. O’Hara, P. Williams, J. McGowan Jr.,

F. Tenover (Atlanta, US)

P448 Evaluation of new VITEK 2 AST cards for

detection of ESBL mediated resistance in

E. coli and Klebsiella spp.

H. Rodriguez-Villalobos, J. Smet, C. Nonhoff,

S. Crevecoeur, R. De Mendonça, M. Struelens

(Brussels, BE)

page 68 Final Programme

P449 Detection of ESBL mediated resistance in

Enterobacter spp. by using new VITEK2 AST

cards and advanced expert system

J. Smet, H. Rodriguez-Villalobos, C. Nonhoff,

S. Crevecoeur, R. De Mendonça, M. Struelens

(Brussels, BE)

P450 Comparison of the E-test method with the

VITEK 2 antimicrobial susceptibility detection

system for screening of extended-spectrum

beta-lactamase Klebsiella and E. coli strains

in a Greek university hospital

O. Vasilaki, C. Manolopoulos, G. Raptis,

S. Alexiou-Daniel (Thessaloniki, GR)

P451 Evaluation of the VITEK 2® ESBL test in

detecting ESBL-positive clinical Escherichia

coli and Klebsiella pneumoniae isolates

J.A. Severin, N.M. Mertaniasih, K. Kuntaman,

N. Lemmens, H.A. Verbrugh, W.H.F. Goessens

(Rotterdam, NL; Surabaya, ID)

P452 Overestimation of extended-spectrum

beta-lactamases by VITEK-2 and possible

consequences for antibiotics policy

C. Ceyssens, L. Ide, J. Verhaegen, K. Lagrou,

J. Van Eldere (Leuven, BE)

P453 Detection of decreased susceptibility of

Staphylococcus aureus to vancomycin with

the VITEK 2 System

K. Engelhard, R. Griffith, J. Mayer, J. Slaughter,

M. Ullery, L. Beiner, S. Messina-Powell, D. Pyse,

G. Zambardi, D. Shortridge (Hazelwood, US;

LaBalme, FR)

P454 Bench validation of methicillin-resistance

detection by Vitek 2 AST P-536 card combined

with cefoxitin disc diffusion in clinical

staphylococci isolates

G. Prod’hom, K. Jaton, J. Bille, A. Wenger

(Lausanne, CH)

P455 Capability of the VITEK ® 2 System to screen

the beta-lactamase producing Enterococcus


N. Bal, V. Monnin, B.E. Murray, G. Zambardi,

I. Canard, C. Davenas, P. Dufour

(La Balme les Grottes, FR; Houston, US)

P456 Performance evaluation of the Streptococcus

pneumoniae antimicrobial susceptibility

investigative use only SPCA3 card on the

VITEK ® 2 system

C. Brosnikoff, J. Fuller, S. Shokoples, R. Rennie,

M. Traczewski, S. Brown, D. Fuller, R. Buckner,

J. Talbott, T. Davis (Edmonton, CA; Wilsonville,

Indianapolis, US)


Epidemiology of MRSA

Poster Sessions Sunday, April 2, 2006

P457 Molecular epidemiology of community-associated

methicillin-resistant Staphylococcus


S. Donabedian, V. Huang, A. Singh, S. Davis,

M. Perri, D. Vager, K. Speirs, B. Robinson-Dunn,

M. Hayden, R. Muder, M. Zervos (Detroit,

Atlanta, Royal Oak, Chicago, Pittsburgh, US)

P458 Clinical epidemiology of community-associated

methicillin-resistant Staphylococcus aureus

S. Davis, A. Singh, M. Perri, C. Manierski,

S. Donabedian, D. Vager, V. Huang, K. Spiers,

B. Robinson-Dunn, M. Hayden, R. Muder,

M. Zervos (Detroit, Royal Oak, Atlanta, Chicago,

Pittsburgh, US)

P459 Comparison of epidemic MRSA isolated in the

three Nordic countries Denmark, Finland and

Sweden during 2003–2004 –

How similar are they?

S. Haeggman, A. Rhod Larsen, A. Vainio,

B. Olsson-Liljequist, R. Skov, J. Vuopio-Varkila

(Solna, SE; Copenhagen, DK; Helsinki, FI)

P460 Genotyping as a tool for naming epidemic

methicillin-resistant Staphylococcus aureus

strains in Finland

A. Vainio, M. Karden-Lilja, S. Ibrahem,

A-M. Kerttula, S. Salmenlinna, A. Virolainen,

J. Vuopio-Varkila (Helsinki, FI)

P461 Hospital- and community-acquired methicillinresistant

Staphylococcus aureus in Germany

C. von Eiff, F. Hasenberg, A. Anders, F. Kipp,

A.W. Friedrich, G. Peters, S.G. Gatermann,

K. Becker (Munster, Bochum, DE)

P462 Molecular spa and SCCmec typing of MRSA

isolates from northern Germany

N. Wiese, H. Mueller, I. Fenner, K. Lunkenheimer,

T. Fenner (Hamburg, Lubeck, DE)

P463 Methicillin-resistant S. aureus in German

university hospitals: changes in resistance

2002 – 2005

I. Noll, B. Wiedemann, J. Beer, T. Pietzcker,

W. Pfister, S. Schubert, S. Ziesing, O. Hamouda

(Berlin, Bonn, Leipzig, Ulm, Jena, Kiel,

Hannover, DE)

P464 Methicillin-resistant Staphylococcus aureus

epidemiological setting in the emergency

ward of a large French teaching hospital

B. Téqui, N. Asseray, D. Lepelletier, D. Tewick,

M.E. Juvin, G. Potel, H.B. Drugeon (Nantes, FR)

P465 Molecular characterisation of Staphylococcus

aureus isolated in a nationwide prevalence

study in Spain

O. Cuevas, E. Cercenado, A. Vindel, C. Castellares,

J. Guinea, E. Bouza (Madrid, ES)

P466 First report of infection with communityacquired

methicillin-resistant Staphylococcus

aureus in Spain

E. Cercenado, M. Marín, A. Vindel, B. Padilla,

O. Cuevas, A. Navarro, E. Bouza

(Madrid, Majadahonda, ES)

P467 Epidemiology of methicillin-resistant

Staphylococcus aureus in Bilbao

J.L. Barrios, M.J. Unzaga, C. Ezpeleta, D. Suárez,

J. Sánchez, J.A. Alava, A.B. López, R. Cisterna

(Bilbao, ES)

P468 Identification epidemic methicillin-resistant

S. aureus in Russian hospitals: multicentre

study 1998 – 2002

O. Dmitrenko, V. Prohorov, I. Shilov, N. Lavrova,

A. Gintsburg (Moscow, RU)

P469 Methicillin-resistant Staphylococcus aureus

nasal colonisation in a rehabilitating / nursing

home in Italy

A. Pan, T. Ceruti, M. Bresciani, C. Geroldi,

S. Lorenzotti, S. Magri, L. Soavi, L. Signorini,

A. Pani (Brescia, Cremona, IT)

P470 Methicillin-resistant Staphylococcus aureus

from airway secretions from patients with

cystic fibrosis

H. Alexandrou-Athanasoulis, S. Doudounakis,

A. Sergounioti, I. Loucou, A. Pangalis (Athens, GR)

P471 A new computer software for methicillinresistant

Staphylococcus aureus typing based

on spa-sequencing: comparison to MLST

K. Boye, M.D. Bartels, A. Mellmann, D. Harmsen,

H. Westh (Hvidovre, DK; Munster, DE)

P472 A multiplex PCR for easy screening of

methicillin-resistant Staphylococcus aureus

SCCmec types I to V

K. Boye, M.D. Bartels, A.R. Larsen, H. Westh

(Hvidovre, Copenhagen, DK)

P473 Evaluation of real-time PCR as a rapid method

to detect carriage of methicillin-resistant

S. aureus in the investigation of a ST30


M.D. Bartels, K. Kristoffersen, K. Boye, H. Westh

(Hvidovre, DK)

page 69

Poster Sessions Sunday, April 2, 2006

P474 Methicillin-resistant Staphylococcus aureus

and pig-farming

B. van Dijke, H. Koppen, W. Wannet,

X. Huijsdens, H. de Neeling, A. Voss

(Weert, Bilthoven, Nijmegen, NL)

P475 Methicillin-resistant coagulase-negative

staphylococci isolated from horses

M. Corrente, G. Greco, V. Martella, G. Normanno,

E. Tarsitano, C. Buonavoglia (Valenzano, IT)

P476 First report of non-prototypic Tn1546 among

vanA vancomycin-resistant-enterococci

isolated from domestic chickens in Korea:

evidence of communication between VRE

niche of human and those of chicken?

M.N. Kim, S.H. Lee, E.J. Lee, H.S. Jun, H. Sung

(Seoul, KR)

P477 Identification and genotyping of vancomycinresistant

enterococci isolated from slaughtered

poultry in Hungary from 2001 to 2004

Á. Ghidán, O. Dobay, É.J. Kaszanyitzky, K. Nagy,

F. Rozgonyi, S.G.B. Amyes

(Budapest, HU; Edinburgh, UK)

P478 Antimicrobial susceptibility of enterococcal

strains isolated from slaughter animals in

Hungary from 2001 to 2004

É.J. Kaszanyitzky, M. Tenk, Á. Ghidán,

G. Fehérvári, M. Papp (Budapest, HU)



P479 Analysis of mortality in septic shock patients

J. Martinez Alario, J. Villegas, S. Huidobro,

C. Christophe Henry, R. Santacreu, M.L. Mora

(Tenerife, ES)

P480 The significance, clinical presentation and

evolution of recurrent E. coli bloodstream


M. Sanz, A. Fernandez, P. Muñoz, E. Cercenado,

M. Rodríguez-Creixems, J. Feyjoo, E. Bouza

(Madrid, ES)

P481 The influence of SIRS criteria on outcome in

Gram-negative versus Gram-positive sepsis

M. Lupse, A. Bica, A. Slavcovici, A. Radulescu,

C. Bondor, D. Tatulescu (Cluj-Napoca, RO)

P482 Haemophilus influenzae bloodstream

infections: a reappraisal

G. Muñoz, L. Cuadra, E. Calbo, M. Xercavins,

J. Garau (Terrassa, ES)

page 70 Final Programme

P483 Protein C levels in plasma and APACHE II

scoring system for risk evaluation in patients

with sepsis

E. Doyuk Kartal, E. Karkac, N. Erben, S. Nayman

Alpat, I. Özgünes, Z. Gulbas, G. Usluer

(Eskisehir, TR)

P484 The role of plasma BNP levels in the early

prognostic stratification of septic patients at

the emergency department

G. Ruggiano, R. Camajori Tedeschini, A. Rosselli

(Florence, IT)

P485 Monocyte CD14 and soluble CD14 in

predicting the mortality of patients with

severe community-acquired infection

H. Aalto, A. Takala, H. Kautiainen, H. Repo

(Helsinki, Heinola, FI)


Tigecycline in vitro studies – I

P486 Tigecycline in vitro activity in an outpatient

vs. inpatient global population

B. Johnson, S. Bouchillon, T. Stevens,

J. Johnson, D. Hoban, M. Dowzicky

(Schaumburg, Collegeville, US)

P487 Tigecycline antibacterial activity in current

(2004 – 06) U.S. pathogen population

B. Johnson, S. Bouchillon, T. Stevens,

J. Johnson, D. Hoban, M. Dowzicky

(Schaumburg, Collegeville, US)

P488 In vitro evaluation of tigecycline against

261 recent isolates of vancomycin-resistant

enterococci C T.E.S.T. Program 2006

B. Johnson, S. Bouchillon, T. Stevens,

J. Johnson, D. Hoban, M. Dowzicky

(Schaumburg, Collegeville, US)

P489 Evaluating tigecycline against cross-resistant

Enterobacteriaceae in the Global T.E.S.T.


B. Johnson, S. Bouchillon, T. Stevens,

J. Johnson, D. Hoban, M. Dowzicky

(Schaumburg, Collegeville, US)

P490 Tigecycline in vitro activity in current

European pathogens – T.E.S.T. Program 2006

D. Hoban, S. Bouchillon, B. Johnson,

T. Stevens, J. Johnson, M. Dowzicky

(Schaumburg, Collegeville, US)

P491 Tigecycline in vitro activity against multidrugresistant

Acinetobacter spp. in the T.E.S.T.

Program Global Data

D. Hoban, B. Johnson, S. Bouchillon,

T. Stevens, J. Johnson, M. Dowzicky

(Schaumburg, Collegeville, US)

Poster Sessions Sunday, April 2, 2006

P492 Evaluating cross-resistance for Enterobac -

teriaceae as compared to tigecycline for the

T.E.S.T. Program in Europe

D. Hoban, B. Johnson, S. Bouchillon,

T. Stevens, J. Johnson, M. Dowzicky

(Schaumburg, Collegeville, US)

P493 Tigecycline in vitro activity against inpatient

and outpatient pathogens collected from

centres in Europe – T.E.S.T. Program 2006

J. Johnson, D. Hoban, B. Johnson,

S. Bouchillon, T. Stevens, M. Dowzicky

(Schaumburg, Collegeville, US)

P494 Tigecycline in vitro activity against often

difficult to treat pathogens from centres in

Asia/Pacific Rim – T.E.S.T. Program 2006

J. Johnson, D. Hoban, B. Johnson,

S. Bouchillon, T. Stevens, M. Dowzicky

(Schaumburg, Collegeville, US)

P495 Acinetobacter resistance in clinical isolates

from the United States evaluated against

tigecycline and 10 comparators

J. Johnson, D. Hoban, B. Johnson,

S. Bouchillon, T. Stevens, M. Dowzicky

(Schaumburg, Collegeville, US)

P496 The in vitro activity of tigecycline and

10 comparators in a global population –

T.E.S.T. Program 2006

S. Bouchillon, T. Stevens, J. Johnson,

D. Hoban, B. Johnson, M. Dowzicky

(Schaumburg, Collegeville, US)

P497 Tigecycline in vitro evaluation of 1,145 methicillin-resistant

Staphylococcus aureus

S. Bouchillon, T. Stevens, J. Johnson,

D. Hoban, B. Johnson, M. Dowzicky

(Schaumburg, Collegeville, US)

P498 Antibiotic cross-resistance for Staphylococcus

aureus and Enterococcus spp. among tigecycline

and 10 comparator antimicrobial agents –

T.E.S.T. Program in Europe 2006

S. Bouchillon, T. Stevens, J. Johnson,

D. Hoban, B. Johnson, M. Dowzicky

(Schaumburg, Collegeville, US)

P499 Asia and Pacific Rim community vs. hospitalacquired

infections: in vitro activity against

tigecycline and comparators

T. Stevens, J. Johnson, D. Hoban,

B. Johnson, S. Bouchillon, M. Dowzicky

(Schaumburg, Colllegeville, US)

P500 Extended-spectrum beta-lactamase producing

Enterobacteriaceae evaluated in vitro against

tigecycline and comparator agents –

T.E.S.T. Program 2006

T. Stevens, J. Johnson, D. Hoban,

B. Johnson, S. Bouchillon, M. Dowzicky

(Schaumburg, Collegeville, US)

P501 Activity of tigecycline against wellcharacterised

multi-resistant Gram-positive


C. Cascone, A. Lupo, S. Borbone, M. Mezzatesta,

M. Santagati, S. Stefani (Catania, IT)


ESBLs and cephalosporins

P502 Prevalence of extended-spectrum betalactamases

among Enterobacteriaceae:

a Bulgarian survey

R. Markovska, E. Keuleyan, I. Schneider,

M. Sredkova, D. Ivanova, K. Rachkova,

B. Markova, T. Kostyanev, E. Draghijeva, I. Mitov,

A. Bauernfeind (Sofia, BG; Munich, DE; Pleven,

Stara Zagora, BG)

P503 Surveillance of PER-1 producers among

Gram-negative bacilli isolated at a tertiary

care hospital over a five-year period and

analysis of the genetic location of blaper-1

B. Eraç, Z. Gülay (Izmir, TR)

P504 Plasmid-mediated carbapenem-hydrolysing

oxacillinase OXA-58 in Acinetobacter

baumannii in Italy

A. Giordano, A. Bertini, P. Varesi, L. Villa,

A.M. Dionisi, I. Luzzi, C. Mancini, A. Carattoli

(Rome, IT)

P505 Outbreak of OXA-58-producing carbapenemresistant

Acinetobacter baumannii isolates in

a paediatric university hospital in Athens,


L. Poirel, E. Lebessi, C. Héritier, A. Patsoura,

M. Foustoukou, P. Nordmann (Le Kremlin Bicetre, FR;

Athens, GR)

P506 Characterisation of conjugative plasmids

encoding CTX-M-type extended-spectrum

beta-lactamases in Italian clinical isolates of

Escherichia coli

C. Mugnaioli, F. De Luca, A. Carattoli,

G.M. Rossolini (Siena, Rome, IT)

P507 Unusual CTX-M enzyme variants in the

United Kingdom

E. Karisik, M.J. Ellington, R. Pike, E.J. Fagan,

D.M. Livermore, N. Woodford (London, UK)

page 71

Poster Sessions Sunday, April 2, 2006

P508 Differential expression of CTX-M-15 betalactamase

between two major Escherichia

coli strains in the UK

E. Karisik, M.J. Ellington, R. Pike,

D.M. Livermore, N. Woodford (London, UK)

P509 Dominance of CTX-M beta-lactamases among

Escherichia coli isolates in an Algerian


N. Ramdani-Bouguessa, N. Mendonça,

J. Leitão, E. Ferreira, M. Tazir, M.M. Caniça

(Algiers, DZ; Lisbon, PT)

P510 Extended-spectrum beta-lactamases and

plasmid-mediated AmpC enzymes among

clinical isolates of Escherichia coli and

Klebsiella pneumoniae, Taiwan

J-J. Yan, P-R. Hsueh, J-J. Lu, F-Y. Chang,

J-M. Shyr, J-H. Wan, Y-C. Liu, Y-C. Chuang,

Y-C. Yang, S-M. Tsao, H-H. Wu, L-S. Wang,

T-P. Lin, H-M. Wu, H-M. Chen, J-J. Wu

(Tainan, Taipei, Taichung, Hualien, TW)

P511 Salmonella enterica serovar enteritidis

producing a TEM-52 B-lactamase.

First report in Spain

M. Fernández Vázquez, J.L. Muñoz-Bellido,

J.A. García-Rodríguez (Salamanca, ES)

P512 Biochemical characterisation of the plasmidencoded

class C B-lactamase FOX-7

J.D. Docquier, S. Prandi, S. Cresti, G.M. Rossolini

(Siena, IT)

P513 Analysis of the promoter/attenuator region

of the ampC gene in clinical isolates of

Escherichia coli with “AmpC phenotype”

M.C. Conejo, G. Amblar, F. Fernández-Cuenca,

A. Pascual, E.J. Perea, L. Martínez-Martínez

(Seville, ES)

P514 Evaluation of an AmpC disk test and genetic

detection of imported ampC-genes in

Norwegian clinical strains of E. coli

B. Haldorsen, E. Lundblad, B. Aasnæs, K. Dahl,

A. Hanssen, G. Simonsen, T. Walsh,

A. Sundsfjord (Tromsø, NO; Bristol, UK)

P515 Detection of extended-spectrum betalactamase

in Enterobacteriaceae with AmpC

beta-lactamase type of inducible resistance

Sp. Fokas, St. Fokas, E. Lauranou, I. Sarris,

M. Kalkani, M. Dionysopoulou (Sparta, GR)

P516 Modelling the effect of copy number of

plasmids carrying ESBL genes on resistance

levels to beta-lactam antibiotics

M. Stepanova, M. Edelstein (Smolensk, RU)

page 72 Final Programme


Molecular typing

P517 Genetic relatedness between sporadic and

epidemic methicillin-resistant Staphylococcus

aureus in Belgian hospitals

M. Hallin, R. De Mendonca, O. Denis, A. Deplano,

R. De Ryck, S. Rottiers, M.J. Struelens (Brussels, BE)

P518 Analysis of polymorphisms within mid-region

inserts of vacuolating cytotoxin alleles of

Helicobacter pylori to identify genotypic

markers of geographic adaptation

R.J. Owen (London, UK)

P519 Differences in group A Streptococcus clinical

and molecular epidemiology between Belgian

and Brazilian children

P.R. Smeesters, A. Vergison, D. Campos Junior,

E. de Aguiar, L. Van Melderen

(Brussels, BE; Brasília, BR; Gosselies, BE)

P520 AFLP analysis of international Clostridium

difficile strains of different toxin type reveals

major toxin-dependent clonal clusters

H. Pituch, W. van Leeuwen,

P. Obuch-Woszczatynski, D. Wultanska, H. Kato,

F. Meisel-Mikolajczyk, M. Luczak, A. van Belkum

(Warsaw, PL; Rotterdam, NL; Tokyo, JP)

P521 Molecular epidemiology and genetic diversity

of Mycobacterium tuberculosis clinical

isolates in Okinawa, Ryu-Kyu islands, Japan

J. Millet, T. Zozio, C. Miyagi-Shiohira, N. Yamane,

N. Rastogi, C. Sola (Abymes, FR; Okinawa, JP)

P522 A view of the Neisseria gonorrhoeae

population transmitted in Arkhangelsk,

Russia: phenotypic and genetic characteristics

M. Unemo, V. Vorobieva, N. Firsova, T. Ababkova,

I. Lenev, B. Haldorsen, H. Fredlund, V. Skogen

(Örebro, SE; Tromsö, NO; Arkhangelsk, RU)

P523 Discrimination between E. coli O157 isolates

using PCR-mediated fingerprinting based on

SER element

G. Kardos, M. Antal, I. Tóth, I. Kiss, B. Nagy

(Debrecen, Budapest, HU)

P524 Application of amplified fragment length

polymorphism as an epidemiological tool for

infections due to Mycobacterium haemophilum

L.E.S. Bruijnesteijn van Coppenraet, N. Buffing,

M.W. van der Bijl, J.A. Lindeboom, P.H. Savelkoul,

E.J. Kuijper (Leiden, Amsterdam, NL)

Poster Sessions Sunday, April 2, 2006

P525 Distribution of toxinotypes and detection of

binary toxin in 199 Clostridium difficile strains

at a university hospital, Montpellier, France

A. Boulier, H. Marchandin, D. Decre, J. Campos,

R. Devine, H. Jean-Pierre (Montpellier, Paris, FR)

P526 Molecular analysis of pneumococci isolated

from invasive infections of children in


M. Füzi, B. Libisch, B. Krucso, J. Pászti,

T. Tirczka, Z. Meszner (Budapest, HU)

P527 Prevalence and typing of adenoviruses in

stool of Iranian children with acute diarrhoea:

a comparative study by molecular and

serological assays

F. Roohvand, F. Motevali, M. Ghazanfari,

S. Salmanzadeh-Ahrabi, F. Jafari, M. Zali

(Tehran, IR)

P528 Molecular and physiological characterisation

of fungal opportunists belonging to the genus


L. Kredics, Z. Antal, A. Szekeres, L. Hatvani,

M. Láday, M. Komon, J. Varga, L. Manczinger,

C. Vágvölgyi, E. Nagy, C. Kubicek, I.S. Druzhinina

(Szeged, Budapest, HU; Vienna, AT)

P529 a European-wide certification

trial for sequence-based typing of microbial


A.W. Friedrich, A. Mellmann, W. Witte,

D. Harmsen, H. de Lencastre, W. Hryniewicz,

J. Scheres, H. Westh and the


P530 Genetic typing of enteroviruses for the

investigation of two local outbreaks in

France in 2005

A. Mirand, F. Girault, C. Archimbaud, Y. Michel,

F. Charbonné, H. Peigue-Lafeuille, J.L. Bailly

(Clermont-Ferrand, Paris, FR)

P531 Development of a novel SNP based assay to

speciate Brucella isolates

M.R. Stubberfield, J.C. Scott, A.M. Whatmore

(Addlestone, UK)

P532 Multiplex SCCmec typing of hospital,

community and multi-resistant methicillinresistant

Staphylococcus aureus

J. Rollason, A.C. Hilton, J.M. Caddick,

P.A. Lambert, T. Worthington, T.S.J. Elliott

(Birmingham, UK)

P533 Fast, accurate, and automated workflow for

multi locus sequence typing of Staphylococcus


J. Tan, M. Langvik, A. Yang, B. Turner, A. Rico,

S. Jankowski, J. Theelen, A. Pradhan, R. Nutter

(Foster City, US; Loerenskog, NO)

P534 Use of the isoschizomers SmaI and XmaI to

generate a common PFGE pattern database

for both mef-negative and mef-positive

S. pyogenes isolates

P.T. Tassios, G. Diamantopoulou, A. Stathi,

L. Zachariadou, A. Pangalis, J. Papaparaskevas,

N.J. Legakis & the Hellenic Strep-EURO Group

P535 Genotypes of Chlamydophila psittaci causing

zoonotic infection

E.R. Heddema, E.J. van Hannen, B. Duim,

Y. Pannekoek (Amsterdam, Nieuwegein, NL)

P536 A comparative study of Escherichia coli

strains isolated from the intestinal mucosa of

Crohn’s disease patients and healthy subjects

M. Martinez-Medina, X. Aldeguer,

F. Gonzalez-Huix, D. Acero, L.J. Garcia-Gil

(Girona, ES)

P537 Molecular typing of Shigella sonnei isolates

by RAPD-PCR and ribotyping

F. Jafari, S. Salmanzadeh-Ahrabi, M.M. Feizabadi,

H. Mohaghegh-Shalmani, M. Zali (Tehran, IR)

P538 Evaluation of gyrB RFLP analysis for the

typing of clinical and environmental strains of

Stenotrophomonas maltophilia

N.F. Foster, B.J. Chang, A.J. Plant, T.V. Riley

(Perth, AU)

P539 Molecular analysis of Mycobacterium kansasii

isolates from Taiwan

T.-S. Wu, M.-H. Lee, H.-S. Leu

(Taoyuan Hsien, TW)


Bacterial pathogenesis – I

P540 Resistance to colistin and carbapenems

with detection of class 1 integrons on

Pseudomonas aeruginosa clinical isolates

E. Platsouka, H. Kraniotaki, G. Tourouki, V. Doga,

E. Perivolioti, K. Kanellos, G. Kalogeras,

O. Paniara (Athens, GR)

P541 Molecular epidemiology of Pseudomonas

aeruginosa strains isolated from intensive

care unit

P. Nowak, A. Targosz, A. Budak, M. Skalkowska,

E. Filip (Cracow, PL)

page 73

Poster Sessions Sunday, April 2, 2006

P542 Increase in incidence of serogroup C invasive

meningococcal disease in Italy and rise of

decreased susceptibility to penicillin

P. Mastrantonio, C. Fazio, A. Neri, T. Sofia,

P. Stefanelli (Rome, IT)

P543 Detection and identification of bacterial DNA

in cardiac valves from infective endocarditis


M. Kemp, J. Bangsborg, A. Kjærulf, T. Schmidt,

J. Christensen, A. Irmukhamedov, N.E. Bruun,

R. Dargis, K. Andresen, J.J. Christensen

(Copenhagen, DK)

P544 Spectrum of bacterial pathogens causing IE

in our hospital

M. Slany, J. Cerny, T. Freiberger (Brno, CZ)

P545 Molecular characterisation and prevalence of

tick-borne diseases pathogens in Lithuania

D. Ambrasiene, J. Turcinaviciene, A. Paulauskas,

R. Mikalauskas (Kaunas, Vilnius, LT)

P546 Tick-borne Rickettsiae in Russia

S. Shpynov, P.E. Fournier, N. Rudakov,

I. Tarsevich, D. Raoult (Omsk, RU; Marseille, FR;

Moscow, RU)

P547 Microbiological characterisation of invasive

group A streptococci in the UK during 2003–04

S. Neal, C. Dhami, M. Emery, S. Flynn, T. Lamagni,

N. Alhaddad, C. Keshishian, A. Efstratiou

(London, UK)

P548 Detection of pcaA gene in M. tuberculosis

strains isolated from clinical specimens

R. Ramazanzadeh (Tehran, IR)

P549 Isolation and identification of Legionella

(legionnaires’ disease agents) from fish ponds

and environmental water sources by culture

and PCR methods

S.M. Moosavian, A. Dashti (Ahwaz, IR)

P550 Three females with asymptomatic infection of

Mycoplasma pneumoniae, carrying genes for

MDS and lymphoma detected with FISH


S. Kokkinou, A. Lindou, K. Pavlou,

A. Charalambopoulou, I. Fotopoulou, H. Alafaki,

R. Hatzikyriakou, E. Fakiri (Athens, GR)

P551 Aseptic meningitis: aetiologic diagnosis

L. Santos, J. Simões, S. Conde, R. Costa

(Porto, PT)

P552 Characterisation of the recombinant

S-adenosylhomocysteine hydrolase from

Cryptosporidium parvum

F. Stejskal, V. Ctrnacta, I. Hrdy, J.S. Keithly

(Prague, CZ; Albany, US)

page 74 Final Programme

P553 VIM-1- producing Klebsiella pneumoniae

strains with class 1 integrons isolated from

bloodstream infections

H. Kraniotaki, E. Platsouka, H. Belesiotou,

G. Antonakis, E. Kontou, O. Paniara (Athens, GR)

P554 Molecular detection of the cefoxitin-resistance

gene, cfxA, and the 3’ regulatory sequence

of its resistance element, MTn4555

J. Soki, M. Toth, Z. Bessenyei, E. Urban, E. Nagy

(Szeged, HU)


Emerging microbial infections

P555 Severe cutaneous anthrax and toxaemic


M. Doganay, O. Yildiz, E. Alp, D. Esel, B. Aygen

(Kayseri, TR)

P556 Visceral leishmaniasis in immuno -

compromised patients: two cases and

review of the literature

M. Weisser, B. Khanlari, U. Flückiger (Basel, CH)

P557 Nontyphoidal Salmonella invasive bloodstream

infections resistant to quinolone

and/or an extended-spectrum cephalosporin

in a country with extensive use of these

antimicrobials in food animals

W. Kulwichit, T. Chatsuwan, C. Unhasuta,

C. Pulsrikarn, A. Bangtrakulnonth,

A. Chongthaleong (Bangkok, TH)

P558 Detection of Coxiella burnetii and anti-

Coxiella antibodies by molecular and

serological methods among risk groups

M. Eyigor, S. Kirkan, B. Gultekin, S. Yaman,

S. Tekbiyik, N. Aydin (Aydin, TR)

P559 Dermatophytosis by Trichophyton violaceum:

an emerging pathogen in European urban


M. Aguilar, A. Badell, J. Graells, R. Olivella,

M. Gomis (Cornellà de Llobregat, ES)

P560 Characterisation of Listeria monocytogenes

strains isolated from human and ruminant

clinical cases and from food products by

serotyping and automated ribotyping

E. Bozzetta, M. Pezzolato, R. Nappi, C. Grattarola,

R. Serra, A. Catalano, L. Decastelli, M. Caramelli

(Turin, IT)

P561 Lethal Ehrlichia ruminantium infections in

humans in South Africa

M.E.P. Allsopp, M. Louw, E.C. Meyer,

K. Matsumoto, P. Brouqui

(Onderstepoort, ZA; Marseille, FR)

Poster Sessions Sunday, April 2, 2006

P562 Value of serology in diagnosing Lympho -

granuloma venereum

T. Meyer, C. Noah, R. Arndt, H.J. Stellbrink,

S. Unger, A. Plettenberg (Hamburg, DE)

P563 Investigation of Francisella tularensis using

real time TaqMan PCR in water sources in

Turkey where tularaemia cases seen mostly

as pharyngeal form

A. Karadenizli, H. Leblebicioglu, G. Celebi,

D. Ozdemir, S. Gurcan, H. Vahaboglu

(Kocaeli, Samsun, Zonguldak, Bolu, Edirne, TR)

P564 Outbreak of tularaemia: the first case-control

study in Turkey

H. Leblebicioglu, S. Esen, D. Turan, Y. Tanyeri,

A. Karadenizli, F. Ziyagil, G. Goral (Samsun,

Kocaeli, Amasya, Bursa, TR)

P565 Tularaemia: a misdiagnosed disease in France

B. Doudier, L. De labrusse, J.M. Rolain, D. Raoult,

P. Brouqui (Marseille, FR)

P566 Anaerobic bacteraemia in patients with

leukaemia and lymphoma. Oropharyngeal

mucositis and status of haematologic disease

are the most important predisposing


A. Candoni, S. Buttignol, E. Simeone, R. Fanin

(Udine, IT)

P567 Non-toxigenic Corynebacterium diphtheriae

as a cause of bacterial endocarditis in children

with congenital heart defects

M.G. Dove, R.P. Loxton, E.J. Olivier, B. Prinsloo

(Pretoria, ZA)

P568 Shiga toxin producing Escherichia coli isolated

from one-humped camels (Camelus dromedarius)

T. Pál, Á. Sonnevend, K. Al-Dhaheri, M. Herpay,

T. Mag, A. Usmani, J. Kolodziejek, N. Nowotny

(Al Ain, AE; Budapest, HU; Vienna, AT)

P569 Achievements of the first European project on

severe group A streptococcal disease

A. Jasir, C. Schalen (Lund, SE)


Vaccines and immunotherapy

P570 Evaluation of gamma-interferon kinetic in

vaccinated BALB/c mice by gD expression

vector of HSV-1 and its recombinant protein

E. Arefian, T. Bamdad, H. Soleimanjahi, F. Sabahi,

A. Ghaemi, J. Keiani (Tehran, IR)

P571 Is MMRV vaccination cost-effective in HCWs

in Turkey?

A. Celikbas, O. Ergonul, S. Aksaray, N. Tuygun,

G. Tanir, H. Esener, S. Eren, N. Baykam,

E. Guvener, B. Dokuzoguz (Ankara, TR)

P572 Parasitic diseases in children as one of the

reasons for postvaccinal complications

M.V. Kuropatenko, L.A. Jelenina

(Saint-Petersburg, RU)

P573 Vaccination with adeno-associated virus

vector encoding severe acute respiratory

syndrome coronavirus S protein induces

potent and prolonged antibodies

L. Du, Y. Zhou, Y. He, S. Ma, K.Y. Yuen, S. Jiang,

B.J. Zheng (Hong Kong, HK; Beijing, CN;

New York, US)

P574 Appropriateness of rabies post-exposure

treatment received by patients presenting

to an anti-rabies treatment unit

M.J. Pinidiyapathirage, O. Wimalaratne

(Ragama, Colombo, LK)

P575 Adverse effects of rabies postexposure


F. Mattner, S. Kuhn, F. Bitz, M. Goedecke,

S. Becker, K. Radsack, B. Jansen, A. Viertel,

P. Gastmeier, F. Biertz, A. Heim, C. Henke-Gendo,

A. Martens, T. Schulz, M. Strueber (Hannover,

Hannoversch Münden, Marburg, Mainz, DE)

P576 Design and construction of an expression

vector containing immunogenic epitopes of

HIV-1 P24 and gp 41 proteins as a vaccine

candidate against HIV-1

F. Roodbari, F. Mahboudi, F. Sabahi,

F. Barkhordary, R. Sarami Foroshani, A. Adeli

(Tehran, IR)

P577 Clinical course study in post BCG vaccination


A. Hamedi, A. Velayati (Mashad, Tehran, IR)

P578 A flow cytometric opsonophagocytic assay

for measurement of functional antibodies

elicited after immunisation with the Neisseria

meningitidis serogroup A capsular polysaccharide-serogroup

B outer membrane vesicle

conjugate vaccine in animal model

M. Kheirandish, S.D. Siadat, Q. Behzadiyannejad,

B. Tabaraiee, H. Ahmadi, S. Najar Pirayeeh,

M. Nejati, K. Mahmoodi (Tehran, IR)

page 75

Poster Sessions Sunday, April 2, 2006

P579 Immunological evaluation of Neisseria

meningitidis serogroup B outer membrane

vesicle containing PorA conjugated with

Neisseria meningitidis serogroup

A capsular polysaccharide in rabbit

S.D. Siadat, Q. Behzadiyannejad, B. Tabaraiee,

H. Ahmadi, S. Najarpirayeeh, D. Nouroziyan

Shamasbi, M. Nejati, M. Kheirandish, H. Rezvan,

K. Moosavi Hossaini, B. Adibi Motlagh, A. Moshiri

(Tehran, IR)

P580 Efficacious vaccination against serogroup C

meningococcal disease by one shot at the age

of 14 month in the Netherlands

A. van der Ende, S. de Greeff, H. de Melker,

L. Spanjaard (Amsterdam, Bilthoven, NL)

P581 Streptococcus pneumoniae: proteomics of

surface proteins for vaccine development

C. Morsczeck, J. Sigh, M. Bille-Nielsen,

M. Pfeiffer, T. Prokhorova, A. Boysen,

J. Petersen, N. Frimodt-Møller, N. Pia, J. Crawford,

T. Kofoed (Odense, Copenhagen, DK)

P582 Seropathotypes, adherence ability and

inflammatory effect induced to cellular

substratum by enteropathogenic E. coli

strains isolated from aquatic environments

R. Cernat, V. Lazar, M.C. Balotescu (Bucharest, RO)

P583 Characterisation of intestinal lactobacilli as

potential second-generation probiotics

P. Kõll, R. Mändar, I. Smidt, M. Mikelsaar (Tartu, EE)

P584 Immunological determinants of disease

pathogenesis in Indian leishmaniasis

N. Ansari, V. Ramesh, S. Saluja, P. Salotra

(New Delhi, IN)

P585 Association of polymorphism in genes

encoding human innate immunity factors

and persistent nasal Staphylococcus aureus


A. van Belkum, H. Wertheim, C. de Jongh,

M. Emonts, J.L. Nouwen, A. Cole, A.L. Cole,

H.A.M. Boelens, S. Snijders, H. Verbrugh,

W.B. van Leeuwen (Rotterdam, NL; Orlando, US)

P586 Interference with pathogenic bacteria in

cystic fibrosis

Å. Sullivan, F. Karpati, L. Hjelte, B. Wretlind,

C.E. Nord (Stockholm, SE)

P587 New insights into the role platelets in

antifungal host defence

C. Lass-Flörl, S. Unterdorfer, W. Nussbaumer,

M.P. Dierich (Innsbruck, AT)

page 76 Final Programme

P588 The role of mannose-binding lectin in

susceptibility to infection in premature


A. Dzwonek, O. Neth, J. Hawdon, E. Gulczynska,

H. Tchorzewski, M. Turner, N. Klein

(London, UK; Lodz, PL)

P589 Immunoprophylaxis of wound and urinary

tract infections in urological patients by

application of immunostimulator Urostim

R. Vacheva-Dobrevsky, I. Saltirov, P. Nenkov,

T. Petkov, E. Savov, J. Doncheva (Sofia, BG)

P590 Faropenem enhances the bactericidal activity

of human neutrophils in vitro

K. Clawson Stone, I.A. Critchley, U.A. Ochsner,

N. Janjic (Louisville, US)

P591 Light microscopic appearances of resident

macrophages in the adrenal glands of

pregnant and non-pregnant guinea pigs,

and their immuno-endocrinological


E. Ozbek, A. Ozbek (Erzurum, TR)

P592 Blood lymphocyte subsets in patients with

tick-borne encephalitis

I. Zeltina, V. Sondore, O. Shitova, B. Rozentale

(Riga, LV)

P593 Evaluation of a new immunoassay to detect

antibodies against Treponema pallidum in

sera samples

M.S. Garcia-Valdivia, J.R. León,

M.A. Rodriguez-Iglesias (Cadiz, ES)

P594 Monocyte chemoattractant protein-1:

role in the pathogenesis and progression

of acute pyelonephritis in infants

E. Demetriou, F. Haliotis, A. Margeli, M. Sourani,

L. Zachariadou, I. Papassotiriou (Athens, GR)

P595 Vaccination delays maedi-visna lentivirus

infection in naturally infected sheep flock

M. Gudnadóttir, A. Demosthenous

(Reykjavik, IS; Limmasol, CY)



P596 Free anonymous HIV testing sites are an

opportunity to offer hepatitis B virus

vaccination to high-risk non-immune patients

E. Bouvet, P. Preziosi, M. Branger, M. Rotily

(Paris, Bagneux, FR)

P597 Morphologic and molecular evidence of viral

infection in human brainstem

V. Militello, A. Porzionato, G. Masi, M. Trevisan,

G. Sarasin, V. Macchi, L. Barzon, R. De Caro,

G. Palù (Padua, IT)

Poster Sessions Sunday, April 2, 2006

P598 Prevalence and risk factors of QTc interval

prolongation in HIV-positive patients

P. Chinello, F. Papetti, E. Boumis, A. Conte,

B. Gigli, F. Lisena, C. Angeletti, N. Petrosillo

(Rome, IT)

P599 Prevalence of paediatric septicaemia in a

tertiary hospital in Tanzania and the impact

of aetiology, antimicrobial susceptibility

and HIV co-infection on clinical outcome

B. Blomberg, K.P. Manji, W.K. Urassa,

M. Holberg-Petersen, M.G. Tellevik, N. Langeland

(Bergen, NO; Dar es Salaam, TZ; Oslo, NO)

P600 Microarray analysis during adipogenesis

identifies new genes altered by antiretroviral


L. Barzon, M. Pacenti, K. Fincati, F. Favaretto,

G. Milan, R. Vettor, G. Palù (Padua, IT)

P601 Indeterminate HIV Western blot profiles:

how may we proceed?

G. Saliba, S. Matheron, F. Damond (Paris, FR)

P602 Best practices in model-based HIV drug


W. Poland, R. Bruno, M. Hovde,

J. Kuwabara-Wagg (Mountain View, US;

Marseilles, FR; Kennett Square, US)

P603 Primary pneumocystis infection in children

hospitalised with acute respiratory tract


H.H. Larsen, M.-L. von Linstow, B. Lundgren,

B. Høgh, H. Westh, J.D. Lundgren (Hvidovre, DK)

P604 Increasing reports of gynecomastia among

HIV-infected patients treated with highly

active antiretroviral therapy. Epidemiological

and clinical correlates, and suggestions for

pathogenetic investigation

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P605 Insulin resistance and glucose intolerance in

HIV-infected subjects during their protease

inhibitor treatment: three oral hypoglycemic

drugs in comparison

L. Calza, R. Manfredi, F. Chiodo (Bologna, IT)

P606 Advanced, lethal acute myelogenous

leukaemia during HIV disease favourably

managed with HAART

R. Manfredi, S. Sabbatani, F. Chiodo (Bologna, IT)

P607 Isolated, dual nucleoside analogue antiretroviral

therapy in the year 2005. Frequency,

reasons, significance and outcome of this

persisting phenomenon, nine years after

the introduction of HAART

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P608 The two non-nucleoside HIV reverse

transcriptase inhibitors: significantly

different dysmetabolic profile between

efavirenz and nevirapine

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P609 Opportunism related to a late, first AIDS

diagnosis. Paradoxical increasing frequency

at the time of HAART

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P610 Immigration and HIV infection in North-Eastern

Italy. Inpatient admissions, 2000–2004

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P611 Management of hyperlipidaemia related to

antiretroviral therapy with the novel statin

rosuvastatin: a pilot study

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P612 Increased frequency of syphilis among

patients who remained unaware of their

underlying HIV infection

R. Manfredi, L. Calza, S. Sabbatani, F. Chiodo

(Bologna, IT)

P613 Loss of bone mass in chronically HIV-infected

patients. Significant association with male

gender amd protease inhibitor administration

L. Calza, L. Tampellini, B. Farneti, M. Borderi,

M. Pajno, C. Biagetti, R. Manfredi, F. Chiodo

(Bologna, IT)

P614 Different HIV 1-subtypes and diseases

observed in a group of immigrants

hospitalised between 2001–2005

M.E. Valencia, A. Holguin, A. Alvarez, V. Moreno,

M. Lago, J. González Lahoz (Madrid, ES)

P615 Immigrants with HIV infection:

hospitalisations during 5 years

V. Moreno, M.E. Valencia, A. Holguin, A. Alvarez,

M. Lago, J. González Lahoz (Madrid, ES)

P616 Poor response to trimethoprim-sulfametho -

xazole in HIV-infected patients with

Pneumocystis jiroveci pneumonia and

concurrent opportunistic infections

P. Werarak, S. Ratanasiri, S. Sungkanuparph,

S. Kiertiburanakul (Bangkok, TH)

P617 Impact of occult HBV infection in HIV patients

naive for anti-retroviral therapy

P. Filippini, N. Coppola, R. Pisapia, C. Marrocco,

A. Zaccariello, C. Nacca, G. De Stefano, T. Ferraro,

C. De Stefano, E. Sagnelli (Naples, Caserta,

Matera, Catanzaro, Potenza, IT)

page 77

Poster Sessions Sunday, April 2, 2006

P618 Studies of the mechanism of the inhibitory

effect on HIV-1 infection by stimulation of the

VPAC2 neuroendocrine receptor

P.B. Bokaei, D. Sakac, X-Z. Ma, D.R. Branch

(Toronto, CA)

P619 Dramatic changes in survival and death rates

after AIDS through the evolution of antiretroviral

therapy, Paris

C. Couzigou, C. Semaille, R. Pinget, Y. Le Strat,

J. Pillonel, F. Lot, F. Cazein, D. Vittecoq,

J.C. Desenclos and the AIDS Survival Study Group

P620 Determinants of persistent nasal carriage and

population structure of Staphylococcus

aureus in HIV patients

D.C. Melles, E. Hardeman, L. van den Boogaard,

H.A.M. Boelens, J. Peters, J.K. Peeters,

M. van Min, W. van Leeuwen, H.A. Verbrugh,

A. van Belkum, J.L. Nouwen

(Rotterdam, Wageningen, NL)

P621 Pulmonary hypertension among HIV positive

subjects: findings from the Latium Regional


N. Petrosillo, E. Boumis, S. Cicalini, P. Chinello

on behalf of Latium Registry of Pulmonary

Hypertension in HIV

P622 Proteinuria in tenofovir-exposed and nonexposed

patients: audit of screening processes

within a United Kingdom HIV cohort

M.J. Parsonage, J. Vilar, G. Barlow, F. Qasim

(Cottingham, Manchester, UK)

P623 A meta-analysis of the frequency of side

effects for HAART drugs

S. Andreassen, L. Vidal, U. Pielmeier

(Aalborg, DK; Tel Aviv, IL)

P624 Immune-virological status and psycho-social

factors concerning vertically contamined

HIV-infected children at the time of transfer

to adult care

V. Mondain, J. Durant, E. Cua, I. Perbost,

F. Monpoux, A. Deville, P. Boutte, P. Dellamonica

(Nice, FR)

P625 Variation in interpretation and counselling of

blood exposure incidents

P.T.L . van Wijk, A. Timen, M. Pelk-Jongen,

C. Wijkmans, A. Voss, P. Schneeberger

(‘s-Hertogenbosch, Utrecht, Nijmegen, NL)

page 78 Final Programme


Detection of viruses

P626 The measurement of 9-carboxymethoxy -

methylguanine in human body fluids by

high-performance liquid chromatography

M. Darville, A. Lovering, A. MacGowan

(Bristol, UK)

P627 Transient HBsAg reactivity after hepatitis B


C. Koidl, B. Waitzl, A. Holensteiner, C. Kreuzer,

E. Daghofer, E. Marth (Graz, Vienna, AT)

P628 Development of human anti-rubella IgG

and IgM assays for the Abbott ARCHITECT


G.T. Maine, R. Vickstrom, K. Krishnan, J. Prostko,

Z. Kogan, J. Morey, J. Lagedrost, J. Jacob,

Rn. Stricker, Rt. Stricker, B. Pustowoit

(Abbott Park, US; Geneva, CH; Leipzig, DE)

P629 Preliminary evaluation of the Abbott

ARCHITECT anti-cytomegalovirus IgG,

IgM and IgG avidity assays

G.T. Maine, I. Curdt, J. Herzogenrath, H. Braun,

R. Eichler, H. Christ, M. Hausmann, R. Stricker,

R. Stricker, T. Lazzarotto (Abbott Park, US;

Wiesbaden, DE; Geneva, CH; Bologna, IT)

P630 A novel method for distinguishing between

bacterial and viral infections that incorporates

standard clinical laboratory data and

quantitative analysis of neutrophil

complement receptors, CR1 and CR3

J. Nuutila, U. Hohenthal, I. Laitinen, P. Kotilainen,

A. Rajamäki, J. Nikoskelainen, E-M. Lilius (Turku, FI)

P631 Epitope specific IgG response to Epstein-Barr

virus capsid protein p18 among different age


I. Astrakhantseva, O. Morozova, S. Rjabinina,

V. Puzyrev, T. Ulanova, A. Burkov, A. Obriadina

(Nizhny Novgorod, RU)

P632 Antigenic properties of new recombinant

polypeptide from TBEV gE protein

V. Pimenov, R. Plokhov, N. Savelieva,

J. Zagriadskaya, V. Puzyrev, T. Ulanova,

A. Obriadina (Niznyi Novgorod, RU)

P633 Development a new enzyme immunoassay

for detection anti-EBNA1 antibody to Epstein-

Barr virus based on new p72 mosaic protein

O. Morozova, M. Gladysheva, T. Ulanova,

V. Puzyrev, A. Burkov, A. Obriadina

(Nizhny Novgorod, RU)

Poster Sessions Sunday, April 2, 2006

P634 Rapid detection of rotavirus in children:

comparison of Vikia rota-adeno and Diarlex

MB, two immunochromatographic tests

H. Crehalet, F. Vandenesch, A.M. Freydiere

(Lyon, FR)

P635 Evaluation of rubella IgG and IgM assays on

the new vidia instrument

L. Grangeot-Keros, C. Vauloup-Fellous

(Clamart, FR)

P636 RNA extraction from respiratory samples

using the NucliSens easyMAG system

P. van Deursen, A. Verhoeven, P. de Bie,

M. Jacobs (Boxtel, NL)

P637 Evaluation of automated sample processing

using the MagNA Pure LC instrument for use

with the COBAS AMPLICOR HCV (ver 2) test

S. Palladino, I. Kay (Perth, AU)

P638 Development of sensitive and specific realtime

PCR assay for simultaneous diagnostics

and genotyping of cytomegalovirus

O. Vankova, O. Morozova, T. Ulanova, V. Loparev

(Nizhny Novgorod, RU; Atlanta, US)

P639 Detection of human papillomavirus

(Type 16, 18) in pathological sample from

patients with cervical cancer by PCR and

RFLP methods

P. Maleknejad, S. Shahsavan (Tehran, IR)

P640 Detection of human papillomavirus by

PCR genotyping and immunostaining in

population of Bosnian women

S. Mahmutovic, P. Gravitt, A. Hardick, E. Beslagic,

M. Slakovic, M. Herawi, C.A. Gaydos

(Sarajevo, BA; Baltimore, US)

P641 A novel system for the simultaneous

detection of seven respiratory viruses

D. Canter, B. Brigham, R. Haigis, M. Smith,

J. Shaw (San Diego, US)

P642 Evaluation of the multiplex reverse

transcription real time PCR ProFlu-1 LC

real-time assay for the detection of RSV,

influenza A and influenza B in a single test

J. Le Goff, C. Chemin, C. Charpentier, M. Matta,

A. Si-Mohamed, L. Belec, P. Lebon (Paris, FR)

P643 Detection of respiratory pathogens including

coronaviruses using PCR

I. Duerud, T.O. Jonassen, M. Steinbakk,

C.M. Jonassen (Lørenskog, Oslo, NO)

P644 An evaluation of the predictive value of HPV

testing and genotyping in the mass-screening

against cervical cancer in Norway

T. Nguyen, T.Ø. Jonassen, V. Lauvrak,

U. Westerhagen, A. Trope, S. Thoresen,

M. Steinbakk, A.K. Lie (Lørenskog, Oslo, NO)

P645 Comparison between two commercial assays

for HBV monitoring

S. Galli, M. Meliconi, G. Furlini (Bologna, IT)

P646 Detection of herpes simplex viruses type I and

II in dermal, genital, oral, cerebrospinal fluid,

and lower respiratory specimens by a Roche

HSV I/II analytic specific reagent kit on realtime

polymerase chain reaction

S. Liu, J. Tichota-Lee, D.S. DeBoer, S.A. Marum,

R.J. Van Santen, M.R. Koch (Sioux Falls, US)

P647 Survey of Crimean-Congo haemorrhagic fever

in Iranian suspected patients by Elisa and

RT-PCR method

S. Chinikar, F. Ahmadnejad , A. Fayaz, R. Mirahmadi,

N. Hoseini, N. Afzali, B. Hooshmand, M. Bouloy,

A. Lundkvist, M. Nilsson, A. Mirazimi

(Tehran, IR; Paris, FR; Stockholm, SE)

P648 Comparative evaluation of the vidas and

liaison toxoplasmosis, cytomegalovirus and

rubella panels in a French university hospital

M.J. Carles, C. Enault, L. Lachaud, S. Charachon

(Nîmes, FR)

P649 Different sensitivity of chemiluminescent

immunoassay for the detection of HBsAg

A. Rodella, L. Terlenghi, E. Cariani, N. Manca

(Brescia, IT)

P650 Evaluation of a new assay for simultaneous

detection of HCV core antigen and anti-HCV


S. Carlos, C. Fornieles, N. Chueca, M. Alvarez,

C. Bernal (Granada, ES)

P651 Comparison of molecular and serological

assays in the diagnosis of HCV infection

C. Fornieles, S. Carlos , N. Chueca, A. Peña,

F. García, C. Bernal (Granada, ES)

P652 Evaluation of an automated multiplexed

assay of heterophile antibody in comparison

with a latex agglutination test for assessment

of Epstein-Barr virus induced infectious


C. Lingenfelter, A. Villarreal, D. Kaur, H. Scholz

(Hercules, US)

page 79

Poster Sessions Sunday, April 2, 2006

P653 Real-time polymerase chain reaction and HCV

RNA quantification: comparison of Cobas

Ampliprep-Cobas TaqMan and branched DNA


T. Allice, S. Gabella, S. Varetto, F. Pittaluga,

A. Smedile, F. Cerutti, V. Ghisetti (Turin, IT)

P654 Automated fractal microscope for virus-cell


O.P. Fedchuk, A.O. Fedchuk, A.S. Fedchuk

(Odessa, UA)

P655 Comparison of HCV genotype and subtype

determination using Inno-LiPA HCV II and a

laboratory-developed HCV 5’UTR sequencing


S. Gabella, T. Allice, S. Varetto, F. Pittaluga,

V. Ghisetti (Turin, IT)

P656 Comparison of IMMULITE ® 2000 anti-HAV IgM

and anti-HAV total to Abbott AxSYM ® assays

C. Lee (Los Angeles, US)


Nosocomial infections

P657 National Resource for Infection Control (NRIC)

S.S. DSouza, S. Wiseman, P. Kostkova,

J. Mani-Saada (London, UK)

P658 An independent review of computerised

systems for alert organism and alert

condition surveillance

M. Jones, A. Pearson, S. Hanratty for the

Infection Control IT Implementation and

Evaluation Project Board, UK

P659 Knowledge, attitudes and practices of health

care workers in Kosovo hospitals regarding

nosocomial infections

L. Raka, S. Kalenic, D. Zoutman, L. Berisha,

M. Berisha, D. Salihu, L. Begolli, S. Krasniqi,

A. Jaka, I. Begolli (Pristina, CS; Zagreb, HR;

Kingston, CA)

P660 Worldwide implementation strategy of the

World Health Organization “Guidelines on

Hand Hygiene in Health Care”

B. Allegranzi, P. Philip, J. Storr, M. Fletcher,

S. Lazzari, L. Donaldson, D. Pittet

(Verona, IT; Geneva, CH; Lyon, FR)

P661 Considerations on optimal glove use within

the World Health Organization “Guidelines on

Hand Hygiene in Health Care”

B. Allegranzi, G. Dziekan, E. Larson, C.L. Pessoa

da Silva, P. Philip, L. Donaldson, D. Pittet

(Verona, IT; Manila, PH; New York, US; Geneva, CH)

page 80 Final Programme

P662 Alcoholic hand disinfectant use in a general

hospital: impact of an intervention

E. Divari-Katsiki, C Loupa, H. Antonopoulou,

K.J Karnezi, V. Tsolaki, M. Lelekis (Athens, GR)

P663 Does sufficient hand hygiene influence

hospital-acquired infections?

S. Laustsen, E. Lund, R. Andersen Leth,

J. Kjølseth Møller on behalf of the Hospital

Hygiene Group, Aarhus University Hospital,


P664 Adherence to hand hygiene in an Italian


A. Pan, K. Posfay-Barbre, P. Catenazzi, N. Poli,

A. Grandi, S. Lorenzotti, S. Magri, L. Soavi,

P. Mondello, G. Carnevale (Brescia, Cremona IT;

Geneve, CH)

P666 Evaluation of parameters influencing

compliance of HCWs with hand hygiene in

two university departments of internal

medicine in a Greek tertiary hospital

S. Athanasia, E. Giannitsioti, H. Fitrou,

A. Papadopoulos, P. Bourvani, K. Athanassiou,

P. Evangelopoulou, A. Ghika, H. Giamarellou

(Athens, GR)

P667 Nosocomial meningitis after spinal anesthesia

R. Kryeziu, L. Raka, G. Mulliqi-Osmani, H. Hyseni,

I. Dedushaj, D. Kryeziu, N. Ramadani, S. Omeragiq,

S. Muçaj (Pristina, CS)

P668 Infections after open heart surgery

C. Ezpeleta, E. Gomez, C. Busto, I. Atutxa,

J.A. Alava, J. Unzaga, R. Cisterna (Bilbao, ES)

P669 Surgical site infections after colon surgery

C. Ezpeleta, I. Atutxa, E. Gomez, C. Busto,

J.A. Alava, J. Unzaga, R. Cisterna (Bilbao, ES)

P670 Hospital-acquired infection: a hospital-wide

prevalence study at a London hospital

N. Desai, B. Houston, E. Stewart, J. Ikonnen,

S. Watts, S. Chuttarsing, I. Eltringham

(London, UK)

P671 Surveillance of nosocomial bloodstream


R.A. Leth, J.K. Møller (Aarhus, DK)

P672 A morbidity and mortality conference to

evaluate nosocomial infections and hospital


M. Demory, A. Decoster (Lomme, FR)

Poster Sessions Sunday, April 2, 2006

P673 Point prevalence of nosocomial infections in

Western Greece

E. Jelastopulu, F. Mesolara, C. Petropoulos,

M. Kardara, I. Detorakis (Patras, Erymanthia, GR)

P674 Levofloxacin plus rifampicin treatment of

staphylococcal prosthetic-joint infections

with prosthesis retention

J. Barberán, M.J. Giménez, L. Aguilar,

G. Carroquino, B. Sánchez, D. Martínez, J. Prieto

(Madrid, ES)

P675 Prosthetic joint infections: results of a

collaborative protocol between orthopaedist

surgeons and infectious diseases physicians

J. Vicente, V. Abril, R. Benítez, A. Bru, P. Segarra,

M. Gomis, S. Escrivá, E. Ballester,

M. García-Deltoro, M. García-Rodríguez,

L. Castellano, E. Ortega (Valencia, ES)

P676 Predictive value of oral colonisation by Candida

yeasts on the onset of a nosocomial infection

in elderly hospitalised patients

S. Fanello, J.P. Bouchara, V. Delbos, E. Parot,

M. Sauteron (Angers, FR)

P677 Impact of antifungal treatment on Candida-

Pseudomonas interaction

S. Nseir, E. Josefowicz, B. Cavestri, B. Sendid,

C. Di Pompeo, S. Soubrier, A. Durocher (Lille, FR)

P678 Nosocomial urinary tract infections caused by

extended-spectrum beta-lactamases producing

Enterobacteriaceae in Latvia

R. Paberza, T. Chumak, A. Zilevica, S. Selderina,

L. Luzbinska, J. Storozenko, B. Rozentale

(Riga, LV)


Infection in the immunocompromised host

(except HIV)

P679 Comparison of cytomegalovirus viral load

measured by real-time PCR with pp65 antigenemia

for the diagnosis of cytomegalovirus

disease in solid organ transplant recipients

S. Hernando, M.D. Folgueira, C. Lumbreras,

J.R. Otero (Madrid, ES)

P680 Incidence of acquired toxoplasmosis in

seronegative recipients of solid organ


V. Meroni, E. Zerrilli, F. Genco, B. Nocita,

F. Poletti, L. Minoli (Pavia, IT)

P681 Changing trends of bacteraemia in patients

with cancer: analysis of 2,080 quantitative

blood cultures during 1998 and 2004

A. Safdar, G. Rodriguez, M. Balakrishnan,

J. Tarrand, K. Rolston (Houston, US)

P682 Infections complicating unrelated donor cord

blood stem cell transplantation: 281 episodes

in recipients of 100 CBST at a comprehensive

cancer centre (1996 – 2005)

A. Safdar, G. Rodriguez, K. Chan, M. DeLima,

K. Rolston, R. Champlin (Houston, US)

P683 A risk profile for invasive aspergillosis in liver

transplant recipients

M. Rosenhagen, R. Feldhues, H.K. Geiss,

T. Hoppe-Tichy (Heidelberg, DE)

P684 Antifungal prophylaxis with caspofungin

in high-risk liver transplant recipients:

a non-comparative, open-label prospective

clinical trial

J. Fortun, P. Muñoz, J.M. Cisneros, M. Montejo,

A. Ramos, C. Sanz-Rodriguez on behalf of


P685 Effect of quinolone prophylaxis on resistance

in afebrile neutropenic patients –

systematic review

A. Gafter-Gvili, M. Paul, A. Fraser, L. Leibovici

(Petah Tikva, IL)

P686 The complications associated with use of

peripherally inserted central catheters in

cancer patients in Northern Ireland

R. McMullan, V. Coyle, R. Wilson, S. Hedderwick

(Belfast, UK)

P687 Prospective study of viral infection and

nephropathy in paediatric renal transplant


L. Murer, M. De Pieri, L. Barzon, M. Pacenti,

M.A. Biasolo, C. Mengoli, M. Della Vella,

C. Carasi, G. Montini, G. Zacchello, G. Palù

(Padua, IT)

P688 Trend towards reduced burden of proven/

probable invasive fungal infections in adult

non-allo-HSCT neutropenic patients with

acute leukaemia

L. Senn, T. Calandra, J. Robinson, O. Marchetti

(Lausanne, CH)

P689 Prevalence of HHV6 and parvovirus B19 in

transplant recipients liver tissue:

clinical outcomes and viral correlates

S.G. Parisi, S. Barbieri, C. Boldrin, P. Boccagni,

M.A. Biasolo, P. Feltracco, U. Cillo, A. Bortolato,

I. Cerbaro, D. D’Amico, G. Palù (Padua, IT)

P690 Nocardiosis: a retrospective study of

41 French cases

F. Laurent, B. Pangon, R. Sanchez, P. Boiron

(Lyon, Le Chesnay, Périgueux, FR)

page 81

Poster Sessions Sunday, April 2, 2006

P691 Kluyvera species as opportunistic pathogens

in paediatric cancer patients

H. El-Mahalawy, H. Morcos, L Shalaby (Cairo, EG)

P692 Risk factors for pulmonary aspergillosis in

patients with cancer and pneumonia

M. Aguilar-Guisado, E. Cordero, J.M. Cisneros,

I. Espigado, M. Noguer, R. Parody, J. Pachón

(Seville, ES)

P693 Pneumonia risk factors in patients with febrile


M. Aguilar-Guisado, E. Cordero, J.M. Cisneros,

I. Espigado, M. Noguer, R. Parody, J. Pachón

(Seville, ES)

P694 Once daily outpatient quinolone monotherapy

for low-risk febrile neutropenic cancer


K. Rolston, S. Patel, S. Frisbee-Hume,

E. Manzullo, R. Benjamin (Houston, US)

P695 Empiric monotherapy with cefepime in

standard-risk, paediatric, febrile neutropenic


K. Rolston, C. Mullen (Houston, Rochester, US)

P696 Urinary tract infections after renal transplantation:

bacterial isolates and resistance


S. Karampa, G. Miserlis, P. Sikalidou,

D. Takoudas, D. Sofianou (Thessaloniki, GR)

P697 Seroepidemiology of Bartonella henselae/

quintana in immunocompromised patients

(human immunodeficiency virus infected/

end-stage renal disease patients)

M. Pape, P. Kollaras, K. Mandraveli, A. Sioulis,

P. Nikolaidis, S. Alexiou-Daniel (Thessaloniki, GR)

P698 Tobramycin once vs. three times a day given

with penicillin G to cancer patients with

febrile neutropenia: a prospective randomised

multicentre trial

D. Torfoss, E.A. Høiby for the Norwegian Febrile

Neutropenia Study Group

P699 Enterococcal bacteraemia in patients with

haematological malignancies

N.S. Bagirova, N.V. Dmitrieva (Moscow, RU)

P700 Aetiology of infections and antimicrobial

resistance in patients treated for cancer

at a cancer institute in Slovakia.

Results from June 1999 to May 2003

O. Babelova, R. Babela, V. Krcmery (Trnava, SK)

P701 Interest of Candida antigen and antibody

ELISA for hepatosplenic candidiasis diagnosis

F. Persat, A. Thiebaut, F. Loiseau, M.A. Piens,

S. Picot, M. Michallet (Lyon, FR)

page 82 Final Programme

P702 Cefepime therapy is effective for children with

febrile neutropenia

G.T. Kovacs, M. Csoka, H. Erlaky, M. Garami,

J. Muller (Budapest, HU)


Antibacterial susceptibility studies – I

P703 A comparison study of amoxicillin-clavulanate

and azithromycin efficacy in treatment of

acute sinusitis

M. Zangeneh, N. Shariati, A. Yazdanyar,

M. Jamshidi Makiani, S. Haghighi (Tehran, IR)

P704 In vitro activities of various piperacillin and

sulbactam combinations against bacterial

pathogens isolated from intensive care units

in Taiwan: SMART program 2004 data

P.R. Hsueh, M.N. Hung, C.Y. Liu for the

Surveillance of Multicenter Antimicrobial

Resistance in Taiwan (SMART)

P705 Hetero-glycopeptide-intermediate Staphylococcus

aureus: prevalence and antibiotic

susceptibilities in long-term care facilities

from the Flemish part of Belgium

P. Declercq, A. Bolmstrom (Izegem, BE; Solna, SE)

P706 Uncomplicated urinary tract infections, what

about fosfomycin and nitrofurantoin in 2006?

P. Honderlick, J. Gravisse, P. Cahen, D. Vignon

(Suresnes, FR)

P707 Antimicrobial activity of linezolid and other

agents against nosocomial pneumonia

Streptococcus pneumoniae isolates

M.M. Ijzerman, M.A. Cohen, M.D. Huband,

P.J. Pagano, K.J. Tack (Ann Arbor, US)

P708 Low-level resistance to ciprofloxacin in

Salmonella strains isolated from humans

in Belarus

D. Tapalski (Gomel, BY)

P709 The influence of UV radiation on the

antibacterial activity of ciprofloxacin in

aqueous solutions

A.V. Polishchuk, E.T. Karaseva, V.E. Karasev

(Vladivostok, RU)

P710 In vitro activity of linezolid against

Bacteroides and Prevotella recovered from

soft tissue infections

H. Canawati, S. Bughi, A. Sharma, H. Canawati

(Downey, US)

Poster Sessions Sunday, April 2, 2006

P711 In vitro activities of cefepime, cefpirome and

ceftazidime in combination with amikacin or

ciprofloxacin against Pseudomonas aeruginosa

B. Ozbek, G. Otuk (Istanbul, TR)

P712 Antimicrobial resistance of Streptococcus

pneumoniae and Haemophilus influenzae in


I. Narkeviciute, G. Bernatoniene (Vilnius, LT)

P713 Cefepime alone or in combination with

clavulanic acid, gentamicin, and tobramycin

against clinical isolates of methicillin-resistant

Staphylococcus aureus

J. Chin, M. Rybak, C. Cheung, K. Lau, H. Sader,

R. Jones (Detroit, US)

P714 In vitro activities of daptomycin, linezolid,

and quinupristin-dalfopristin against clinical

isolates of Staphylococcus aureus and

Staphylococcus epidermidis from Germany

M. Kresken, J. Brauers (Rheinbach, DE)

P715 In vitro antichlamydial activity of moxifloxacin

versus a range of antimicrobial


R. Cevenini, M. Donati, S. Pignanelli, S. Accardo,

F. Cavrini, C. Mazzeo (Bologna, IT)

P716 Time-killing of viable Staphylococcus spp.

against Helicobacter pylori clinical isolates

J. Díaz-Regañón, T. Alarcón, E. Aznar,

D. Domingo, M. López-Brea (Madrid, ES)

P717 IBC-1 survey in Acinetobacter baumannii

isolates in a tertiary care hospital in

Thessaloniki, Greece

K. Koraki, P. Karapavlidou, D. Sofianou

(Thessaloniki, GR)

P718 Antibacterial activity of fractions of Quercus

infectoria (nut galls) against enterohaemorrhagic

Escherichia coli

S.P. Voravuthikunchai, S. Suwalak, T. Supawita

(Hatyai, Songkla, TH)

P719 In vitro synergy between glycopeptides and

carbapenems against methicillin-resistant

Staphylococcus aureus

Ö.K. Azap, H. Arslan, F. Timurkaynak, G. Yapar,

Ü. Çazir (Ankara, TR)

P720 Susceptibility rates of co-trimoxazole,

cefepime, imipenem, meropenem against

ESBL-producing and non-producing E. coli

and Klebsiella strains

Ö.K. Azap, F. Timurkaynak, G. Yapar, Ü. Çazir,

H. Arslan (Ankara, TR)

P721 Comparison of the minimal inhibitory

concentration values of vancomycin and

teicoplanin against staphylococci with the

results obtained 7 years ago

Ö.K. Azap, F. Timurkaynak, E. Oruç, T. Togan,

H. Arslan (Ankara, TR)

P722 Serotypes and quinolone resistance in

Salmonella enterica isolated from Greek

diarrhoeal patients

S. Maraki, G. Samonis, E. Nioti, A. Georgiladakis,

Y. Tselentis (Heraklion, Crete, GR)

P723 Co-trimoxazole resistance in urinary tract

infection agent E. coli in 1995 and 2005:

a multi-centre study in Ankara, Turkey

N. Coplu, H. Simsek, A. Gozalan, G. Hascelik,

S. Ercis, Z. Senses, M. Baysallar, I. Mumcu,

N. Balaban, S. Terzioglu, S. Ozkan, B. Esen

(Ankara, TR)

P724 Profile and phenotypes of resistance of

microorganisms from pregnant women

with asymptomatic bacteriuria in Russia

A. Shevelev, V. Kulakov, A. Ankirskaya,

A. Nikonov, S. Belokrysenko, V. Krasnopolski,

E. Dvoinikova, E. Ailamazyan, A. Savicheva,

G. Ershov, N. Nikiforovski, L. Stratchounski

(Smolensk, Moscow, Saint-Petersburg,

Volgograd, RU)

P725 Activity of moxifloxacin against the

urogenital mycoplasmas Ureaplasma spp.

and Mycoplasma hominis

C.M. Bebear, H. Renaudin, C. Planty, S. Pereyre,

Ch. Bebear (Bordeaux, FR)

P726 Activity of moxifloxacin against Mycoplasma


C.M. Bebear, H. Renaudin, J.S. Jensen,

Ch. Bebear (Bordeaux, FR)

P727 Emergence of extended-spectrum betalactamases

in a university hospital,

Hamburg, Germany in 2004

BS Timmerbeil, E Stürenburg, P Heisig

(Hamburg, DE)


Identification and antifungal susceptibility

testing for yeasts and moulds

P728 Candida krusei: the most frequent Candida

non-albicans species isolated from superficial

candidosis in Romania

F.S. Alecu, C. Tenea (Bucharest, RO)

page 83

Poster Sessions Sunday, April 2, 2006

P729 Variation of galactomannan level during

24-hour period in haematooncological

patients with/without invasive aspergillosis

Z. Racil, I. Kocmanova, E. Kubicova,

J. Lochmanova, A. Sevcikova, J. Mayer

on behalf of the Working party of opportunistic

infections, IHOK, Brno, CZ

P730 Laboratory diagnosis of pulmonary

aspergillosis in tuberculosis patients

A. Kulko, I. Doroshkova (Moscow, RU)

P731 Identification of Malassezia isolates of

patients with pityriasis versicolor by using

PCR-restriction enzyme method

H. Mirhendi, K. Makimura, B. Tarazooei,

N. Jalalizand (Tehran, IR; Tokyo, JP)

P732 Haemolytic activity of Candida albicans and

C. dubliniensis isolated from the oral cavity

of immunocompromised patients

I. Kosalec, B. Matica, N. Jarza-Davila, T. Maretic,

J. Granic, S. Pepeljnjak (Zagreb, HR)

P733 Candida albicans panuveitis and an uneven

therapeutic ground, passing through all

available and potentially effective antifungal

drugs: fluconazole, liposomal amphotericin B,

caspofungin, and voriconazole

R. Manfredi, S. Sabbatani, G. Marinacci, F. Chiodo

(Bologna, IT)

P734 AIDS-associated Cryptococcus laurentii

meningoencephalitis resistant to amphotericin

B, apparently prompted by a cured

Cryptococcus neoformans disease

R. Manfredi, C. Fulgaro, G. Legnani, S. Sabbatani

(Bologna, IT)

P735 Outbreak of neonatal candidiasis: drug

susceptibility and molecular epidemiology

of the isolates

S. Asticcioli, E. Nucleo, G. Perotti, L. Sacco,

R. Daturi, C. Matti, A. Cardillo, L. Pagani (Pavia, IT)

P736 A new in vitro model system to study

antimycotic drugs

S. Cagnacci, A. Palenzona, E.A. Debbia,

A. Marchese, R. Corvò, L. Rossi

(Genoa, San Remo, IT)

P737 EFISG survey of current practices in clinical

mycology laboratory services in Europe

J. Bille, G. Atherton, D.W. Denning, O. Lortholary,

C. Lass-Flörl, M.C. Arendrup, M. Cuenca,

E. Roilides, M. Tod, S. Bretagne, A. Voss,

P. Gaustad, H. Sambatakou, P. Eggimann,

J. Garbino, M. Akova, A. Ullmann, H. Hebart,

P. Muñoz, F.M. Mueller for EFISG (ESCMID

Fungal Infection Study Group)

page 84 Final Programme

P738 Comparison of the Sensititre YeastOne colorimetric

antifungal panel with reference M38:

a method for testing susceptibility Aspergillus

spp. to caspofungin

E. López-Oviedo, C. Martín, A. Martos, C. Castro,

M. Ramirez, A. Romero, J. Palomares, E. Martín-

Mazuelos (Seville, ES)

P739 Efficacy of anidulafungin against Candida

albicans in candidaemia and other forms of

invasive candidiasis

B. Goldstein, B. Johnson, W. Wible, D.S. Krause,

H. Schlamm (King of Prussia, Shaumberg,

New York, US)

P740 Ability of Spanish clinical laboratories in

diagnosing Candida krusei infections and in

monitoring susceptibility testing. Results of

the SEIMC Quality Control Program

R. Guna, J.L. Pérez, N. Orta, C. Gimeno for the

Programa de Control de Calidad SEIMC, Spain

P741 FungaLit-multi-parameter bioassay for

antifungal compounds mode-of-action studies

O. Kozlova, N. Christofi (Edinburgh, UK)

P742 Fungaemia at a tertiary-care hospital:

species distribution, antifungal susceptibility

and antifungal therapy

K. Lagrou, J. Verhaegen, W.E. Peetermans,

T. De Rijdt, J. Maertens, E. Van Wijngaerden

(Leuven, BE)

P743 A new in vitro kinetic model to study the

pharmacodynamics of antifungal agents:

Comparison of the activity of voriconazole

and amphotericin B administered alone

and in combination against Candida albicans

A. Lignell, A. Johansson, J. Larsson, O. Cars,

E. Löwdin, J. Sjölin (Uppsala, Linköping, SE)

P744 Is terbinafine a good antifungal drug to

combine with voriconazole or caspofungin?

Study of the activity of double combinations

against invasive clinical isolates of A. fumigatus

J. Guinea, T. Peláez, P. Muñoz, Ó. Cuevas-Lobato,

E. Bouza (Madrid, ES)

P745 In vitro activity of fluconazole and voric

onazole against invasive Candida albicans

isolates in patients with candidaemia from

2001–2005 in Hong Kong

M. Hui, R.W.F Li, P.L. Chan, M.L. Chin, K.C. Chu,

C.Y. Chan (Shatin, HK)

P746 The effect of aminocandin compared to

caspofungin and micafungin

M.A. Ghannoum, S. Dutta, N. Isham (Cleveland, US)

Poster Sessions Sunday, April 2, 2006

P747 Antifungal susceptibility testing of

dermatophytes isolated from a worldwide

tinea capitis clinical trial

M.A. Ghannoum, J. Matevish, A. Cirino, N. Isham

(Cleveland, US)

P748 In vitro activities of caspofungin and four

other antifungal agents against Trichophyton

spp. isolates

M. Demirbilek, F. Can, T. Gulec, Y. Saray,

H. Arslan (Ankara, TR)

P749 Update on Candida albicans antifungal

resistance trends among hospitalised patients

in a tertiary hospital in Greece

E.I. Kazakos, C. Manolopoulos, V. Papageorgiou,

E. Tsiakiri, S. Alexiou-Daniel (Thessaloniki, GR)


Virology – I

P750 Subclinical reactivation of VZV in patients

with tick-borne encephalitis

K. Soltysova, K. Roubalova, D. Picha,

V. Maresova, H. Rohacova (Prague, CZ)

P751 Epstein-Barr virus and p53 protein expression

in gastric carcinoma without Helicobacter

pylori infection

A. Szkaradkiewicz, W. Majewski, M. Wal,

P. Majewski, J. Bierla (Poznañ, PL)

P752 Cytomegalovirus and Epstein-Barr virus in

ulcerative colitis and Crohn’s disease

A. Szkaradkiewicz, R. Marciniak, P. Majewski,

I. Chudzicka-Strugala, A. Wasilewska, M. Drews

(Poznañ, PL)

P753 Cytomegalovirus infection in recipients of

liver transplant in Ireland

C.F. De Gascun, D. Houlihan, S. Coughlan,

P.G. O’Reilly, F.M. Fitzpatrick, J. Hegarty,

W.W. Hall (Dublin, IE)

P754 Incidence of primary CMV infection during

pregnancy and its transmission rate to the

foetus and newborn

A. Naessens, A. Casteels, L. De Catte,

S. Lauwers, W. Foulon (Brussel, BE)

P755 In situ PCR and in situ RT-PCR to distinguish

productive and non-productive human cyto -

megalovirus infection in blood leukocytes

B. Zawilinska, M. Kosz-Vnenchak, K. Bulek,

J. Kopec, E. Daszkiewicz (Cracow, PL)

P756 A real-time PCR assay to detect human

cytomegalovirus DNA in whole blood of solid

organ transplant patients: optimal threshold

for guiding pre-emptive therapy

T. Lazzarotto, C. Vaccari, L. Gabrielli, P. Monari,

S. Pop, M.P. Landini (Bologna, IT)

P757 Evaluation of a real-time NASBA assay for the

detection of herpes simplex virus type 1 and 2

C. Zintilini, P. Van de Wiel, F. Jacobs, B. Deiman,

S. Vermeer (Grenoble, FR; Boxtel, NL)

P758 Detection of herpes simplex virus in cerebro -

spinal fluid using real-time PCR

E. Aznar, J. Díaz-Regañón, T. Alarcón, C. Sánchez-

Zamora, M. López-Brea, L. Cardeñoso (Madrid, ES)

P759 BK polyoma virus replication in de novo renal

transplant recipients. Results of a prospective


M. Koukoulaki, E. Grispou, G. Saroglou,

D. Pistolas, K. Balaska, T. Apostolou,

M. Anagnostopoulou, V. Hadjiconstantinou,

O. Paniara, S. Drakopoulos, N. Legakis (Athens, GR)

P760 JC virus genotype distribution differs

between healthy and immunocompromised

Irish individuals

K. Schaffer, N. Sheehy, S. Coughlan, C. Bergin,

W.W. Hall (Dublin, IE)

P761 Prevalence of human papillomavirus

genotypes in genital samples

A. Suárez, C. Sánchez, E. Vázquez, J.J. Picazo

(Madrid, ES)

P762 Prevalence of human papillomavirus types in

cervical samples from HIV-infected women

F. Zara, A. Spinillo, R. Brerra, B. Gardella,

R. Mainini (Pavia, IT)

P763 Physical status of HPV-16 in patients with

LSIL or cervical carcinoma

S. Szostek, M. Klimek, J. Kopec, B. Zawilinska

(Cracow, PL)

P764 Prevalence of HPV in Lithuania according to

data based on PCR technique

I. Gulbinovic, K. Asmonaite, D. Ambrasiene

(Vilnius, Kaunas, LT)

P765 Focal epithelial hyperplasia disease in Panares

Indians from Bolivar state, Venezuela

M. Correnti, S. Hurtado, V. Tovar, M.E. Cavazza,

M. Avila, M. Guevara, T. Sanabria, L. Pocaterra

(Caracas, VE)

P766 Gen tax evidence of HTLV-1 co-infections

in HIV-positive patients in a hospital in Bilbao,


N. Ortiz, M. Basaras, M. Sota, R. Cisterna

(Bilbao, ES)

page 85



Poster Sessions Sunday, April 2, 2006

P767 Virologial and clinical aspect of HBV silent

infection in patient with chronic hepatitis C

E. Sagnelli, N. Coppola, C. Marrocco,

M. Imparato, R. Pisapia, G. Piai, L. Cimmino,

C. Del Vecchio Blanco, A. Giorgio, V. Messina,

F. Piccinino, P. Filippini (Naples, Caserta, IT)

P768 Fulminant hepatitis due to hepatitis B virus

A. Vata, M. Hurmuzache, D. Mihalache, D. Florea,

D. Scripcariu, C. Luca, D. Dimitriu, V. Luca (Iasi, RO)

P769 Acute /recent HCV infection in seronegative

blood donors and IDUs, viral replication

kinetics, immune response and disease


T. Tsertsvadze, L. Sharvadze, L. Dzigua,

N. Chkhartishvili (Tbilisi, GE)

P770 Phylogenetic analysis in a HCV type 5 infected

population in the French central district of


C. Henquell, C. Bonny, S. Ughetto, H. Odent-

Malaure, V. Tixier, J.L. Bailly, P. Deny, H. Peigue-

Lafeuille, A. Abergel

(Clermont-Ferrand, Bobigny, FR)

P771 Quantification of hepatitis C virus in human

plasma samples by using real-time reverse

transcriptase PCR

K. Shahzamani, F. Sabahi, S. Merat (Tehran, IR)

P772 PEG-interferon-alpha 2a (40kda) in patients

on chronic haemodialysis with chronic

C hepatitis: early results

M.K. Celen, C. Ayaz, N.U. Yuce, S. Hosoglu,

M.F. Geyik (Diyarbakir, TR)

P773 Hepatitis C virus infection in haemodialysis


N. Petrosillo, A. Di Napoli, P. Pezzotti, D. Di Lallo,

S. Di Giulio, C. Trivelloni, G. Guasticchi

on behalf of Lazio Dialysis Registry

P774 Anti-HCV IgG Avidity Index in acute hepatitis

C and chronic hepatitis C

N. Coppola, R. Pisapia, S. Martini, C. Marrocco,

L.M. Vatiero, M. Pisaturo, G. Tonziello, P. Filippini,

F. Piccinino, E. Sagnelli (Naples, IT)

P775 Hepatitis B virus genotypes:

a Lebanese hospital-based study

I. Jureidini, P. Rassam, S. Keleshian, J.P. Aoun,

S. Khoury, Z. Daoud, N. Irani- Hakimé (Beirut, LB)

page 86 Final Programme

P776 Evaluation of Bayer Advia Centaur chemiluminescent

assays for the analysis of hepatitis B

HBs antigen and HBc total antibodies and

hepatitis C total antibodies

D. Burki, F. Rich, J. Carlsen, L. Matter (Basel, CH)

P777 Relationships between luetic infection and

acute viral hepatitis

R.F. Botgros, C.P. Popescu, S-A. Florescu,

A.M. Nicolescu, M. Cotiga, L. Raduta,

P.I. Calistru, E. Ceausu (Bucharest, RO)

P778 The distribution of HBV genotypes,

serotypes and YMDD variants among chronic

HBV patients in Kuwait

M. Ali, S. Farhan, H. Askar, F. Hassan, S. Ahmad,

W. Al-Nakib (Kuwait, KW)

P779 Immunogenicity of recombinant hepatitis B

vaccine in treatment-naïve and treatmentexperienced

chronic hepatitis C patients.

The effect of pegylated interferon plus

ribavirin treatment

I.S. Elefsiniotis, M. Pirounaki, E. Vezali,

K. Kamposioras, K. Pantazis, H. Brokalaki,

A. Moulakakis, G. Saroglou (Athens, GR)

P780 Serum neopterin levels in patients with

replicative and non-replicative HBV carriers

I. Kaleli, M. Demir, N. Cevahir, M. Yilmaz,

S. Demir (Denizli, TR)

P781 Investigation of the serum neopterin levels in

patients with infected hepatitis B

I. Gonen, F.Z. Akcam, O. Kaya, G. Yayli (Isparta, TR)

P782 The HBV seroprevalance among high school

students in Izmir, Turkey

B. Karaca, H. Tarakci, E. Tumer, H. Guven

(Izmir, TR)

P783 The epidemiology of hepatitis A in Poland.

Prevalence of hepatitis A antibodies in


W. Janaszek-Seydlitz, B. Bucholc, J. Slusarczyk,

A.A. Wiatrzyk (Warsaw, PL)

P784 Changing epidemiology of acute hepatitis A

and hepatitis B in Italy. Further counselling

and prophylactic measures are needed for

male homo-bisexual subjects?

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P785 Intrafamilial transmission of hepatitis E in


A. Ducancelle, E. Nicand, C. Payan, H. Le Guillou,

P. Calès, F. Lunel-Fabiani (Angers, Paris, Brest, FR)

Poster Sessions Sunday, April 2, 2006

P786 Molecular detection and sequence analysis of

hepatitis E viruses in humans and animals in


G. Reuter, D. Fodor, P. Forgách, B. Molnár,

J. Zentai, A. Kátai, G. Szucs

(Pécs, Szeged, Budapest, Vecsés, HU)

P787 TT virus prevalence and distribution of

genotypes and genogroups in Korea

H.S. Kim, K.M. Lee (Anyang, KR)

P788 Presence and significance of TT virus infection

in voluntary blood donors and patients on

maintenance hemodialysis in Tabriz, Iran

L. Gachkar, M. Taremi, M. Khoshbaten,

M. Kheradpajouh (Tehran, IR)

P789 The prevalence and phylogeny of GBV-C/

HGV in eastern Taiwanese indigenes

H.-F. Liu, D.-H. Chen, C.-W. Teng, C.-L. Lin,

Y.-J. Lee, L.-Y. Wang (Taipei-Tamshui, Keelung,

Hualien, TW)

P790 Three years lamivudine therapy in adults with

HBeAg-positive chronic hepatitis B

M.K. Celen, C. Ayaz, S. Hosoglu, M.F. Geyik,

M. Ulug (Diyarbakir, TR)


Paediatric infectious diseases

P791 Antimicrobial susceptibility of Haemophilus

influenzae ocular isolates collected from

outpatients in paediatric hospital

A. Makri, T. Guajardo, H. Papavasileiou, H. Iliadis,

I. Varzakakos, N. Manios, A. Voyatzi (Penteli, GR)

P792 Bacterial pathogens isolated from children

with bloodstream infection

A. Makri (Athens, GR)

P793 Characterisation of Haemophilus

influenzae isolates from conjunctivitis

(Portugal, 2001–2005)

M.P. Bajanca-Lavado, D. Louro, M.M. Caniça

(Lisbon, PT)

P794 Antimicrobial susceptibility and serotyping of

pneumococci in a Tunisian paediatric hospital

H. Smaoui, J. El Amri, A. Kechrid (Tunis, TN)

P795 Pneumococcal infection in a children’s

hospital in 2004, Taoyuan, Taiwan

Y.C. Huang (Taoyuan, TW)

P796 Repeated isolation of a pneumococcus from a

child suffering from IRAK-4 deficiency

O. Dobay, J. Szabó, Á. Borbély, M. Erdõs,

F. Rozgonyi, K. Nagy, L. Maródi

(Budapest, Debrecen, HU)

P797 Nasopharyngeal colonisation by

Streptococcus pneumoniae in children.

Impact of amoxicillin treatment

A. Díaz, R. Garcia, C. García-Rey, E. Cuchí, E. Calbo,

L. Tobeña, M. Díaz-Infantes, J.E. Martín-Herrero,

J. Garau and the Spanish Pneumococcal Infection

Study Network

P798 Prevention of perinatal group B streptococcal

infections: evaluation of a new chromogenic


C. Roure, V. Fiaty, Y. Gilles, H. Salord, S. Tigaud

(Lyon, FR)

P799 Invasive group a streptococcal infections and

incidence of resistance in children’s hospital

D. Garantziotou, M. Vlachou, O. Koureli,

T. Apostolaki, P. Michail, V. Rouli, A. Gatopoulou,

A. Spiliopoulou (Patras, GR)

P800 Community-acquired methicillin-resistant

Staphylococcus aureus in Greek children

J. Dotis, M. Tsiakou, M. Tsivitanidou, D. Sofianou,

E. Roilides (Thessaloniki, GR)

P801 Seroprevalence of serogroup specific antibodies

against different serogroups of Neisseria

meningitidis (Serogroup A, C, W 135 and Y) in

healthy individuals in different age groups

I. Yildirim, R. Borrow, G. Lal, N. Andrews

(Ankara, TR; Manchester, London, UK)

P802 Increasing nasopharyngeal carriage rate of

Neisseria meningitidis serogroup W135 in

healthy Turkish primary school students after

2000 Hajj epidemic

I. Yildirim, S. Ercis, S. Uygun, G. Secmeer

(Ankara, TR)

P803 Evaluation of IgA secretory antibodies in

children with Helicobcater pylori infection

M.E. Cavazza, D. Ortiz, M.I. Urrestarazu,

M. Correnti, G. Daoud, N. Daoud , M. Perrone

(Caracas, VE)

P804 Resistance pattern of Staphylococcus aureus

clinical isolates from children

A. Kyratsa, E. Kontekaki, N. Charalambaki,

A. Zambou, E. Trikka-Graphakos (Athens, GR)

P805 Incidence and antimicrobial resistance of

pathogens causing gastroenteritis in


A. Kyratsa, E. Kontekaki, F. Ioannidou, Z. Kyriazi,

E. Trikka-Graphakos (Athens, GR)

P806 Evaluation of bacterial microflora in the colon

of children with inflammatory bowel disease

T. Gosiewski, M. Strus, P. Heczko, M. Brzychczy-

Wolch, K. Fyderek (Cracow, PL)

page 87

Poster Sessions Sunday, April 2, 2006

P807 Molecular epidemiology of Escherichia coli

diarrhoea in children in Tehran

S. Salmanzadeh-Ahrabi, E. Habibi, F. Jafari,

M. Zali (Tehran, IR)

P808 Antimicrobial susceptibility of urinary

pathogens in children from two tertiary care

Greek hospitals

O. Vasilaki, P. Sikalidou, S. Karampa, A. Tzanakari,

S. Alexiou-Daniel, D. Sofianou (Thessaloniki, GR)

P809 Urinary tract infection in neonates, a five-year

study (2000–2005)

Z. Mosayebi, A. Movahedian, R. Moniri

(Kashan, IR)

P810 Longitudinal development of tobramycin

resistance in Pseudomonas aeruginosa

isolates from children with cystic fibrosis and

the effect on clinical outcome

M.M. Doyle, P. McNally, G. Leen, J. Dier,

P. Greally, P.G. Murphy (Dublin, IE)

P811 Predictors of mortality in children with


A.C. Pasqualotto, A.B. de Moraes, R.R. Zanini,

L.C. Severo (Manchester, UK; Porto Alegre, BR)

P812 Bacterial isolates during bacteraemia in

neonatal units of a medical university hospital

in Gdansk

B. Rybak, D. Piasecka-Pazik, A. Samet, M. Bronk,

J. Szczapa (Gdansk, PL)

P813 Incubation time for clinically significant

positive neonatal blood cultures

H.L. Lim, A.J. Bint, A. Fenton, S.J. Moss

(Newcastle-upon-Tyne, UK)

P814 Predictive value of procalcitonin and serum

amyloid A protein levels in early detection of

pyelonephritis in childhood

M.P. Sourani, F. Haliotis, A. Kariyiannis, E. Hantzi,

L. Zachariadou, S. Avlonitis, I. Papassotiriou,

K. Karavanaki (Athens, GR)

P815 Is there a place for moxifloxacin in paediatric

practice? A report from a tertiary care

paediatric hospital

S. Jourdain, O. Stevart, P.R. Smeesters, P. Lepage,

A. Vergison (Brussels, BE)

P816 Leptin as an acute-phase reactant in urinary

tract infections in children

E. Demetriou, A. Margeli, F. Haliotis, M. Sourani,

L. Zachariadou, I. Papassotiriou, A. Konstantopoulos

(Athens, GR)

page 88 Final Programme

P817 Treatment of acute otitis media in primary

paediatric care and the risk factors for

antibiotic prescribing

K. Banasova, H. Hupkova, V. Foltan, J. Trupl

(Bratislava, SK)

P818 The hygiene hypotheses revisited? Recurrent

childhood upper respiratory tract infections

do not reduce the risk of adult atopic disease

M.M. Rovers, W.A. Balemans, A.G. Schilder,

E.A. Sanders, G.A. Zielhuis, C.K. van der Ent

(Utrecht, NL)


Microbial biofilms

P819 Genetic analysis of the biofilm phenotype in

methicillin-resistant Staphylococcus aureus

E. O’Neill, H. Humphreys, J.P. O’Gara (Dublin, IE)

P820 Combined exposure to sub-inhibitory levels

of vancomycin and therapeutic levels of

aspirin enhances biofilm formation by

Staphylococcus epidermidis

M. Aljeldah, M. Upton (Manchester, UK)

P821 Lactobacillus as a competitive bacteria in

Staphylococcus strains biofilm formation

E. Walencka, B. Sadowska, M. Wieckowska-

Szakiel, W. Hryniewicz, B. Rozalska

(Lodz, Warsaw, PL)

P822 Dual species biofilms: do staphylococci like

other bacteria?

E. Walencka, B. Sadowska, B. Rozalska (Lodz, PL)

P823 Evaluation of the biofilm-forming ability of

Staphylococcus aureus and Staphylococcus

epidermidis mastitis isolates

M. Oliveira, R. Bexiga, S.F. Nunes, L.M. Cavaco,

F. Bernardo, C.L. Vilela (Lisbon, PT; Glasgow, UK;

Copenhagen, DK)

P824 Comparative activity of linezolid,

quinupristin/dalfopristin and vancomycin

against biofilm produced by cystic fibrosis

isolates of Staphylococcus aureus normal

and small colony variant phenotypes

P. Morelli, M. Mentasti, G. Manno (Genoa, IT)

P825 Low prevalence of BAP gene (coding for

biofilm-associated protein) in French isolates

of Staphylococcus aureus recovered from

human and animals species

E. Vautor, H. Carsenti-Dellamonica, R. Thiery

(Sophia-Antipolis, Nice, FR)

Poster Sessions Sunday, April 2, 2006

P826 Contribution of biofilm phenotype to the

pathogenesis of Staphylococcus epidermidis

neurosurgical device-related meningitis

N. Stevens, H. Humphreys, E. O’Neill,

J.P. O’Gara, C. Greene, T. Dillane, T. Sattar

(Dublin, IE)

P827 Biofilm formation of invasive GAS isolates

collected in immunocompromised and

immunocompetent patients

R. Gattringer, S. Reichmann, W. Graninger,

E. Presterl (Vienna, AT)

P828 Biofilm formation by E. faecalis in the

microtitre-plate assay does not correspond

to biofilm formation on clinically relevant


A. Hallgren, G. Dunny (Linköping, SE;

Minneapolis, US)

P829 Cell surface hydrophobicity, motility, and

biofilm formation of Stenotrophomonas

maltophilia clinical isolates

G. Di Bonaventura, C. Picciani, A. Pompilio,

R. Piccolomini (Chieti, IT)

P830 Molecular epidemiology and phenotypic

characteristics of chronic Pseudomonas

aeruginosa populations in cystic fibrosis


H.K. Johansen, L. Yang, A. Frost, L. Jelsbak,

J. Haagensen, N. Høiby, S. Molin

(Copenhagen, Lyngby, DK)

P831 Morphological changes induced by sub -

inhibitory concentrations of imipenem and

piperacillin/tazobactam on surface properties

and adhesion abilities of Pseudomonas


A.P. Fonseca, C.I. Extremina, A. Freitas da

Fonseca, J.C. Sousa (Porto, PT)

P832 Influence of the salt concentration on biofilm

formation by Salmonella spp.

I. Cirkovic, M. Svabic Vlahovic, N. Opavski,

V. Mijac, S. Djukic, S. Stepanovic, I. Cirkovic

(Belgrade, CS)

P833 Effect of the acquisition of quinolone

resistance in biofilm formation by

Acinetobacter baumannii clinical isolates

S. Marti, J. Sanchez-Cespedes, S. Soto,

E. Oliveira, D. Bellido, L. Actis, J. Vila

(Barcelona, ES; Miami, US)

P834 Virulence factors of Proteus mirabilis involved

in encrustation of urinary catheters

A. Torzewska, S. Klinder, A. Czyrznikowska,

A. Rozalski (Lodz, PL)

P835 In vitro biofilm formation by Candida spp.

on the surface of polyurethane and PVC


D. Estivill, Á. Torres-Lana, Á. Arias, M.P. Arévalo

(Manresa, La Laguna, ES)

P836 Biofilm production in well characterised

Candida spp. isolated in Italy during the

period 2002–2005 from paediatric and adult


A. Marchese, L. Gualco, R. Bandettini, C. Peri,

L. Pescetto, L. Ricagni, A. Cavallero, M.C. Ossi,

E.A. Debbia, G.C. Schito (Genoa, Milan, IT)

P837 Biofilm communities on different construction


A. Kimiran Erdem, E. Arslan, N. Dogruöz, Z. Zeybek,

N. Sanli Yürüdü, I. Türetgen, A. Cotuk (Istanbul,


P838 Biofilm-positive microbes isolated from the

environment of life-boxes for allogenic transplantations

and from immunocompromised


V. Hola, L. Horakova, F. Ruzicka, M. Votava,

R. Tejkalova (Brno, CZ)

P839 The effectiviness of impregnation of graft

with cefazolin in foreign body infection

D. Kilic, C. Agalar, E. Denkbas, F. Agalar,

E. Ozturk, M. Emirdogan, O. Deveci (Ankara, TR)

P840 Biofilm production by different strains of

Salmonella typhimurium: genetics,

morphology and role of surface and

nutrient content of medium

J.M. Romanova, N. Alekseeva, A.L. Andreev,

T.A. Smirnova, T.V. Stepanova, A.L. Gintsburg

(Moscow, RU)

P841 Biofilm-associated anaerobic sulphate

reducing bacteria on galvanized steel surfaces

E. Ilhan-Sungur, I. Türetgen, A. Cotuk (Istanbul, TR)

P842 Mechanism and effects of biofilm formation

on fat-based materials

G. Cayli, I. Türetgen (Istanbul, TR)

P844 The development of an Aspergillus fumigatus

biofilm model to determine the effectiveness

of antifungal treatments in vivo

J. Butcher, G. Ramage, C. Williams (Glasgow, UK)

P845 Influence of subinhibitory vancomycin

concentrations on biofilm formation in

coagulase negative staphylococci

A. Longauerova, D. Kotulova, L. Slobodnikova

(Bratislava, SK)

page 89

Poster Sessions Sunday, April 2, 2006


Brucella and Lyme borreliosis

P846 Brucellosis: retrospective evaluation of

133 hospitalised cases

Y.Z. Demiroglu, T. Turunc, H. Uncu, H. Arabaci,

S. Colakoglu, H. Arslan (Ankara, TR)

P847 Brucellar epididymo-orchitis in south-eastern

Anatolia, Turkey

M.K. Celen, M.F. Geyik, C. Ayaz, S. Hosoglu,

M. Ulug (Diyarbakir, TR)

P848 Neurobrucellosis: experience with 8 cases

C. Ayaz, M.K. Celen, M. Ulug, S. Hosoglu,

M.F. Geyik (Diyarbakir, TR)

P849 The effects of oxidative stress in patients with

infection of Brucella melitensis

M. Gul, E. Kurutas, P. Ciragil, M. Kilinc, M. Aral,

O.F. Kokoglu (Kahramanmaras, TR)

P850 Doxycycline plus streptomycin versus

ciprofloxacin plus rifampicin in spinal


E. Alp, R. Koc, A. Durak, O. Yildiz, B. Aygen,

B. Sumerkan, M. Doganay (Kayseri, TR)

P851 Epidemiological features and clinical

manifestations of adult brucellosis in Turkey

M.A. Yetkin, C. Bulut, G.R. Yilmaz, F.S. Erdinc,

S. Kinikli, B. Oral, N. Tulek, A.P. Demiröz

(Ankara, Samsun, TR)

P852 Analysis of the risk factors for brucellosis in

an endemic region

O. Ergonul, S. Deniz, N. Baykam, A. Celikbas,

B. Dokuzoguz (Ankara, TR)

P853 Neurologic involvement among brucellosis


K. Ugurlu, O. Ergonul, S. Eren, A. Celikbas,

N. Baykam, B. Dokuzoguz (Ankara, TR)

P854 Clinical manifestations of Lyme borreliosis in

Bulgaria and identification of Borrelia species

in ticks

I. Christova, E. Tasseva, T. Gladnishka (Sofia, BG)

P855 Seasonal patterns of the activity of hostseeking

Ixodes ricinus ticks in a tick-borne

encephalitis and Lyme borreliosis natural

focus (Czech Republic)

M. Daniel, K. Zitek, J. Valter, I. Kott, V. Danielova,

J. Holubova, B. Kriz (Prague, CZ)

page 90 Final Programme


Diagnositic and laboratory methods in

parasites and fungi

P856 Diagnosis of Giardia lamblia with microscopy,

striptest, ELISA and real-time PCR

M. Brinkman, D. Vastert, H. Wilke, B. Mulder

(Enschede, NL)

P857 Diagnosis of Cryptosporidium parvum

with microscopy, striptest, ELISA and

real-time PCR

D. Vastert, M. Brinkman, H. Wilke, B. Mulder

(Enschede, NL)

P858 New diagnostic method for pneumocystis

using flow cytometry

C. Pina Vaz, S. Costa de Oliveira, G. Monteiro,

T. Carvalho, A. Rodrigues (Porto, PT)

P859 Rapid identification and separation of the

yeast according to their isoelectric point

F. Ruzicka, V. Hola, M. Horka, M. Votava

(Brno, CZ)

P860 Evaluation of a rapid colorimetric test based

on trehalose use for identification of Candida


S. Kirdar, B. Gultekin, G. Evcil, A. Ozkutuk,

G. Sener, N. Aydin (Aydin, TR)

P861 Immunodiagnosis of invasive candidiasis:

prospective serological evaluation of at-risk

patients in the French university hospital

of Grenoble

M. François, O. Faure, B. Lebeau, R. Grillot,

H. Pelloux, C. Pinel (Grenoble, FR)

P862 Influence of culture medium on performance

of a yeast identification system (MICRONAUT


G. Haase, H. Schulze (Aachen, Bornheim, DE)

P863 Function of Candida albicans ALS5 and

ALS7 genes on adhesion to FEP (polymer of

tetrafluoroethylene and hexafloropropylene)

catheter and polyurethane catheter

P.L. Chan, R.W.F. Li, M.L. Chin, K.C. Chu, M. Hui,

C.Y. Chan (Sha Tin, Hong Kong, HK)

P864 Comparative evaluation of Candida DNA,

mannan, anti-mannan antibodies and

(1-3)-beta-D-glucan in the diagnosis of


Z.U. Khan, F. Alam, A.S. Mustafa (Kuwait, KW)

P865 Evaluation of tobacco agar for differentiation

of Cryptococcus neoformans

Z.U. Khan, R. Chandy (Kuwait, KW)

Poster Sessions Sunday, April 2, 2006

P866 Comparison of Aspergillus fumigatus DNA

and galactomannan in serum and broncho -

alveolar lavage specimens of experimentally

infected rats

S. Ahmad, Z.U. Khan, A. Theyyathel (Kuwait, KW)

P867 Candida spp. colonisation and serum

anticandidal antibody levels in patients with

chronic urticaria

M.C. Ergon, T. Ilknur, M. Yucesoy, S. Ozkan

(Izmir, TR)

P868 Performance of three differential media for

the presumptive identification of yeasts

M. Yucesoy, M.C. Ergon, S. Ozer (Izmir, TR)

P869 Detection of Aspergillus galactomannan

antigen levels for antimicrobial agents by


M. Yucesoy, M.C. Ergon (Izmir, TR)

P870 Mycological evaluation and suitability for

detecting dermatophytes on sabouraudgentamicin-chloramphenicol-2-agar

M. Mempel (Munich, DE)



P871 Pregnant women and toxoplasmosis

I. Machado, I. Sousa, H. Angelo (Porto, Lisbon, PT)

P872 Congenital toxoplasmosis prevention in


I. Machado, I. Sousa, H. Angelo

(Porto, Lisbon, PT)

P873 Screening for Toxoplasma gondii, rubella

virus and cytomegalovirus in pregnant


S. Baka, E. Makrakis, D. Hassiakos, I. Logginidis,

S. Meretaki, E. Kouskouni (Athens, GR)

P874 Screening for acute toxoplasma infection

during pregnancy: compliance to the French

programme of 41086 pregnancies in the

Rhône-Alpes region

C. Cornu, A. Bissery, R. Ecochard, F. Gueyffier,

F. Peyron, M. Wallon (Bron, Lyon, FR)

P875 High prevalence of IgM antibodies against

Toxoplasma gondii in Mexican pregnant


R. Figueroa, D. Correa, M. Vela, A. Fernandez,

I. Cañedo, M. Perez, H. Luna, C. Gonzalez,

E. Calderon, H. Gonzalez, J. Ortiz, J.L. Hernandez,

V. Ortega (Mexico City, MX)

P876 Impact of health education for the primary

prevention of Toxoplasma infection in

pregnancy: lessons from the ERIS study

M. Wallon, D.T. Nguyen Hoang Hanh, F. Peyron,

G. Chêne (Lyon, Bordeaux, FR)

P877 Multicentre proficiency testing programme

for molecular detection of Toxoplasma gondii

in amniotic fluid

K. Kaiser, A. Van Loon, H. Pelloux, J. Ferrandiz,

S. Picot, P. Wallace, F. Peyron (Lyon, FR; Utrecht, NL;

Grenoble, FR; Glasgow, UK)

P878 Using the new IMMULITE 2000 toxoplasmosis

IgM (µ-capture) kit for the diagnosis of human


E. Woitrin, I. Jost, R. Fassotte (Dudelange, LU)

P879 Development of novel cytomegalovirus and

toxoplasma IgG avidity assays using an

antigen competitive format “AVIcomp” on

the Abbott ARCHITECT Instrument

G.T. Maine, S. Hsu, D. Smith, I. Curdt,

J. Herzogenrath (Abbott Park, US; Wiesbaden, DE)

P880 Preliminary evaluation of the Abbott

ARCHITECT anti-toxoplasma IgG, IgM and IgG

avidity assays

G.T. Maine, S. Hsu, C. Patel, D. Smith, J. Munoz,

M. Gardiner, M. Palafox, E. Frias, L. Gu, M. Wilson,

R. Holzman, Rn. Stricker, Rt. Stricker

(Abbott Park, US; Geneva, CH)

P881 Performance evaluation of the VIDIA

toxoplasmosis IgG and IgM assays

P. Thulliez, C. Leprince, M. Marcoux, J. Piche

(Paris, Marcy l’Etoile, FR)

P882 Toxoplasma gondii antibodies in 72 patients

who attended emergency wards in three

hospitals in Stockholm due to infective cat


K. Westling, C. Jorup-Rönström, B. Evengård

(Stockholm, SE)


Staphylococci and surgical infections

P883 Survey of the epidemiology of methicillinresistant

Staphylococcus aureus infections

in Greece

V. Chini, A. Foka, O. Koureli, A. Athanassiadou,

G. Dimitracopoulos, I. Spiliopoulou (Patras, GR)

P884 Nasal carriage rates of Staphylococcus aureus

which are resistant and sensitive to oxacillin

in hospital staff and hospitalised patients

H. Irmak, S. Cesur, F. Yildiz, C. Bulut, S. Kinikli,

A.P. Demiröz, Z. Aygün (Ankara, TR)

page 91

Poster Sessions Sunday, April 2, 2006

P885 Nasal carriage of Staphylococcus aureus

among patients and personnel of a

haemodialysis unit

A. Sergounioti, F. Sergouniotis, A. Basdeki,

P. Sergouniotis, E. Papoulia, E. Petinaki

(Amfissa, Larissa, GR)

P886 MRSA carriage in children undergoing cardiac

surgery in Georgia

A. Nanuashvili, N. Jashiashvili (Tbilisi, GE)

P887 Coagulase-negative staphylococci in a

surgical hospital

A. Zilevica, R. Treimane, R. Paberza, T. Tracevska

(Riga, LV)

P888 Prevalence of methicillin-resistant Staphylococcus

aureus infection among inpatients

colonised with MRSA

C. McVeigh, S.F. FitzGerald, L.E. Fenelon

(Dublin, IE)

P889 The role of screening and antibiotic

prophylaxis in the prevention of percutaneous

gastrostomy site infection caused by

methicillin-resistant Staphylococcus aureus

S. Thomas, S. Cantrill, D.J. Waghorn,

A. McIntyre (High Wycombe, UK)

P890 Surgical site infection and delayed sternal

closure after open-heart surgery

A. Arnaiz, J.P. Horcajada, J.M. Bernal,

J.D. García-Palomo, A. Sarralde, M.C. Fariñas

(Santander, ES)

P891 The importance of risk indexes for stratifying

surgical site infection rates

S. Cairns, R. Hill, J. Reilly (Glasgow, UK)

P892 MRSA hand colonisation among health

care workers

Z. Kocak Tufan, H. Irmak, S. Cesur, C. Bulut,

S. Kinikli, A.P. Demiroz (Ankara, TR)

P893 Susceptibility of MRSA to octenidine


Z. Al-Doori, D. Morrison, P. Goroncy-Bermes,

G.F.S. Edwards, C.G. Gemmell

(Glasgow, UK; Norderstedt, DE)

P894 Study on bacterial contamination of surgical

rooms and delivery centres of Hamadan

hospitals and health care centres

R. Yousefi mashouf, S. Sahamas Vala

(Hamadan, IR)

P895 Reduction in the incidence of staphylococcal

infections in hospital environment after the

starting of the guideline of perioperative

antibiotic prophylaxis

G. Gattuso, D. Tomasoni, L. Palvarini, D. Berra,

C. Chiarelli, R. Stradoni, A. Scalzini (Mantua, IT)

page 92 Final Programme


Streptococci – skin and soft tissue infections

P896 Characterisation of a clone of methicillinresistant

Staphylococcus aureus responsible

for community-acquired staphylococcal toxic

shock syndromes

P.-Y. Donnio, C. Michelet, C. Collet, N. Lafforgue,

O. Petsaris, P. Tattevin, M. Cormier (Rennes, FR)

P897 Antibiotic resistance of Gram-positive

bacteria that cause severe skin and soft tissue

infections in a Turkish university hospital

S. Gündes, F. Özkan, S. Akhan (Kocaeli, TR)

P898 Contrasting features of Group A streptococci

from asymptomatic carriage and diverse

infection sites

D. Rolo, R. Pires, L. Sobreira, A. Morais, L. Lito,

M.J. Salgado, R.M. Barros, I. Peres, G. Trigueiro,

C. Cardoso, J.G. Marques, I. Santos-Sanches

Caparica, Oeiras, Lisbon, Miraflores, PT)

P899 Description of the epidemiology of multiple

clusters of Streptococcus pyogenes infection

in a rehabilitation hospital

J. Dave, J. Bell, C. Fraser, H. Venkatesh, E. Olson,

M. Emery, A. Efstratiou (Edinburgh, London, UK)

P900 The EPISA study: a recent epidemiological

study in outpatients with skin and soft tissue

infection in France

V. Jarlier, P. Bernard, P. Menday, A. Santerre

Henriksen (Paris, Reims, FR; Ballerup, DK)

P901 Serotypes and antimicrobial susceptibilities

of pneumococci isolated from children with

acute otitis media during 2003–2004

I. Paraskakis, H. Kirikou, A. Makri, M. Papadatou,

E. Bozavoutoglou, E. Petridou, A. Charisiadou,

A. Chrissaki, A. Vogiatzi, N.J. Legakis,

D.A. Kafetzis (Athens, GR)

P902 Serotype distribution and antimicrobial

resistance of Streptococcus pneumoniae

causing invasive disease in childhood

(2001-2004); microbiological observations

from Central Greece prior to the systemic

pneumococcal vaccination era

I. Paraskakis, A. Charisiadou, H. Kirikou, A. Makri,

M. Papadatou, E. Bozavoutoglou, A. Chrissaki,

H. Papavasileiou, D.A. Kafetzis, N.J. Legakis,

A. Pangalis (Athens, GR)

P903 Clinical characteristics and outcome of

22 patients with invasive infection due to

vancomycin-resistant E. faecium

C. Theilacker, H. Bertz, M. Bussmann,

J. Huebner, W.V. Kern for the VRE Task Force

Poster Sessions Sunday, April 2, 2006

P904 Molecular characterisation of group B

Streptococcus serotype III subtypes 1–4 in

Hong Kong

M. Ip, E. Cheuk, M. Tsui, F. Kong, D.T.N. Leung,

G.L. Gilbert (Hong Kong, HK; Westmead –

Sydney, AU)

P905 Role of isolation of Corynebacterium spp.

organisms in different clinical settings,

including intensive care

R. Manfredi, A. Nanetti, S. Morelli, R. Valentini,

L. Calza, F. Chiodo (Bologna, IT)

P906 Skin colonisation of Corynebacterium


M. Demirbilek, F. Can, A. Kundakci, A. Guven,

E. Sirma, P. Cay, H. Arslan (Ankara, TR)

P907 Serotype distribution of Streptococcus

pneumoniae-resistant strains isolated in

Western Pomeranian Region of Poland in


M. Nowosiad, S. Giedrys-Kalemba (Szczecin, PL)


ESBL and carbapemenase producing

Gram-negative organisms

P908 First report of a metallo beta-lactamase

produced by a Klebsiella pneumoniae clinical

isolate in the United Kingdom

F. M’Zali, T.A. Collyns, M. Taylor, M. Elliot,

H. Inns, S. Picton, N. Young (Leeds, UK)

P909 Pandrug-resistant Providencia rettgeri

producing PER-1 extended-spectrum betalactamase

and VIM-2 metallo-beta-lactamase

K.S. Shin, B.R. Son, J. Kim (Cheongju, Daegu, KR)

P910 An outbreak of VIM-4 producing multidrugresistant

Pseudomonas aeruginosa isolates

from three different towns in Hungary

B. Libisch, M. Muzslay, M. Knausz, M. Gacs,

L. Rókusz, J. Minárovits, I. Kustos, M. Füzi

(Budapest, Gyõr, Pécs, HU)

P911 Molecular epidemiology of VIM-producing

P. aeruginosa isolated in four European


C. Giske, B. Libisch, C. Colinon, E. Scoulica,

M. Füzi, G. Kronvall, G.M. Rossolini (Stockholm, SE;

Budapest, HU; Siena, IT; Heraklion, GR)

P912 Metallo-beta-lactamase-producing

Pseudomonas spp. and Acinetobacter spp.

in Korean hospitals: emergence of SIM-1producing

Acinetobacter baumannii

K. Lee, M.N. Kim, T.Y. Choi, K.S. Hong, S. Lee,

D.H. Whang, D. Yong, Y. Chong (Seoul, KR)

P913 Outbreak of multidrug-resistant Acinetobacter

baumannii producing the carbapenem

hydrolysing beta-lactamase OXA-58 in a

general intensive care unit in southern Italy

L. Pagani, R. Migliavacca, E. Nucleo,

M.M. D’Andrea, M. Spalla, C. Terulla, E. Aquilini,

M. Labonia, M. Li Bergoli, G.M. Rossolini

(Pavia, Siena, San Giovanni Rotondo, IT)

P914 Carbapenem-hydrolysing oxacillinase

OXA-40 in an Acinetobacter haemolyticus

clinical isolate

S. Quinteira, L. Peixe (Porto, PT)

P915 Influence of carbapemen resistance on

outcome in Acinetobacter baumannii

bacteraemia in an intensive care unit

R. Zaragoza, J.J. Camarena, A. Artero, S. Sancho,

R. Gonzalez, J.C. Navarro, J.M. Nogueira

(Valencia, ES)

P916 Risk factors for nosocomial imipenemresistant

Acinetobacter baumannii infections

G. Baran, A. Erbay, H. Bodur, P. Onguru, E. Akinci,

N. Balaban, M.A. Cevik (Ankara, TR)

P917 Dissemination of extended-spectrum betalactamase

producers in natural environments

in northern Portugal

J. Rocha, H. Neto Ferreira (Porto, PT)

P918 The presence of extended-spectrum betalactamase-producing

Escherichia coli is a

prognostic factor for patients with E. coli


G. Peralta, J. Pelayo, E. Lopez, L. Garcia-Mauriño,

M.P. Roiz, I. De Benito, J.C. Garrido, S. Sanchez-

Ortiz, P. Fombellida, M.J. Rodriguez-Lera,

L. Ansorena (Torrelavega, ES)

P919 Extended-spectrum beta-lactamase producing

Enterobacteriaceae in Lebanese ICU patients:

epidemiology and patterns of resistance

Z. Daoud, N. Hanna, R. Hajj, C. Moubareck,

F. Doucet-Populaire, N. Hakimé

(Beirut, LB; Paris, FR)

P920 Susceptibility pattern and prevalence trend

over four years of extended-spectrum

beta-lactamase producing Klebsiella spp.

from intensive care units:

MYSTIC Program Brazil

C. Kiffer, S. Andrade, P.J. Turner, C. Mendes

(Sao Paulo, BR; Cheshire, UK)

P921 Nosocomial outbreak due to an extendedspectrum

betalactamase producer Enterobacter


A. Manzur, A. Soriano, L. Calatayud, F. Tubau,

M. Saballs, M. Pujol, F. Gudiol, J. Ariza

(Hospitalet Llobregat, ES)

page 93

Poster Sessions Sunday, April 2, 2006

P922 Clinical and epidemiologic features of extendedspectrum

beta-lactamases strains for a twoyear

period in a third level hospital

M.V. García, R. Rodriguez, M.M. Gallardo,

F. Ropero, E. Granados, A. Hernandez, A. Pinedo

(Málaga, ES)

P923 Risk factors for cephalosporin-resistant

(ESBL and AMPc producing) Gram-negative

enteric bacilli infection in renal and kidneypancreas

transplant patients

L. Linares, C. Cervera, F. Marco, J.A. Martinez,

R. Perello, F. Cofán, M.J. Ricart, N. Esforzado,

F. Oppenheimer, A. Moreno (Barcelona, ES)

P924 Distribution of class 1 and class 2 integron

types among ESBL-producing Entero -

bacteriaceae recovered from Portuguese


E. Machado, R. Cantón, F. Baquero, J. Sousa,

T. Coque, L. Peixe (Porto, PT; Madrid, ES)


Metallo beta-lactamases and integrons

P925 Interactions of ceftobiprole with serine


A.M. Queenan, W. Shang, K. Bush (Raritan, US)

P926 Post-genomic detection of CAR-1, a new

subclass B3 metallo-beta-lactamase from the

important plant pathogen Erwinia carotovora

M. Stoczko, J.M. Frère, G.M. Rossolini,

J.D. Docquier (Siena, IT; Liège, BE)

P927 Co-existence of VIM-type metallo-betalactamase

and PER-1 type extended-spectrum

beta-lactamase in clinical isolates of

Pseudomonas aeruginosa

G. Metan, N. Gurkan Aydin, P. Zarakolu

(Kayseri, Ankara, TR)

P928 VIM-2 metallo-beta-lactamase in

Pseudomonas aeruginosa strains from

Zagreb, Croatia

B. Bedenic, A. Mazzariol, N. Jarza-Davila,

V. Plecko, G. Cornaglia, R. Fontana

(Zagreb, HR; Verona, IT)

P929 First detection of blaVIM-2 and blaVIM-4

metallo-beta-lactamase genes in

Pseudomonas putida isolates in Belgium

P. Bogaerts, H. Rodriguez, C. Bauraing,

A. Deplano, Y. Glupczynski, M.J. Struelens

(Yvoir, Brussels, BE)

page 94 Final Programme

P930 Genetic structure of a VIM-2-encoding

integron from a Pseudomonas aeruginosa

clinical isolate from Belgium

J.D. Docquier, M.M. D’Andrea, G. Christiaens,

R. Boreux, T. Giani, J.M. Frère, P. De Mol,

G.M. Rossolini (Siena, IT; Liège, BE)

P931 Spread of In58 containing blaVIM-2 among

Pseudomonas aeruginosa

A. Brizio, A. Silva, E. Canas, T. Ferreira, L. Lito,

J. Melo-Cristino, M.J. Salgado, A. Duarte

(Lisbon, PT)

P932 Metallo-beta-lactamase gene blaSPM-1:

evaluation of its vicinities in unrelated

Pseudomonas aeruginosa strains isolated

from distinct Brazilian hospitals

M. Castanheira, M.A. Toleman, T.R. Walsh,

H.S. Sader, A.C.C. Pignatari, A.C. Gales

(Sao Paulo, BR; Bristol, UK; North Liberty, US)

P933 Discrepancy in the metallo-beta-lactamase

phenotypic tests results associated with

diversity in the promoter region of class 1


M. Castanheira, R.C. Picao, R.E. Mendes,

A.C.C. Pignatari, H.S. Sader, A.C. Gales

(Sao Paulo, BR; North Liberty, US)

P934 Biochemical characterisation of IND-NF16


M. Perilli, B. Segatore, B. Caporale, C. Pellegrini,

G. Celenza, F. De Santis, M. Fiore, C. Luzi,

J.D. Docquier, G.M. Rossolini, G. Amicosante

(L’Aquila, Siena, IT)

P935 Phenotypic detection of metallo-betalactamases

in Acinetobacter baumannii

strains intermediately resistant to imipenem

and susceptible to meropenem

A. Koutsoukou, A. Stylianakis, S. Tsiplakou,

M. Tachtatzis, E. Tsakona, I. Feskou, A. Sideri

(Athens, GR)

P936 Metallo-beta-lactamase production in

Gram-negative bacteria detected by double

disk synergy and combined disk tests in


I. Yildirim, D. Gur, S. Uygun, G. Secmeer

(Ankara, TR)

P937 Real-time PCR detection of free circular

intermediates of gene cassettes inserted in

resistance integrons

S. Pollini, E. Del Tordello, M.R. Oggioni,

G.M. Rossolini (Siena, IT)

Poster Sessions Sunday, April 2, 2006

P938 ISAba1 transposition induced by ciprofloxacin

produces hyperexpression of the AmpC

cephalosporinase of Acinetobacter baumannii

M. Ruiz, S. Martí, F. Fernández Cuenca,

Á. Pascual, J. Vila (Barcelona, Seville, ES)

P939 Prevalence of class 1 integrons and MIC

values in indigenous and pathogenic

E. coli strains in different age groups

K. Truusalu, E. Sepp, J. Shchepetova, K. Loivuke,

P. Naaber, K. Stroo, K. Sepp, M. Mikelsaar

(Tartu, EE)

P940 New integron-independent trimethoprim

resistance gene dfr24, detected in urinary

isolate of Escherichia coli

M. Grape, L. Sundström, G. Kronvall

(Stockholm, Uppsala, SE)

page 95

Poster Sessions Monday, April 3, 2006


Molecular detection of microbes

P941 Direct detection of Salmonella spp. in faecal

specimens by real-time PCR assay

I. Pachiadakis, V. Karavassilis, A. Vasdeki,

A. Melidou, A. Goudouva, P. Lisgara, E. Petinaki,

A. Maniatis (Larissa, GR)

P942 Multicentric evaluation of Onychodiag® for

diagnosis of dermatophyte onychomycosis by


C. Savin, S. Huck, C. Rolland, M. Benderdouche,

O. Faure, G. Noacco, J. Menotti, E. Candolfi,

H. Pelloux, R. Grillot, F. Derouin, S. Coupé

(Emerainville, Strasbourg, Grenoble, Paris, FR)

P943 Validation of PCR-RFLP analysis of the gap

gene as a useful tool for the species-level

identification of staphylococcal isolates

S. Grzeszczuk, A. Sabat, M. Bartoszewicz,

A. Przondo-Mordarska, W. Hryniewicz

(Warsaw, Wroclaw, PL)

P944 Clonal complexity in coagulase negative

Staphylococcus catheter-related bloodstream


C. Aldea-Mansilla, D. García de Viedma,

E. Cercenado, E. Bouza, M. Marín (Madrid, ES)

P945 Effect of treatment on Toxoplasma-specific

IgG antibodies and IgG avidity maturation

V. Meroni, F. Genco, G. Ferraris, L. Bollani,

L. Piccoli, C. Bodini, P. Lanzarini (Pavia, Milan, IT)

P946 Evaluation of rapid molecular methods in

diagnosis of B-streptococci under delivery

B. König, B. Ghebremedhin, W. König

(Magdeburg, DE)

P947 Diagnosis of human brucellosis using


W. Yu, K. Nielsen, T. Grushina,

T. Meka-Mechenko (Nepean, CA; Almaty, KZ)

P948 Evaluation and comparison of molecular tests

for identification of methicillin-resistant

Staphylococcus aureus

A-M. Kerttula, A. Vainio, S. Mero, T. Pasanen,

J. Vuopio-Varkila, A. Virolainen (Helsinki, FI)

P949 Comparison of fluorescent in situ hybridization

and histological method for diagnosis of

Helicobacter pylori in gastric biopsy samples

S. Tajbakhsh, A.R. Samarbaf-Zadeh,

S.M. Moosavian (Bushehr, Ahwaz, IR)

page 96 Final Programme

P950 Comparison of a real-time PCR assay and a

chromogenic MRSA selective medium for the

detection of methicillin-resistant Staphylococcus

aureus directly from nasal and rectal swabs

R. Reyes, B. Catanzariti, E. Isaac, M. John,

L. Stoakes, J. Vandierendonck, Z. Hussain

(London/Ontario, CA)

P951 Evaluation of SeptiFast – a new commercially

available broad-range real-time PCR assay for

detection of bacteria and fungi in blood

G. Lisby, H. Westh (Hvidovre, DK)

P952 Multiple aetiology of urethritis and cervicitis

in sexually transmitted disease clinics

caused by Chlamydia trachomatis, Neisseria

gonorrhoeae, Mycoplasma genitalium,

and Trichomonas vaginalis

C.A. Gaydos, N.E. Maldeis, A. Hardick, J. Hardick,

M. Barnes, B.J. Wood (Baltimore, US)

P953 Advances in diagnostic testing of Chlamydia


M. Eickhoff, S. Cramer, T. Grewing

(Hamburg, DE)

P954 LCR method for detection of Chlamydia

trachomatis in patients with chronic

nonbacterial prostatitis

N. Draskovic (Belgrade, CS)

P955 Improvement of an existing magnetic particle

based NAAT sample preparation system for

C. trachomatis in urine by significantly

reducing processing time while maintaining


M. Anglés d’Auriac, T. Engen, U.H. Refseth

(Oslo, NO)

P956 A comparative study of three different

PCR assays for detection of Mycoplasma

genitalium in genital specimens from men

and women

A. Edberg, E. Johansson, E. Wikander, A. Höög,

T. Ahlqvist, M. Jurstrand, L. Falk, J.S. Jensen,

H. Fredlund (Karlstad, Örebro, SE; Copenhagen, DK)

P957 A new real-time quantitative TaqMan PCR to

detect Chlamydia trachomatis DNA in urine

and in urogenital swabs

K. Jaton, J. Bille, C. André, G. Greub (Lausanne, CH)

P958 First void urine can be used as transport

medium for cervical swab specimen for

detection of Mycoplasma genitalium by

polymerase chain reaction

T. Ahlqvist, A. Edberg, E. Johansson, H. Fredlund,

F. Aronsson (Karlstad, Örebro, SE)

Poster Sessions Monday, April 3, 2006

P959 Automation for generic nucleic acid sample

prep in a routine diagnostic laboratory

T.E. Schutzbank, N. Kahmann, C. Jarvis,

M. Weimer, A. Yount, K. Lopez (Dayton, US)

P960 Multiplex real-time PCR for detection of

Candida infections in blood

Å. Innings, M. Ullberg, A. Johansson, C.J. Rubin,

N. Noréus, M. Isaksson, B. Herrmann (Uppsala, SE)

P961 The application of MALDI-TOF mass

spectrometry for the quality control of NCTC


L. Molenaar, D. Dare, H. Sutton, J. Russell,

H. Shah, M. Roberts, M. Lunt

(London, Manchester, UK)

P962 LightCycler® SeptiFast Test: rapid detection

of nosocomial pathogens by real-time PCR

T. Emrich, M. Moczko, S. Lohmann, J. Mayr,

H. Stockinger, G. Haberhausen (Penzberg, DE)

P963 Comparison of real-time and conventional

PCR assays for diagnosis of cat scratch

disease in patients with lymph node


C. Le Brun, S.J. De Martino, Y. Hansmann, J. Debs,

C. Walter, Y. Piemont, B. Jaulhac (Strasbourg, FR)


Fast detection of respiratory microbes

P964 Advances in PCR detection of Pneumocystis

jiroveci in immunocompromised patients:

count seems to be important

J. Lochmanova, Z. Racil, M. Lengerova,

D. Minarikova, P. Volfova, D. Dvorakova, J. Mayer

(Brno, CZ)

P965 Evaluation of a new assay for the detection

and differentiation of B. pertussis,

B. parapertussis and B. bronchiseptica

based on real-time PCR technology

A. Burmeister, T. Grewing, H. Petersen,

N. Kahmann, T.E. Schutzbank, M. Hess

(Hamburg, DE; Moraine, US)

P966 Molecular diagnosis of Mycoplasma

pneumoniae and Chlamydia pneumoniae

infections by real-time NASBA

P. van Aarle, P. van Deursen, K. Loens,

P. Sillekens, M. Overdijk, M. Ieven, H. Goossens

(Boxtel, NL; Edegem, BE)

P967 Development of a real-time PCR using SYBR

Green and melting curve analysis to identify

Bordetella pertussis and Bordetella

parapertussis in clinical specimens,

and evaluation of its effectiveness in current


P. Lehours, A. Menard, J. Sarlangue, C. Laguente,

C.H. Bebear, F. Megraud, B. De Barbeyrac

(Bordeaux, FR)

P968 Diagnosis of pertussis by real-time

LightCycler PCR

M. Alves, G. Rocha, A. Magalhães-Sant’Ana,

C. Nogueira (Coimbra, PT)

P969 Bordetella pertussis real-time PCR: sample

preparation by different kits from one


M. Riffelmann, C. Wirsing von Koenig, J. Schmetz,

S. Bock (Krefeld, DE)

P970 Comparison of specificity and sensitivity of

various diagnostic methods of ureaplasma

respiratory tract infections in newborns

M. Biernat-Sudolska, D. Rojek-Zakrzewska,

B. Zawilinska (Cracow, PL)

P971 Evaluation of real-time nucleic acid

sequence-based amplification and dipstickbased

detection with conventional NASBA

and PCR for rapid detection of Mycoplasma

pneumoniae in respiratory specimens

K. Ohkusu, M. Komatsu, N. Ishiwada, T. Hoshino,

N. Takeda, H. Sakata, T. Takeshima, T. Ezaki

(Gifu, Nara, Chiba, Hokkaido, Shizuoka, JP)

P972 Identification of Legionella species using DNA

sequence analysis and online tools

N.K. Fry, B. Afshar, W. Bellamy, A. Underwood,

R.M. Ratcliff, T.G. Harrison

(London, UK; Adelaide, AU)

P973 A real-time PCR for Mycoplasma pneumoniae

V.J. Chalker, D. Pitcher, T.G. Harrison (London, UK)

P974 Detection of Legionella DNA in clinical

samples using real-time PCR

L. Franzin, D. Cabodi, N. Bonfrate, F. Tortorelli

(Turin, IT)

P975 Rapid diagnosis of Mycobacterium

tuberculosis by a triplex real-time PCR assay

W. Sougakoff, C. Truffot-Pernot, G. Millot,

V. Jarlier (Paris, FR)

page 97

Poster Sessions Monday, April 3, 2006


Diagnostic and laboratory methods

for bacteria – I

P976 The antimicrobial susceptibility and API

CORYNE profile code for 34 strains of the

newly reported Corynebacterium resistens

Y. Otsuka, Y. Kawamura, Y. Yamaguti,

H. Takahashi, K. Ohkusu, H. Hanaki, T. Ezaki

(Tokyo, Gifu, JP)

P977 Rapid phenotypic detection of pneumococci

and beta-haemolytic streptococci directly

from blood cultures

J. Montgomery, B. Mayall (Melbourne, AU)

P978 Perioperative monitoring of the endotoxin

chemical markers and procalcitonin blood

plasma concentrations in cardiosurgical


N.V. Beloborodova, D.A. Popov, A.Y. Olenin,

A.S. Archipova, E.A. Chernevskaya (Moscow, RU)

P979 Are blood cultures necessary in the

management of women with complicated


Y. Chen, O. Nitzan, W. Saliba, B. Chazan,

R. Colodner, R. Raz (Afula, Haifa, IL)

P980 Procalcitonin marker for sepsis diagnosis

A. Emami Naeini, S. Montazerolghaem

(Isfahan, IR)

P981 Brain natriuretic peptide as diagnostic and

prognostic marker in patients with bacterial

infection and sepsis

A. Charalampopoulos, A. Stavrianou,

C. Kotsovassilis, P. Tsiodra, C. Keramidas

(Athens, GR)

P982 The value of the automatized blood culture

systems in the diagnosis of CAPD peritonitis

Ö.K. Azap, F. Timurkaynak, S. Sezer, Ü. Cagir,

G. Yapar, H. Arslan, N. Özdemir (Ankara, TR)

P983 No beneficial impact of shortened micro -

biological procedures for either hospitalised

patients overall or for patients with


M.J. Bruins, H.C.A. Oord, P. Bloembergen,

M.J.H.M. Wolfhagen, A.F. Casparie, J.E. Degener,

G.J.H.M. Ruijs (Zwolle, Rotterdam, Groningen, NL)

P984 Routine use of the BacT/ALERT FAN

anaerobic bottle: indicated or not?

B. Van Meensel, J. Verhaegen, J. Frans,

H. Castryck, N. Blanckaert (Leuven, BE)

page 98 Final Programme

P985 Developing clinical rules and a urinary

dipstick rule to predict urinary tract infection

in primary care settings

P. Little, S. Turner, K. Rumsby, G. Warner,

M. Moore, H. Smith, C. Hawkes, M. Mullee

(Southampton, Hastings, UK)

P986 Quantitative sputum culture versus direct

sputum culture

O. Akan, E. Ozyilmaz, K. Ahmed, S. Uysal,

M. Gulhan (Ankara, TR)

P987 Quantitative urine microscopy as a quick,

reliable examination for bacteriuria

S. Mhalla, A. Ferjani, N. Hannechi, J. Boukadida

(Sousse, TN)

P988 Detection of extended-spectrum betalactamases

among Enterobacteriaceae

using automated microbiology systems

and manual detection procedures

H. Seifert, H.K. Geiss, D. Mack, E. Stürenburg,

I. Wiegand (Cologne, Heidelberg, DE; Swansea, UK;

Hamburg, Bonn, DE)

P989 Assessment of the delay in reporting blood

culture results – development of a method to

identify defects in quality

U. Saarela, P. Kärpänoja, H. Sarkkinen (Lahti, FI)

P990 Validation of commercial kits for detection of

antibodies to Legionella

P. Elverdal, S.A. Uldum (Copenhagen, DK)

P991 Intrathecal synthesis of anti-Borrelia

antibodies in multiple sclerosis

J. Bednarova, P. Stourac (Brno, CZ)

P992 Antimicrobial susceptibility as a complementary

diagnostic tool for the identification of

rarely encountered non-fermenting Gramnegative


Y. Glupczynski, G. Detry, C. Berhin, M. Janssens,

G. Wauters (Yvoir, Brussels, BE)

P993 An improved protocol for the serological

diagnosis of atypical pneumonia

C. Jenkins, I. Balakrishnan (London, UK)

P994 Potential antigenic determinants of

Chlamydia trachomatis major outer

membrane protein modeled by overlapped

recombinant proteins

N. Savel’eva, J. Zagriadskaya, S. Klimashevskaya,

V. Puzyrev, A. Obriadina, A. Burkov, T. Ulanova

(Nizhnyi Novgorod, RU)

Poster Sessions Monday, April 3, 2006

P995 Evaluation of the Giardia-strip: an in vitro

immunochromatographic test for the

detection of Giardia lamblia cysts in faecal


D. Van Kerkhoven, M. Lontie, J. Verhaegen,

K. Lagrou (Leuven, BE)

P996 Use of the T tube test in the setting of a

paediatric tuberculosis clinic

J. Paton, C. Lucas, C. Williams (Glasgow, UK)

P997 Do hyaluran levels determine the outcome of

bacterial infections?

H. Lydatakis, I. Hager, I. Binikos, P. Afentra,

H. Chrisanthidou, T. Peppas, S. Pappas,

I. Diamantis (Piraeus, Athens, GR)

P998 Evaluation of the new chromogenic medium :

CHROMagar Salmonella Plus for the detection

of all Salmonella species including Salmonella

typhi and Salmonella lactose plus

A. Rambach, Q. Tran, A.C. Le Dantec (Paris, FR)


Bloodstream infections

P999 Characteristics of healthcare-associated

bloodstream infections in adults in Korea

Y.K. Kim, S.Y. Shin, M.S. Kim, Y.S. Park, Y-A. Kim,

H.J. Yoon, J.Y. Choi, Y.G. Song, K.H. Roh,

D. Yong, K. Lee, J.M. Kim (Seoul, KR)

P1000 Secular trends of antimicrobial resistance of

blood isolates in a newly founded Greek


P. Rafailidis, S. Kasiakou, P. Morfou,

G. Georgoulias, D. Nikita, M. Falagas (Athens, GR)

P1001 Hospital-acquired bacteraemia: occurrence of

pathogens throughout a decade

H. Moraitou, M. Makarona, A. Koundourakis,

I. Kousseris, N. Makrygiannis, V. Tzolos,

M. Panagi, S. Kanavaki (Athens, GR)

P1002 Positive central venous catheter cultures and

bloodstream infections

C. Papadopoulou, Z. Afkou, G. Kythreotou,

D. Tokatlidou, M. Tsivitanidou, D. Sofianou

(Thessaloniki, GR)

P1003 Laboratory-based epidemiology of nosocomial

candidaemia in a tertiary teaching hospital

L.G.O. Cardoso, P. Trabasso (Campinas, BR)

P1004 Nosocomial bloodstream infection following

cardiac surgery in children

N. Jashiashvili, A. Nanuashvili, M. Chkhaidze

(Tbilisi, GE)

P1005 Nosocomial bloodstream infections in the

cardiovascular surgery centre, Iasi, Romania

A. Mereuta, M. Dan, L. Colar, G. Tinica,

G.I.M. Georgescu, D. Buiuc (Iasi, RO)

P1006 Rifampin and minocycline impregnated

central venous catheters: a meta-analysis

of randomised controlled trials assessing

catheter colonisation and catheter-related

bloodstream infection

M. Falagas, K. Fragoulis, I. Bliziotis,

I. Chatzinikolaou (Athens, GR)

P1007 Infections related with tunelled haemodialysis


T. Aldabó, R. Luque, M.J. Marcos, Y. Blanco,

J. Ibeas, E. Bouza for the Red Española de

Investigación en Patología Infecciosa (REIPI)

P1008 Bacillus spp. bacteraemia in children on

parenteral nutrition

E. Lebessi, G. Antonaki, A. Zafiropoulou,

K. Malliou, N. Paleologou, M. Foustoukou

(Athens, GR)

P1009 Survey of virulence factors of clinical isolates

from neutropenic patients with enterococcal


S.H. Park, S-M. Choi, D-G. Lee, J-H. Choi, J-H. Yoo,

W-S. Shin (Seoul, KR)

P1010 Accuracy of surveillance blood culture to

identify patients with low response to

treatment and high 30-days mortality risk

in MRSA bacteraemia: comparison to a

standard clinical and biological follow-up

E. Forestier, Y. Hansmann, V. Remy, M. Mosheni,

N. Lefebvre, O. Lesens, D. Christmann

(Strasbourg, Clermont-Ferrand, FR)

P1011 Methicillin resistance as a risk factor for

mortality in Staphylococcus aureus

bacteraemia: an analysis from EARSS

Enhanced Bacteraemia Surveillance in

Ireland, 2005

A. Oza, S. Murchan, R. Cunney on behalf of the

Irish EARSS Steering Group

P1012 Mortality from sepsis in Russia:

identifying a gap in epidemiological data

D. Galkin, I. Gudkov, S. Zouzov, R. Kozlov

(Smolensk, RU)

P1013 Cloxacillin sensitivity evolution in

Staphylococcus aureus bacteraemias from

2001 to 2005 and their resistant phenotypes

M.M. Gallardo, M.V. García, R. Rodriguez,

E. Granados, F. Ropero, A. Hernandez, A. Pinedo

(Málaga, ES)

page 99


ICU infections

Poster Sessions Monday, April 3, 2006

P1014 Surveillance of hospital-acquired infections in

intensive care units

J.L. Barrios, C. Ezpeleta, R. Blanco, M.J. Unzaga,

J.A. Alava, R. Cisterna (Bilbao, ES)

P1015 Infections in intensive care unit admitted

multiple trauma patients: incidence, risk

factors and mortality rate

Y-H. Choi, S-H. Baik, Y-J. Lee, K-S. Lee, Y-J. Oh,

J-H. Park, S-S. Shin, K-J. Park, S-C. Hwang

(Suwon, KR)

P1016 Nosocomial infections in a neonatal intensive

care unit: evaluation of frequency, risk factors

and cost

I. Özgünes, H. Naz, N. Tekin, F. Aksit, E.D. Kartal,

N. Erben, S.N. Alpat, G. Usluer (Eskisehir, TR)

P1017 Colonisation surveillance can predict

microbial aetiology of infection in the

critically ill

F. Kontopidou, E. Papadomichelakis,

A. Antoniadou, E. Koratzanis, E. Galani,

A. Armaganidis, H. Giamarellou (Athens, GR)

P1018 Administration of antibiotics via the

respiratory tract for the prevention of

ICU-acquired pneumonia: a meta-analysis

of comparative trials

M. Falagas, I. Siempos, I. Bliziotis, K. Rellos,

A. Michalopoulos (Athens, GR)

P1019 Serial evaluation of CPIS and C-reactive

protein for diagnosing ventilator-associated


M. Koeman, M.J.M. Bonten (Utrecht, NL)

P1020 Aetiology and timing of bloodstream

infections in a liver intensive care unit

F. Pink, E. Sizer, W. Bernal, G. Auzinger,

J. Wendon, I. Eltringham (London, UK)

P1021 Epidemiology of bloodstream infections

in an Israeli general intensive care unit:

a six-year analysis

T. Mashiach, H. Sprecher, R. Finkelstein (Haifa, IL)

P1022 Pseudomonas aeruginosa infection in ICU

patients: highlighting the silent epidemic

A. Agodi, M. Barchitta, L. Giaquinta, M.A. Romeo,

C. Denaro (Catania, IT)

P1023 Meta-analyses of the impact of inappropriate

antibiotic therapy on mortality in patients

with ventilator-associated pneumonia and

bloodstream infections

E. Gillespie, A. Patel, C. Coleman (Hartford, US)

page 100 Final Programme

P1024 Antibiotic resistance and mortality in patients

with severe pneumonia

R. Erbes, M. Raffenberg, H. Mauch, S. Wagner,

M. Schmidt-Ioanas, H. Lode (Berlin, DE)

P1025 Antimicrobial resistance patterns of Gramnegative

bacteria isolated from intensive care

unit in a Greek hospital

P. Sikalidou, S. Karampa, C. Papadopoulou,

G. Kythreotou, D. Sofianou (Thessaloniki, GR)

P1026 Incidence of methicillin-resistant S. aureus in

a prospective study in critical patients


P. Palacián, A. Rezusta, Y. Martin, J. Castillo,

M. Revillo (Zaragoza, ES)

P1027 Screening for MRSA on nasal swabs at

admittance at intensive care units

C. Pina-Vaz, R. Carneiro, M. Espinar,

M. Machado-Vaz, A. Rodrigues (Porto, PT)

P1028 Genotypic characterisation and epidemiologic

analysis of vancomycin-resistant enterococci

isolated from patients in intensive care unit

A. Lambiase, M. Del Pezzo, F. Rossano

(Naples, IT)


Gastro-intestinal and hepatic infections

P1029 Norovirus as a cause of acute gastroenteritis

in northern Greece: detection with IDEIA and


S. Mitka, A. Ifantidou, S. Sotiriadis,

D. Karabaxoglou, A. Kansouzidou

(Thessaloniki, GR)

P1030 Epidemiology and molecular analysis of

norovirus outbreaks in Ireland

S. Kelly, B. Foley, S. Coughlan, L. Dunford,

H. O’Neill, B. Smyth, P. McKeown, M. Lynch

(Dublin, Belfast, IE)

P1031 Emergence of Vibrio cholerae O1 biotype

EL Tor, serotype Inaba during last summer

outbreak in Iran

M. Rahbar, R. Sabourian, M. Saremi, M. Abbasi,

H. Masoumi Asl, M. Soroush (Tehran, IR)

P1032 National surveillance of Campylobacter

infections and resistance in the Netherlands;

an overview 2000–2004

B.C. van Hees, M.J. Veldman-Ariesen,

B.M. de Jongh, M. Tersmette, W. van Pelt

(Nieuwegein, Bilthoven, NL)

Poster Sessions Monday, April 3, 2006

P1033 The epidemiology and clinical presentation of

hydatid cyst disease in patients in Imam,

Sina, Shariati and paediatric medical centre

hospitals between 1372–1382

Z. Abdi Liae, A. Soudbakhsh, M. Solemani,

K. Kiyani (Tehran, IR)

P1034 Echinococcus granulosus: lethal effect of low

voltage direct electric current on hydatid cyst


R. Ghasemikhah, H. Ghasemikhah,

M. Sharbatkhory (Tehran, IR)

P1035 Single and multiple pyogenic liver abscesses:

aetiology, clinical course and treatment

F. Mateos, I. Terrancle, G. Peralta, L. Fuentes,

J. Pérez-Arellano, F. Amoros, R. Serrano, M.P. Geijo,

I. Tárraga, M. Rguez-Martín, B. Rguez-Martín,

J. Blanch, E. Martínez-Alfaro for the Infectious

Diseases Group of the Spanish Society for

Internal Medicine (SEMI)

P1036 Comparison of pyogenic liver abscess caused

by non-Escherichia coli and E. coli

F. Mateos, I. Terrancle, G. Peralta, L. Fuentes,

R. Serrano, V. Navarro, M. Hernández, B. Roca,

F. Marcos, I. Tárraga, A. Hernández-Belmonte,

E. Martínez-Alfaro for the Infectious Diseases

Group of the Spanish Society for Internal

Medicine (SEMI)

P1037 Diabetes mellitus as a risk and prognostic

factor for pyogenic liver abscess in Denmark

R.W. Thomsen, P. Jepsen, H.T. Sørensen

(Aalborg, Aarhus, DK)

P1038 Bacteraemia is a poor prognostic factor in

spontaneous bacterial peritonitis

J.H. Cho, W.B. Park, H.B. Kim, N.J. Kim,

M-D. Oh, K.W. Choe (Seoul, KR)


Respiratory tract infections

P1039 Aetiology of lower respiratory tract infections

among primary care patients of family

physicians in Silesian province in the

2000–2005 period

I. Szymczyk, W. Lukas, J. Skorupka, J. Józwiak

(Zabrze, PL)

P1040 Chronic exposure to smoking is not a risk

factor for community-acquired pneumonia in

the elderly population

Y.K. Cho, B.J. Park, H. Kim, N-K. Choi, S-M. Lee

(Incheon, Seoul, KR)

P1041 Antibiotic resistance patterns among

respiratory pathogens isolated during

2003–2005 at a Turkish tertiary hospital

Z. Gülay, H. Özkul (Izmir, TR)

P1042 Differences between Bedouin and Jewish

population in clinical characteristics of

patients admitted with community-acquired


V. Novack, L. Avnon, K. Riesenberg, F. Schlaeffer

(Beer Sheva, IL)

P1043 Prognostic impact of haematological and nonhaematological

malignancies on mortality of

hospitalised pneumonia: a Danish populationbased

cohort study

M. Nørgaard, A. Riis, R.W. Thomsen,

H.C. Schønheyder, H.T. Sørensen

(Aalborg, Aarhus, DK)

P1044 Outbreak of three related cases of psittacosis

detected by real-time PCR

B.M. de Jongh, J.A. Kaan, A.J. Meinders,

J.J. Mager, E.J. van Hannen (Nieuwegein, NL)

P1045 Audit of sputum samples before and after a

national smoking ban

J. Fennell, B. Cryan, G. Corcoran (Cork, IE)

P1046 Prognostic factors in patients with pneumococcal

bacteraemia in a county teaching

hospital, Spain

G. Peralta, E. Lopez, J. Pelayo, M.P. Roiz,

I. De Benito, C. Fariñas, M.B. Sanchez,

J.C. Garrido (Torrelavega, ES)

P1047 Ambulatory treatment with telithromycin

versus clarithromycin of community-acquired

pneumonia in Spain

B. Puchades (Valencia, ES)

P1048 Comparative assessment of levofloxacin and

macrolides in acute exacerbation of chronic

bronchitis: clinical efficacy and symptom-free


L. Dvoretsky, N. Dubrovskaya, S. Yakovlev,

S.A. Grudinina, O.Y. Filimonova, S. Sidorenko

(Moscow, RU)

P1049 Lower respiratory tract infections caused by

Haemophilus influenzae

D. Kofteridis, D. Alegakis, G. Chrysofakis,

T. Anastasopoulos, A. Repa, S. Maraki , G. Samonis

(Heraklion Crete, GR)

page 101

Poster Sessions Monday, April 3, 2006

P1050 Outcomes and diagnostic workups for patients

with community-acquired pneumonia

according to Pneumonia Severity Index

categories: results of a large single-year series

E. Pérez-Trallero, A.M. Martín-Sánchez, R. Dal-Ré,

J.E. Martín-Herrero, J. Garau, F. Baquero

on behalf of the NACER Group

P1051 Factors influencing length of hospital stay

in a large, single-year series of communityacquired


E. Pérez-Trallero, F. Baquero, C. García-Rey,

J.E. Martín-Herrero, A.M. Martín-Sánchez,

J. Garau on behalf of the NACER Group

P1052 Physicians’ attitude towards guidelines and

on choice of regimen for respiratory


T.A. Peppas, O. Kosmopoulou, I. Binikos,

I. Skoura, I.F. Hager, S.I. Pappas, N. Galanakis

(Piraeus, GR)

P1053 Influence of aetiologic diagnosis on mortality

in hospitalised patients with communityacquired

pneumonia: results of a large singleyear


J. Garau, F. Baquero, E. Pérez-Trallero, J.L. Pérez,

A.M. Martín-Sánchez, C. García-Rey

on behalf of the NACER Group

P1054 Echo-guided management of complicated

parapneumonic effusion in children

C.Y. Chiu, K.S. Wong, Y.C. Huang, T-Y. Lin

(Taoyuan, TW)

P1055 Real-life treatment of acute exacerbation of

chronic bronchitis – moxifloxacin compared

to macrolides

T. Schaberg, M. Möller, T. File, K. Stauch,

H. Landen (Rotenburg, Hanau, DE; Akron, US;

Leverkusen, DE)

P1056 Bulgarian Surveillance Tracking Antimicrobial

Resistance – BulSTAR: community-acquired

pneumonia: 2004

T. Velinov, M. Petrov, A. Bachvarova,

T. Kantardjiev (Sofia, BG)

P1057 Clinical manifestations of complicated

pneumococcal pneumonia

M.H. Tsai, T-Y. Lin, Y.C. Huang, C.H. Chiu

(Keelung, Taoyuan, TW)

P1058 Elderly patients hospitalised with communityacquired

pneumonia. Validation and

comparative evaluation of a prognostic rule

F. Alcazar, A. Plata, A. Villalobos, I. Perez de

Pedro, S. Santamaria, B. Sobrino, L. Valiente,

M.A. Garcia-Ordoñez (Malaga, ES)

page 102 Final Programme

P1059 Heart failure and mortality within 90 days

after hospitalised pneumonia:

a population-based cohort study

R.W. Thomsen, N. Kasatpibal, A. Riis,

M. Nørgaard, H.T. Sørensen

(Aalborg, Aarhus, DK; Chiang Mai, TH)

P1060 Rising incidence and persistently high

mortality of hospitalised pneumonia:

a 10-year population-based study in Denmark

R.W. Thomsen, A. Riis, M. Nørgaard, J. Jacobsen,

S. Christensen, C.J. McDonald, H.T. Sørensen

(Aalborg, Aarhus, DK; Indianapolis, US)

P1061 Once daily sequential intravenous/oral

(IV/PO) moxifloxacin is equivalent to IV

ceftriaxone plus twice daily IV/PO

levofloxacin in the treatment of severe

community-acquired pneumonia requiring

hospitalisation: the MOTIV study

A. Torres, R. Read, H. Lode, J. Carlet, J.H. Winter,

J. Garau, T. Welte, P. Arvis, M.-A. Le Berre,

S.H. Choudhri (Barcelona, ES; Sheffield, UK;

Berlin, DE; Paris, FR; Dundee, UK; Hannover, DE;

Puteaux, FR; West Haven, US)

P1062 Antibiotic therapy of acute lower respiratory

tract infections within Slovakia

K. Banasova, H. Hupkova, V. Foltan

(Bratislava, SK)


Sexually transmitted diseases

P1063 Sexually transmitted infections in Kosovo

L. Gashi, N. Ramadani, I. Dedushaj, A. Kalaveshi,

I. Humolli (Pristina, CS)

P1064 Determinants of human papilloma virus

infections in HIV-infected women

S. Ribeiro-Ayeh, D. Labeith, U. Frank

(Mannheim, Freiburg i.Br., DE)

P1065 Infection with HSV in HIV/AIDS patients

L. Manolescu, P. Marinescu, C. Sultana,

S. Ruta (Bucharest, Giurgiu, RO)

P1066 Prevalence of HIV, hepatitis B and C and

syphilis and risk behaviour among drug users

inside and outside prison

C.J.P.A. Hoebe, H.L.G. Ter Waarbeek,

C.W. Rademaker, A. Smismans

(Heerlen, Maastricht, NL)

P1067 Antimicrobial resistance in Neisseria

gonorrhoeae in northeast Romania

A. Badescu, A. Enache, Z. Petrescu, D. Buiuc

(Iasi, RO)

Poster Sessions Monday, April 3, 2006

P1068 Use of polymorphic Treponema pallidum

repeat genes to elucidate syphilis

transmisssion networks in Amsterdam,


S.M. Bruisten, M. Dierdorp, M-E. Kolader,

J.S.A. Fennema, R.A. Coutinho (Amsterdam, NL)


Travel medicine, tropical and parasitic


P1069 Animal-associated injuries and related

diseases among travellers

P. Gautret, P. Gazin, G. Soula, J. Delmont,

P. Brouqui, P. Parola, P. Pandey, D. Kraklau,

M. Shaw, G. Brown, J. Torresi, E. Schwartz

for the GeoSentinel Surveillance Network

P1070 The use of saliva to soothe blood-sucking

arthropod bites and the transmission of

human herpesvirus 8 (HHV-8)

R. Romano, F. Candura, G. Russo, A. Al Hamdani,

L. Ceccherini Nelli, F. Benvegnu’, V. Ascoli,

M. Coluzzi (Rome, Pisa, Padua, IT)

P1071 Prolonged viraemia and viral shedding of

hepatitis E virus in a traveller with fulminant


M. Riffelmann, I. Greiffendorf, M. Roggendorf,

W. Jilg (Krefeld, Essen, Regensburg, DE)

P1072 Dengue fever associated with severe reactive

thrombocytosis and gangrene of the toes:

a case report

S.K. Surrun, D.A. Kandiah (Singapore, SG)

P1073 Localisation of Rift Valley fever virus in

different organs and blood of infected mice

using developed PCR test

A. Belov, N. Potapova (Moscow, RU)

P1074 Presentation of a case with pityriasis rosea

and Brucella infection

F. Kaptan, S. Ural, S. El, N. Turker, N.A. Coskun,

B. Ormen, G. Yilmaz, M. Ermete (Izmir, TR)

P1075 Imported chronic Chagas disease in Valencia,

Spain: epidemiological and clinical features

P. Segarra, M. García-Rodríguez, V. Abril,

C. Parada, E. Ortega, T. Fraile, J. Ballester,

M. García-Deltoro (Valencia, ES)

P1076 Anti-Acanthamoeba activity of caspofungin

S. Bouyer, C. Imbert, C. Kauffmann-Lacroix,

G. Daniault, M-H. Rodier (Poitiers, FR)

P1077 Cyclospora cayetenensis infection in five

immunocompetent patients in a Turkish

university hospital

B. Sancak, Y. Akyon, S. Erguven (Ankara, TR)

P1078 Malaria: current status in Latvia

J. Keiss, I. Zeltina, A. Jeruma, V. Sondore,

N. Ivanova, L. Viksna, B. Rozentale (Riga, LV)

P1079 Correlation of serum bilirubin level with

mortality in P. falciparum malaria

A.K. Aribandi, M.S. Albur (Sheffield, UK)

P1080 Leishmaniasis in travellers in endemic areas

S. Halichidis, S. Rugina, E. Dumea

(Constanta, RO)

P1081 Unusual clinical presentation of visceral

leishmaniasis in an immunocompetent


T. Kontopoulou, E. Vaidakis, E. Bournakis,

N. Alexiou, I. Porfyridis, E. Sioula (Athens, GR)

P1082 Efficacy of medical treatment in hydatid


I. Dumitru, S. Rugina, E. Dumitru, E. Dumea

(Constanta, RO)

P1083 The in vitro effect of levamisole and

praziquantel combination on Echinococcus

granulosus protoscolices

A. Guvenli, M. Hokelek (Samsun, TR)

P1084 Multiple hydatid cysts in the left main

pulmonary artery: an extremely rare location

O.K. Aribas, E. Turk-Aribas, F. Kanat, I. Erayman,

T. Yuksek (Konya, TR)

P1085 An extremely rare location of cardiac hydatid

cyst: interventricular septum

I. Erayman, E. Turk Aribas, S. Avcu, M. Bitirgen

(Konya, TR)

P1086 A 5-year study of intestinal parasitosis in a

general hospital, Piraeus, Greece

S. Konstantopoulou, A. Mourikis, P. Karle,

M. Dimitriou, E. Vlachou, F. Vagia, A. Karle

(Athens, GR)

P1087 Filariasis infection in immigrants in a

Spanish hospital

N. Portocarrero, A. Amor, M. Baquero,

M. Subirats (Madrid, ES)

P1088 Hepatobiliary ascariasis: a case report

A.T. Bastug, A. Erbay, H. Bodur, E. Akinci,

M.A. Cevik (Ankara, TR)

P1089 The pinworm (Enterobius sp.) infection in

lung mimicking tuberculoma – case report

H. Järv, V. Adamson, P. Naaber (Tartu, EE)

P1090 Malnutrition in children in Nairobi’s slums

A. Kolenova, A. Ondrusova (Trnava, SK)

page 103

Poster Sessions Monday, April 3, 2006

P1091 Incidence of tropical diseases at university

clinic in Mapuordit, Sudan

S. Seckova, A. Augustinova, J. Bencza,

M. Bartkoviak, A. Doczeova, M. Taziarova,

V. Sladeckova, M. Vilimova, Z. Kniezova,

K. Kutna, M. Ocenas (Trnava, SK)

P1092 Saturday night fever

R. Gowda, A. Tunbridge, M. McKendrick

(Sheffield, UK)



P1093 Epidemiological features of diphtheria in


I.A. Karpov, A. Kachanka, M. Kozatchenko

(Minsk, BY)

P1094 An analysis of the factors effecting the

prognose of tetanus in a university hospital

between 1991 and 2005

K. Aydin, G. Yilmaz, F. Aksoy, I. Koksal,

R. Caylan (Trabzon, TR)

P1095 Determination of tetanus antibody levels

among emergency department patients

presenting with injuries

K. Caglar, K. Hizel, A. Altuncekic, A. Demircan,

R. Karakus (Ankara, TR)

P1096 Tetanus immunisation status among women

of child-bearing age in three provinces in


B. Esen, D. Kurtoglu, N. Coplu, A. Gozalan,

K. Miyamura, S. Ishida, L. Akin

(Ankara, TR; Tokyo, JP)

P1097 Serological evidence of acute/recent pertussis

infection in Turkey: how big is the threat for


B. Esen, N. Coplu, D. Kurtoglu, A. Gozalan,

L. Akin (Ankara, TR)

P1098 Immunity against tetanus and effect of its

vaccination in Turkey

N. Coplu, B. Esen, A. Gozalan, D. Kurtoglu,

K. Miyamura, S. Ishida (Ankara, TR; Tokyo, JP)

P1099 Prevalence of pertussis antibody and

vaccination status in three provinces in Turkey

D. Kurtoglu, A. Gozalan, N. Coplu, K. Miyamura,

S. Ishida, M. Morita, L. Akin, B. Esen

(Ankara, TR; Tokyo, JP)

P1100 Analysis of the changes in the tetanus course

during the last 40 years – own observations

A. Kalinowska-Nowak, A. Garlicki, M. Bocizga-

Jasik, T. Mach (Cracow, PL)

page 104 Final Programme

P1101 Seroepidemiology of rubella in reproductive

age women in Attica area of Greece during

fifteen years (1990 – 2004)

P. Karabogia-Karafillidis, M. Orfanidou,

H. Vagiakou, E. Sideris, E. Kontekaki, A. Kefalakis,

H. Malamou-Lada (Athens, GR)


Mycobacterial infections

P1102 Diagnosis of tuberculosis in suspects in

endemic area by using enzyme-linked

immunospot assay for gamma-interferon

P.R. Hsueh, J.Y. Wang, C.H. Chou, L.N. Lee,

H.L. Hsu, I.S. Jan, P.C. Yang, K.T. Luh (Taipei, TW)

P1103 Autoantibodies to cytokines in patients with

mycobacterial infections

G.A. Fernandez-Ramirez, M.E. Rosales,

I. Avila-Miyazawa, L. Ceron-Gutierrez, C. Espitia

Pinzon, J. Cabiedes, E. Sada, J.A. Montaraz-

Crespo, R. Doffinger, G. Barcenas-Morales

(Mexico City, MX; Cambridge, UK)

P1104 Tuberculin skin testing among health care

workers in a country with a high tuberculosis

prevalence: booster and conversion rates

K. Hizel, F. Ozer, I. Maral, F. Aktas (Ankara, TR)

P1105 Clinical evaluation of a real-time PCR kit for

the detection and partial differentiation of

the M. tuberculosis complex

S. Cramer, M. Hess, F.C. Bange

(Hamburg, Hannover, DE)

P1106 Serodiagnostic potential of mammalian cell

entry proteins encoded by mce3 operon of

Mycobacterium tuberculosis

S. El-Shazly, A.S. Mustafa, S. Ahmad, R. Al-Attiyah

(Kuwait, KW)

P1107 Rapid identification of mycobacterial species

with test INNO-LiPA mycobacteria v2 isolated

from sputum samples obtained from HIVnegative


J. Paluch-Oles, M. Koziol-Montewka,

M. Dzbrowska, M. Montewka, A. Bogut

(Lublin, PL)

P1108 A new automated method for sample

preparation of Mycobacterium tuberculosis

respiratory specimens based on magnetic


J. Lysèn, T. Engen, H.K. Høidal Berthelsen,

M. Espelund, S. Jeansson, U.H. Refseth

(Oslo, NO)

Poster Sessions Monday, April 3, 2006

P1109 Gold nanoparticle probe-based diagnostic

system for rapid and sensitive detection of

Mycobacterium tuberculosis

M. Koziol-Montewka, J. Paluch-Oles,

P. Baptista (Lublin, PL; Lisbon, PT)

P1110 Development of tools for detection of DNA

and mRNA from mycobacteria in clinical


N. Potapova (Moscow, RU)

P1111 Diagnosis of tuberculous pleuritis by nested

polymerase chain reaction: a comparison of

four different volumes of pleural fluid

N. Jaimchariyatam, K. Kawkitinarong,

K. Naweewitphadung, N. Udomsantisuk,

S. Tumwasorn, W. Kulwichit (Bangkok, TH)

P1112 The value of the QuantiFERON-Gold TB test in

the management of patients with suspected

active tuberculosis

J. Democratis, S. Bailey, M. Barer, N. Pereira,

I. Stephenson, K.G. Nicholson, M.J. Wiselka,

J. Democratis (Leicester, UK)

P1113 Prospective MIRU-VNTR typing of

Mycobacterium tuberculosis isolates: initial

epidemiological analysis of isolates typed in

the Midlands from 2003–2005

J.T. Evans, E.G. Smith, S. Gardiner, J. Mowbray,

H. Mossop, B. Olowokure, P. Monk, P.M. Hawkey

(Birmingham, Leicester, UK)

P1114 Evaluation of clinical utility on direct

detection of MTBC on clinical samples by

BD Protec ET System

J.S. Lin, Y.Y. Yu, C.Y. Lin (Changhua, TW)

P1115 Clonal diversity of Mycobacterium

tuberculosis in sputum specimen from

individual patients of pulmonary tuberculosis

C. Shiohira, Y. Bhusal, N. Yamane (Okinawa, JP)

P1116 Agreement of QuantiFERON-TB Gold In-Tube

and T Spot-TB in HIV-infected patients from

Sub-Saharan Africa in Switzerland

M. Reichmuth, C. Thurnherr, F. Suter-Riniker,

P. Vernazza, H. Furrer, T. Bodmer

for the Swiss HIV Cohort Study

P1117 Role of serologic tests (IgG, IgA, IgM

antibodies against A60 mycobacterial

antigen) in diagnosis of tuberculosis

H. Emadi, M. Rasoolinejad, O. Zarghom,

S. Siroos Jafari, Z. Ahmadinejad, Z. Abdi Liae,

S. Davoudi, M. Hassibi, A. Soodbakhsh

(Tehran, IR)

P1118 Implementing DOTS in settings with high

prevalence of drug-resistant tuberculosis

Y. Balabanova, I. Fedorin, S. Zakharova,

V. Nikolayevskyy, R. Atun, R. Coker,

F. Drobniewski (London, UK; Samara, RU)

P1119 Multidrug-resistant tuberculosis:

guideline tailoring for immigrants

T. Bregenzer, F. Schmid, C. Ebnöther (Aarau, CH)

P1120 Rapid drug sensitivity testing of

M. tuberculosis based on culture on

a porous ceramic support

C. Ingham, A. Ben Ayad, R. Hummelink,

B. Mulder (Den Bosch, Enschede, NL)

P1121 Identification of the Mycobacterium

tuberculosis subtype strongly associated with

multidrug resistance within the Beijing family

V. Nikolayevskyy, T. Brown, Y. Balabanova,

Y. Bazhora, A. Asmolov, F. Drobniewski

(London, UK; Odessa, UA)

P1122 Extrapulmonary tuberculosis in sector III of

Zaragoza, Spain during 2000–2005

M.P. Macipe, A. Vitoria, J.A. Amiguet, A.I. López-

Calleja, M.A. Arias, P. Crusells, J. Cuesta,

C. Rubio (Zaragoza, ES)

P1123 Evaluation of tuberculin skin test and

Quantiferon-TB gold for the identification of

LTBI or active TB among irregular immigrants

in Milan, Italy

G. Orlando, S. Merli, A. Valerio, L. Cordier,

M. Bergonzi, A. Villa, A. Cargnel (Milan, IT)

P1124 Tuberculosis epidemiology in a health care

area of Santiago de Compostela

(Galicia, NW Spain) from 1996 to 2004

V. Túñez, M.L. Pérez del Molino, P.A. Romero,

M. Conde, F. Pardo (Santiago de Compostela, ES)

P1125 Tuberculosis in paediatric and adult

population in Athens, Greece (1994–2004)

S. Kanavaki, S. Karabela, A. Skroubellou,

E. Varonou, S. Anagnostou, A. Raftopoulou,

H. Moraitou, N. Spyridis, S. Nikolaou (Athens, GR)

P1126 Screening of immigrants for tuberculosis in

Greece: implications for health care needs

M. Matsagoura, M. Kompoti, A. Koutsovasili,

A. Salta, A. Papaefstathiou, M. Matsagoura

(Thiva, GR)

P1127 Epidemiology of Mycobacterium bovis

disease in Ferrol, Spain, 1991–2004

J.F. García Rodríguez, H. Álvarez Díaz,

V. Trasancos Buitrago, M.V. Lorenzo García,

A. Mariño Callejo, P. Sesma Sánchez (Ferrol, ES)

page 105

Poster Sessions Monday, April 3, 2006

P1128 Tuberculosis as re-emerging disease in Italy.

Which correlations with HIV infection and

other risk factors, comparing native residents

and foreign immigrants?

R. Manfredi, S. Sabbatani, G. Legnani, F. Chiodo

(Bologna, IT)

P1129 A randomised trial of a short course with

isoniazid plus rifampin in front of isoniazid

during six months in latent tuberculosis


D. Vañó, M.P. Geijo, C. Rosa, A. Molina, M. Pérez,

J.F. Dimas (Cuenca, ES)

P1130 Mycobacterium sherrisii: a new opportunistic

agent in HIV-infected patients?

P. Loulergue, F. Lamontagne, V. Vincent,

A. Rossier, G. Pialoux (Paris, FR)

P1131 Presence of mycobacteria in colon biopsies

from patients with inflammatory bowel


I. Szpinda, A.T. Jorde, I. Olsen, B. Djønne,

M. Vatn, T. Tønjum (Oslo, NO)

P1132 Prevalence of nontuberculous mycobacteria

in a Belgian adult cystic fibrosis population

M. Develter, W. Laffut, L. Dupont, J. Verhaegen

(Leuven, BE)

P1133 Tuberculous Empyema necessitatis involving

chest wall and retroperitoneum

O.K. Aribas, E. Turk-Aribas, I. Erayman, F. Kanat,

A. Ozturk (Konya, TR)

P1134 Increasing incidence of Mycobacterium

xenopi in Zaragoza, Spain: an emerging

pathogen or a product of improved laboratory


S. Terraza, J.A. Amiguet, A. Vitoria, M.A. Lezcano,

C. Ramos, P. Arazo, J. Cuesta (Zaragoza, ES)

P1135 Mycobacterium chelonae and continuous

ambulatory peritoneal dialysis associated

peritonitis. An unrecognised entity?

I. Gupta, P. Cockwell, I. Das (Birmingham, UK)

P1136 Nontuberculous mycobacterial keratitis after

photorefractive keratectomy for myopia

D. Mylona-Petropoulou, G. Vrioni, G. Ganteris,

D. Miltsakakis, A. Kyratsa, C. Mougnai,

A. Kouris, S. Levidiotou, H. Malamou-Lada

(Athens, Ioannina, GR)

P1137 Leprosy elimination campaign in the Qazvin

province, Iran, 2004

R. Qassemi Barqi (Qazvin, IR)

page 106 Final Programme

P1138 The first reported European case of intravascular

catheter infection with Mycobacterium


S. Musaad, N. Young, G. Robinson, D. Gascoyne-

Binzi, A. Rajgopal, A. Barrett, D. Norfolk,

T.A. Collyns (Leeds, Newcastle, UK)

P1139 Impact of differents antimycobacterial

drugs on the survival of patients with

Mycobacterium xenopi pulmonary infection:

89 cases

C. Andrejak, F.X. Lescure, Y. Yazdanpanah,

Y. Douadi, T. May, B. Hoen, P. Chavanet,

G. Laurans, V. Jounieaux, J.L. Schmit

(Amiens, Tourcoing, Nancy, Besancon, Dijon, FR)

P1140 BCG infection following BCG therapy for

bladder carcinoma: results of a multicentre

study, about 23 cases

A. Godel, E. Bonnet, L. Porte, F. Busato,

M. Alvarez, B. Doudie, P. Brouqui,

H. Laurichesse, P. Massip, B. Marchou

and the InfectioSud Group

P1141 Extrapulmonary tuberculosis in immuno -

competent adults

T. Turunc, Y.Z. Demiroglu, H. Uncu, S. Colakoglu,

H. Arslan (Ankara, TR)

P1142 Cigarette smoking and its association with

pulmonary tuberculosis in adults

M. Rasoolinejad, A. Farazi, M. Haj Ab-dul Baghi,

P. Hashemi, P. Kheirandish (Tehran, IR)


Experimental infections: treatment and


P1143 Does reduced susceptibility to disinfectants

compromise colonisation and persistence of

Salmonella enterica serovar typhimurium in


S.W. Cooles, M.A. Webber, L.P. Randall,

N.G. Coldham, L.J.V. Piddock, M.J. Woodward

(Addlestone, Birmingham, UK)

P1144 A study on rat’s pulmonary inflammatory

reaction induced by N-protein of SARS-CoV

and effects of glucocorticoids on it

L. He, D. Hao, J. Qu (Shanghai, CN)

P1145 Brain damage in pneumococcal meningitis:

establishment of an infant mouse model

D. Grandgirard, O. Steiner, S.L. Leib (Bern, CH)

P1146 PCR and culture correlate well for measuring

cure rates for short course treatment of

infections with the Lyme disease spirochete

C. Pavia, D. Liveris, S. Bittker

(Old Westbury, Valhalla, US)

Poster Sessions Monday, April 3, 2006

P1147 Efficacy of aminocandin (IP960/HMR3270) in

temporarily and persistently neutropenic

murine models of disseminated aspergillosis

P. Warn, A. Sharp, D.W. Denning (Manchester, UK)

P1148 Therapeutic drug monitoring of 5-flucytosine

in children aged under 12 years. An elevenyear

review of serum concentrations from a

United Kingdom clinical assay reference


M. Soltani, C.M. Tobin, K.E. Bowker,

A.M. Lovering, A.P. MacGowan (Bristol, UK)

P1149 Experimental dermatophytosis in guinea pigs:

is voriconazole an option for treatment?

D.M. Saunte, N. Frimodt-Moller, E.L. Svejgaard,

M. Haedersdal, M.C. Arendrup (Copenhagen, DK)

P1150 Moxifloxacin is markedly more effective than

levofloxacin, gatifloxacin or azithromycin in

the treatment of pneumococcal pneumonia in

mice caused by a macrolide-resistant isolate

D.J. Bast, L. Dresser, C.L. Duncan, L.A. Mandell,

D.E. Low, J.C.S. de Azavedo (Toronto, CA)

P1151 Moxifloxacin is highly active in a murine

Gelfoam® implant model of complicated skin

and skin structure infections

K. Merfort, S. Obertegger, R. Endermann

(Wuppertal, DE)

P1152 Efficacy of continuous or bolus IV ceftazidime

and combination therapy in septic neutro -

penic mice

J. Buijs, A.S.M. Dofferhoff, J.W. Mouton,

J.W.M. van der Meer (Heerlen, Nijmegen, NL)

P1153 Amoxicillin early and delayed treatment of

serotype 6 pneumococcal acute otitis media

in previously immunised vs. non-immunised


C. Martínez-Marín, G. del Prado, L. Huelves,

M. Gracia, C. Ponte, C. Cenjor, M.J. Giménez,

L. Aguilar, F. Soriano (Madrid, ES)

P1154 Efficacy of amoxicillin-clavulanate in an

experimental murine pneumonia model

caused by AmpC non-hyperproducing clinical

isolates of E. coli resistant to cefoxitin

F. Docobo-Pérez, F. Fernández-Cuenca,

M.E. Pachón-Ibáñez, A. Pascual, C. Pichardo,

L. Martínez-Martínez, J. Pachón (Seville, ES)

P1155 Telithromycin is effective against susceptible,

fluoroquinolone-resistant and macrolideresistant

strains of Streptococcus pneumoniae

in a murine model of pneumonia

J.C.S. de Azavedo, C. Duncan, L. Dresser,

L.A. Mandell, D.E. Low, D.J. Bast

(Toronto, Hamilton, CA)

P1156 Efficacy of daptomycin in the treatment of

experimental endocarditis due to susceptible

and multidrug-resistant enterococci

J.M. Entenza, M. Giddey, J. Vouillamoz,

P. Moreillon (Lausanne, CH)

P1157 Intracellular killing of Staphylococcus aureus

in vivo: comparison of six antibiotics

A. Sandberg, R.L. Skov, N. Frimodt-Møller

(Copenhagen, DK)

P1158 Efficacy of telavancin in the treatment of

experimental endocarditis due to

glycopeptide-intermediately susceptible

Staphylococcus aureus

J.M. Miró, F. Marco, C. Garcia de la Maria,

Y. Armero, E. Amat, D. Soy, A. Moreno,

A. del Rio, M. Almela, C.A. Mestres, J. Gatell,

M.T. Jimenez de Anta for the Barcelona Hospital

Clinic Endocarditis Study Group


Bacterial pathogenesis – II

P1159 Alteration in virulence characteristics of

planktonic and biofilm cells of Pseudomonas

aeruginosa following exposure to

macrophage secretory products

R. Mittal, S. Sharma, S. Chhibber, K. Harjai

(Chandigarh, IN)

P1160 Genetic analysis of alginate production in

140 cystic fibrosis P. aeruginosa isolates from

Scandinavian patients

O. Ciofu, T. Wassermann, U. Johansen, N. Høiby

for the Scandinavian Cystic Fibrosis Study


P1161 Effect of different growth phases on surface

properties and adhesion of Pseudomonas


A.P. Fonseca, C.I. Extremina, A. Freitas da Fonseca,

J.C. Sousa (Porto, PT)

P1162 Effect of subinhibitory concentrations of

ceftazidime and meropenem on the morphology

and adherence ability of Pseudomonas

aeruginosa wild-type strains

J. Vranes, S. Bekic, S. Ljubin-Sternak, B. Bedenic,

N. Bauk, G. Mlinaric-Galinovic, L. Glavas-Obrovac

(Zagreb, Osijek, HR)

P1163 In vitro study of the influence of phenyl lactic

acid produced by lactobacillus probiotic

strains on the pathogenic features of

Pseudomonas aeruginosa strains

V. Lazar, L. Ditu, M.C. Balotescu, C. Bleotu,

M. Bucur, O. Dracea, O. Banu, R. Cernat

(Bucharest, RO)

page 107

Poster Sessions Monday, April 3, 2006

P1164 Bloodstream infections due to Pseudomonas

aeruginosa: clinical outcome associated with

pathogenesis-related genes

A. Endimiani, B. Pini, A. Baj, F. Luzzaro, A. Toniolo

(Varese, IT)

P1165 MR imaging in experimental meningitis –

in vivo correlates for disease severity

C.T. Brandt, H. Simonsen, J.D. Lundgren,

C. Østergaard, N. Frimodt-Møller, L.V. Søgaard,

O.B. Paulsson, I. Rowland (Copenhagen, DK)

P1166 Transmission of community-acquired

methicillin-resistant Staphylococcus aureus

infection in household contacts in Taiwan

Y-C. Huang, C-F. Ho, C-J. Chen, L-H. Su

(Kweishan, Taoyuan, TW)

P1167 Characterisation of Panton–Valentine

leukocidin-positive Staphylococcus aureus

strains isolated in the Czech Republic

P. Petras, I. Machova, M. Marejkova, R. Pantucek,

V. Ruzickova, J. Doskar (Prague, Brno, CZ)

P1168 Increased incidence of higher vancomycin

minimal inhibitory concentration and

changing pattern of antibiotic susceptibility in

methicillin-resistant Staphylococcus aureus

isolates: a single institution study

D. Lu, P. Holtom (Los Angeles, US)

P1169 Prevalence of different virulence factors in

enteroaggregative Escherichia coli isolates

causing diarrhoea in children in Ifakara,


E. Mendez Arancibia, J. Ruiz, M. Vargas,

J. Gascon, J. Vila (Barcelona, ES)

P1170 Profound difference in virulence genes

carriage between Pakistani and Swedish

Escherichia coli strains belonging to

phylogenetic group B2

F.L. Nowrouzian (Göteborg, SE)

P1171 Pathogenicity island I of Escherichia coli

CFT073 and Yersinia high-pathogenicity island

are significantly associated with persistence

of E. coli in the intestine of Swedish infants

A.E. Östblom, I. Adlerberth, A.E. Wold,

F.L. Nowrouzian (Göteborg, SE)

P1172 Relationships between phylogenetic groups

of Escherichia coli isolates and clinical

characteristics in 161 patients with


F. Jaureguy, E. Carbonnelle, S. Bonacorsi,

E. Bingen, B. Picard, X. Nassif, O. Lortholary

(Bobigny, Paris, FR)

page 108 Final Programme

P1173 Burden of Clostridium difficile associated

disease in NHS hospital trusts in England

A.D. Pearson, K. Wagner, A. Talebi, E. Robinson,

L. Saker (London, UK)

P1174 In vitro investigation of pro-inflammatory

properties of Helicobacter pylori strains

involved in low-grade gastric mucosa

associated lymphoid tissue lymphoma

P. Lehours, G. Lasne, A. Gallois, A. Menard,

A. Ruskone Fourmestraux, J.C. Delchier,

F. Megraud (Bordeaux, Paris, Creteil, FR)

P1175 Reduced activation of microglial cells by

Streptococcus pneumoniae after treatment

with nonbacteriolytic antibiotics in

comparison to ceftriaxone

A. Spreer, I.M. Hernekamp, M. Lotz, S. Ebert,

H. Eiffert, R. Nau (Gottingen, DE)

P1176 Contribution of chemokines CXCL10 and

CXCL11 and their receptor CXCR3 to the

accumulation of memory CD4+ T-cells in the

cerebrospinal fluid of patients with tick-borne

encephalitis and neuroborreliosis

S. Zidovec Lepej, O. Dakovic Rode, L. Misic

Majerus, B. Barsic, A. Vince, T. Jeren

(Zagreb, Koprivnica, HR)

P1177 Assessment of monocytic function in patients

with septic syndrome induced by ventilatorassociated


T. Tsaganos, M. Raftogiannis, D. Zervakis,

D. Plachouras, C. Skalioti, S. Kollias,

E.J. Giamarellos-Bourboulis, C. Roussos,

H. Giamarellou (Athens, GR)

P1178 Monocytes in systematic inflammatory

response syndrome: differences between

sepsis and acute pancreatitis

F. Baziaka, T. Tsaganos, V. Kousoulas,

V. Karagianni, A. Pelekanou, A. Antonopoulou,

E.J. Giamarellos-Bourboulis (Athens, GR)

P1179 Recombinant Escherichia coli as a model

to study a potential pathogenic agent of

Burkholderia pseudomallei – phospholipase C

B. Sadowska, M. Wieckowska-Szakiel,

W. Rudnicka, S. Korbsrisate, B. Rozalska

(Lodz, PL; Bangkok, TH)

P1180 Fusobacterium necrophorum in young

patients with tonsillitis and healthy controls

examined by real-time PCR. Concomitant

Group C streptococci may aggravate


A. Jensen, L.H. Kristensen, J. Prag (Viborg, DK)

Poster Sessions Monday, April 3, 2006

P1181 Expression, immunogenicity and apoptotic

potential of Salmonella enterica serovar Typhi

69 kDa phenotype under oxidative stress, iron

limitation and anaerobic conditions

V. Chanana, S. Majumdar, P. Rishi

(Chandigarh, IN)

P1182 Gram-positive and Gram-negative bacteria

induce different cytokines from human

peripheral blood mononuclear cells

irrespective of taxonomic relatedness

S. Johansson, A. Bigsten, C. Hessle, A. Wold

(Goteborg, SE)

P1183 Invasiveness of Providencia alcalifaciens to

HEp-2 cells

A. Maszewska, A. Torzewska, A. Rozalski

(Lodz, PL)

P1184 The exchange of virulence-related and

drug-resistance genes among clinical isolates

of enterococci

N. Amirmozafari, M. Alebouyeh, H. Forohesh

(Tehran, IR)

P1185 Modulation of GRO-alpha and TNF-alpha

production by peripheral blood mononuclear

cells treated with killed Helicobacter pylori

G. Stassi, A. Arena, A. Cascio, C. Iaria,

M. Calapai, D. Gazzara, D. Iannello (Messina, IT)

P1186 Elevated sialidase and prolidase combined

with vaginal pH>5 are biomarker for low birth

weight and early preterm birth

S. Cauci, J. McGregor, P. Thorsen, J. Grove,

D. De Santo, F. De Seta, P. Lanzafame,

S. Guaschino (Udine, IT; Los Angeles, US;

Aarhus, DK; Trieste, IT)

P1187 Levels of IgA against Gardnerella vaginalis

hemolysin (anti-Gvh IgA) before and after

therapy of bacterial vaginosis

S. Cauci, S. Driussi, G. Casabellata,

M. Di Santolo, P. Lanzafame, D. De Santo,

F. De Seta, S. Guaschino (Udine, IT)

P1188 Q fever in Northern Greece: epidemiologic

and clinical data from 58 acute and chronic


M. Pape (Thessaloniki, GR)

P1189 Gram-negative commensal gut bacteria

aggravate small intestinal inflammation via

toll-like receptor 4

M.M. Heimesaat, A. Fischer, H.-K. Jahn,

J. Niebergall, O. Liesenfeld, R.R. Schumann,

S. Bereswill, U.B. Göbel (Berlin, DE)

P1190 The condition of a mucous stomach

membrane of region blood-groove after


M. Chemich, A. Snitsar (Sumy, UA)

P1191 In vitro model to analyse the effect of

mycobacteria infection on HIV replication

A. Boluda, R. Delgado, M.D. Folgueira

(Madrid, ES)

P1192 Prevalence of non-tuberculosis mycobacteria

in the Southeast of Iran

T. Naserpour Farivar, B. Sharifi Moud, M. Naderi,

M. Salehi, N. Salari, N. Naserfar (Zahedan, IR)

P1193 Systemic inflammation in the field of

experimental multiple trauma:

when does bacterial translocation

and subsequent sepsis occur?

P. Koutoukas, T. Tsaganos, N. Efstathopoulos,

K. Panousis, P. Kaldis, M. Klonaris, E.J. Giamarellos-

Bourboulis, A. Papalois (Athens, GR)

P1194 Identification of Borrelia burgdorferi sensu

lato species in erythema migrans and cardial

involvement by real-time PCR and electron


D. Hulinska, M. Bojar, V. Hulinsky, P. Bartunek

(Prague, Nymburk, CZ)

P1195 Seroepidemiological study on toxoplasmic

infection among high-school girls by IFAT test

in Iran, 2002–2003

M. Mahmoudi (Esfahan, IR)

P1196 The faith of Shigella species during contact

with the water-borne free-living amoeba

Acanthamoebae castellanii

A. Saeed, H. Abd, G. Sandström (Stockholm, SE)

P1197 Mannose-rich capsular polysaccharides

enhance uptake and killing of Klebsiella

pneumoniae by human plymorphonuclear


H. Sahly, Y. Keisari, U. Stallforth-Siegel, I. Ofek

(Kiel, DE; Tel Aviv, IL)


Mechanism of antifungal action and

resistance to antifungals in fungal disease

P1198 Management of semi-invasive aspergillosis

and Aspergillus empyema with combination

of systemic antifungals and intrapleural

amphotericin B in an immunocompetent


Y. Tezer, O. Memikoglu, H. Kurt (Ankara, TR)

page 109

Poster Sessions Monday, April 3, 2006

P1199 Clinical presentation and epidemiology of

Mucorales infections in Geneva university


I. Uçkay, M. Djordjevic, J. Garbino, C. Garzoni,

Y. Chalandon, V. Jacomo, P. Rohner,

C. Van Delden (Geneva, CH; Nis, CS)

P1200 Caspofungin therapy in documented fungal

infections: Spanish experience before

licencing of the drug

C. Sanz-Rodriguez, J.M. Cisneros, J.M. Aguado,

R. Martino on behalf of the Spanish Caspofungin

Clinical Study Group

P1201 Zygomycosis in a general hospital during

a 17-year period. Is there an increase in

incidence after introducing voriconazole?

M. Torres-Narbona, J. Guinea, J. Martínez-

Alarcón, T. Peláez, P. Muñoz, E. Bouza

(Madrid, ES)

P1202 Candida colonisation, colonisation index and

invasive candidiasis in patients at a multi -

disciplinary intensive care unit, Sweden

C. Agvald-Ohman, L. Klingspor, H. Hjelmqvist,

C. Edlund (Huddinge, SE)

P1203 Treatment of invasive Pseudallescheria boydii

infections with voriconazole or voriconazole

plus caspofungin

A. Pan, A. Soresina, C. Cattaneo, S. Lorenzotti,

S. Magri, N. Manca, A. Plebani, G. Pinsi, G. Rossi,

L. Soavi, L. Signorini, R. Stellini, G. Carosi

(Brescia, IT)

P1204 The emergence of caspofungin resistance

during treatment of recurrent Candida

glabrata candidaemia

N. Daneman, A.K. Chan, S.M. Poutanen,

R. Rennie, C. Sand, S. Porter

(Toronto, Edmonton, Vancouver, CA)

P1205 An open-label study of anidulafungin in

invasive candidiasis and candidaemia

R. Betts, D. Kett, K. Clark, H.T. Schlamm,

D.S. Krause (Rochester, Miami, New York, US)

P1206 Systemic fungal infection due to Trichosporon

beigelii in immunocompromised patients

I. Radonjic, S. Mitrovic, V. Arsic Arsenijevic,

I. Kranjcic Zec, A. Dzamic (Belgrade, CS)

P1207 Epidemiology of dermatophytosis in

Khouzestan province, southwest Iran,

from 2002 to 2005

A. Rafiei, M. Omidian, M. Radmanesh, M. Mapar,

R. Yaghobi, R. Rasaei, R. Taddaion (Ahwaz, IR)

page 110 Final Programme

P1208 Cutaneous infection by Absidia corymbifera

and Syncephalastrum racemosum treated

with amphotericin B and surgical debridement

R. Bandettini, E. Mantero, A.M. Tamisani, P. Tuo,

R. Ceccarelli, L. Pescetto, L. Ricagni, G. Melioli

(Genoa, IT)

P1209 The Janus head of Histoplasma

E. Vlieghe, M. Ieven, H. Jansens, B. Hendriks,

K. Van de Vyvere, P. Fonteyne, E. Van den Enden,

R. Colebunders (Antwerp, Brussels, BE)

P1210 Successful therapy of zygomycosis with

posaconazole in a patient intolerant of

liposomal amphotericin B

S. Savvanis, A. Papadopoulos, D. Kavvatha,

H. Giamarellou (Athens, GR)

P1211 Carbon assimilation profiles as a tool for

Zygomycetes species identification

P. Schwarz, O. Lortholary, F. Dromer, E. Dannaoui

(Paris, FR)

P1212 Is posaconazole a new treatment option for

brain abscess?

L. Matkham, C. Garzoni, B. Hirschel, S. Harbarth,

K. Bouchuigui-Waf, J. Garbino (Geneva, CH)

P1213 Clinical and epidemiological analysis of

candida bloodstream infection in a university


M. Cuervo, M.A. Miguel, M. Lecuona, S. Campos,

M.I. Montesinos, A. Torres, T. Delgado, A. Sierra

(La Laguna Sta Cruz Tenerife, ES)

P1214 A prospective French national survey to

evaluate renal function in patients treated

with amphotericin B lipid formulations

S. Faouzi (Villejuif, FR)

P1215 Fungal peritonitis in continuous ambulatory

peritoneal dialysis patients

B. Arda, O. Sipahi, G. Asci, M. Ozkahya,

S. Ulusoy (Izmir, TR)

P1216 Intra-abdominal fungal infection in surgical


I. Gutiérrez, N. Batista, A. Varona, O. Díez

(Santa Cruz de Tenerife, ES)

P1217 Mucormycoses: a report of eleven cases

T. Turunc, Y.Z. Demiroglu, H. Uncu,

S. Colakoglu, H. Arslan (Baskent, TR)

P1218 Bipolaris spicifera isolation from the nasal

polyps of an allergic boy: a case report

A. Sergounioti, H. Kirikou, A. Velegraki,

K. Chryssaki, M. Choulakis, K. Stefanaki,

A. Pangalis (Athens, GR)

Poster Sessions Monday, April 3, 2006

P1219 Mucormycosis: still a problem

(a report of four cases)

L. Ammari, B. Kilani, H. Tiouiri ben Aissa,

F. Kanoun, E. Chaker, A. Goubontini,

T. Ben Chaabane (Tunis, TN)

P1220 Candida deep sternal wound infections:

an emerging problem?

T. Ejlertsen, I. Modrau, L. Lemming,

B.S. Rasmussen (Aalborg, DK)

P1221 Survey on dermatophytosis in patients

referred to a dermatology hospital in Ghazvin,


M.R. Aghamirian, D. Keshavarz, J.H. Hashemi

(Ghazvin, IR)

P1222 Caspofungin and G-CSF as first-line therapy

of pulmonary invasive fungal infections in

32 neutropenic patients with haematologic


A. Candoni (Udine, IT)

P1223 Clinical analysis of cryptococcal meningitis

(with 72 case reports)

G. Shi (Shanghai, CN)

P1224 The prevalance of aetiologic agents of

dermatophytosis in wrestlers in Isfahan, Iran

S. Shadzi, A. Karbassian, N. Kassaian, M. Khademi,

Z. Nokhodian (Isfahan, IR)

P1225 Slowly progressing, and indolent pulmonary

mucormycosis (zigomycosis) in a patient with

an underlying multiple sclerosis, managed

without immunosuppressive therapy

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P1226 AIDS-defining fungal opportunism in the

HAART era. Trend of frequency and reduced

incidence when HIV protease inhibitors are


R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P1227 Concurrent invasive cryptococcosis and

candidiasis in AIDS presenters. Clinical

epidemiology and features never observed

also during the pre-HAART era

R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)

P1228 A 3-year study of resistance of Candida

pathogens obtained from patients with

fungaemia with emphasis on new antifungal


A. Koutsoukou, A. Stylianakis, S. Tsiplakou,

M. Tachtatzis, E. Tsakona, A. Vourtsi, A. Sideri

(Athens, GR)

P1229 Candida embolic stroke and secondary fungal

mycotic aneurysm

C. Garzoni, I. Uckay, L. Markham, R. Sztajzel,

K. Bouchuigui-Waf, P. Temperli, J. Garbino

(Geneva, CH)

P1230 Monitoring of voriconazole blood levels

for prevention of serious neurological adverse


A A. Pascual, S. Bolay, O. Marchetti

(Lausanne, CH)

P1231 Influence of azoles on mixed long-term

continuous flow cultures of Candida albicans

and Candida glabrata under aerobic and

anaerobic conditions

H. Bernhardt, M. Knoke, K. Zimmermann,

G. Schwesinger, J. Bufler, K. Ludwig,

J. Bernhardt (Greifswald, Karlsruhe, Rostock, DE)

P1232 Investigation of synergistic effect of sertraline

on fluconazole-resistant Candida spp. by

microbiological methods and electron


N. Nuhoglu, T. San, G. Soyletir (Istanbul, TR)


Antimicrobial resistance, permeability

and fitness

P1233 Fitness costs of antimicrobial resistance

associated with chromosomal mutations and

plasmid-borne resistance genes in Escherichia

coli: in vitro and in vivo studies

A. Petersen, F.M. Aarestrup, M. Bisgaard, J. Olsen

(Frederiksberg, Copenhagen, DK)

P1234 The fitness cost imposed by plasmid RP1 on

Escherichia coli differs from strain to strain

V.I. Enne, P.M. Bennett (Bristol, UK)

P1235 Long-term persistence of resistant strains

in the human intestinal microflora due to

restored fitness

S. Löfmark, H. Billström, C. Jernberg, C. Edlund

(Stockholm, SE)

P1236 Mutators among UK CTX-M B-lactamaseproducing

E. coli pose a risk for the

emergence of fosfomycin resistance

M.J. Ellington, D.M. Livermore, T.L. Pitt,

L.M.C. Hall, N. Woodford (London, UK)

P1237 Ertapenem promoted the selection of totally

resistant pathogens

F. Walsh, S. Bracher, P. Turner, S.G.B. Amyes

(Edinburgh, Cheshire, UK)

page 111

Poster Sessions Monday, April 3, 2006

P1238 Convergent selection of ceftazidime

resistance mutations at position 167 of

CTX-M-3 beta-lactamase in hypermutable

Escherichia coli strains

M. Stepanova, M. Edelstein (Smolensk, RU)

P1239 Mechanisms of high-level ciprofloxacin

resistance in clinical isolates of Escherichia

coli collected in the British Isles

S. Mushtaq, M.J. Ellington, D.M. Livermore,

N. Woodford (London, UK)

P1240 Evaluation of the accumulation of 99m

Tc-ciprofloxacin in S. aureus and P. aeruginosa

J.M. Sierra, D. Rodriguez-Puig, A. Soriano,

J. Mensa, C. Piera, J. Vila (Barcelona, ES)

P1242 Occurence of MexCD-OprJ overexpressing

efflux mutants of Pseudomonas aeruginosa

isolated from hospitalised patients

K. Jeannot, D. Hocquet, P. Plésiat (Besançon, FR)

P1243 Eight non-antimicrobial medicaments induce

multidrug-resistance in Escherichia coli Ag100


M.M. Tavío, V. Aquili, M. Perilli, L. Macià,

C. Balagué, Z. González-Lama, G. Amicosante

(Las Palmas de Gran Canaria, ES; L´Aquila, IT;

Rosario, AR)

P1244 The role of the multi-drug efflux systems of

Pseudomonas aeruginosa in tea tree oil


C.J. Papadopoulos, C.F. Carson, B.J. Chang,

T.V. Riley (Perth, AU)

P1245 Comparative analysis of Salmonella

typhimurium proteomes from MAR mutants

and following treatment with salicylate

N.G. Coldham, L.P. Randall, L.J.V. Piddock,

M.J. Woodward (Surrey, Birmingham, UK)

P1246 Emergence of Enterobacter aerogenes strains

resistant to imipenem mediated by the

coexistence of metallo-beta-lactamase

production and outer membrane permeability

M. Biendo, G. Laurans, B. Canarelli, D. Thomas,

F. Hamdad Daoudi, F. Rousseau, C. Adjide, F. Eb

(Amiens, FR)

P1247 Resistance to cefoxitin and susceptibility to

amoxicillin-clavulanate in clinical isolates of

Escherichia coli not hyperproducing AmpC

and lacking the OmpF porin

F. Fernández Cuenca, G. Amblar, L. Martínez-

Martínez, A. Pascual (Seville, ES)

page 112 Final Programme

P1248 Are target gene mutations the major

mechanisms of fluoroquinolone-resistance in


Y. Jin, J.M. Ling (Hong Kong, HK)

P1249 Emergence of plasmid-mediated Ambler class

A beta-lactamase in association with the

plasmid-mediated quinolone resistance QnrS

determinant in Enterobacter cloacae

L. Poirel, C. Leviandier, A. Soares, P. Nordmann

(Le Kremlin Bicetre, FR)

P1250 Detection of plasmid-mediated low-level

resistance to fluoroquinolones in

Enterobacter cloacae

P. Higgins, H. Seifert, H. Wisplinghoff

(Cologne, DE)

P1251 First characterisation of fluoroquinolone

resistance in Streptococcus suis

J.A. Escudero, A. San Millan, A.M. Catalan,

A.G. De la Campa, M.A. Moreno, L. Dominguez,

B. Gonzalez-Zorn (Madrid, ES)

P1252 Step-wise parC and gyrA mutations in